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CHAPTER I 
 INTRODUCTION 
Background 
Chronic kidney disease (CKD) has emerged as one of the major public health issues worldwide. 
In the United States, it has been estimated that 14% of the adult population suffers from CKD 
(defined by an estimated glomerular filtration rate of <60ml/min/1.73m2) [1]. Moreover, 580, 
741 patients in the US are already reaching the end stage of renal disease (ESRD) (1752 per 
million population) and an additional 200,000 people will develop ESRD in the next 10 years 
[2]. Once diagnosed with ESRD, one needs to undergo renal replacement therapy (RRT) as a 
life-saving treatment. The most common RRT modality in the United States is hemodialysis 
(HD) which account for 98% of total ESRD patients on dialysis [1].  
 ESRD patients experience alarmingly high rates of cardiovascular complications. 
Cardiovascular diseases (CVD) account for 50% of mortality in ESRD patients which is 15-30 
times higher than the age-matched general population [3-5]. Pathophysiology of CVD in this 
population is complex as it involves traditional CVD risk factors as well as non-traditional risk 
factors specific to the uremic population. It is well known that dialysis patients experience 
chronic inflammation due to various dialysis and non-dialysis factors. Because the dialysis 
procedure forces one’s blood through a dialyzer membrane, blood contact with a 
nonbiocompatible membrane or with non-sterile dialysate solutions and an impure dialysate 
triggers the inflammatory process [6]. However, dialysis factors themselves may not be the 
major factors for instigating the inflammatory process, because CKD patients not yet on dialysis 
also have high a incidence of inflammation [6-8].  
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 In addition, another comorbid condition that is highly prevalent in ESRD patients is 
protein-energy wasting (PEW), which is by far the strongest predictor for adverse outcome and 
mortality [9]. PEW is characterized by a loss of muscle mass, unintentional weight loss and a 
significant decline in nutritional parameters such as albumin and prealbumin [10]. Low serum 
albumin (hypoalbuminemia) in this population is partly due to inadequate energy and protein 
intake, loss of amino acid/protein during dialysis, and/or  volume overload as a result of non-
compliance to fluid restriction.  Because albumin contains thiol moieties, which is the most 
important antioxidant in the plasma, low plasma albumin correlates with diminished plasma total 
antioxidant capacity which provides a pathophysiological link to cardiovascular mortality in 
ESRD patients with hypoalbuminemia [11]. Furthermore, PEW and inflammation often occur 
concomitantly in HD patients (referred together as the malnutrition-inflammation complex 
syndrome, MICS). As a matter of fact, persistent inflammation is responsible for a cascade of 
reactions that causes an increase in resting energy expenditure, loss of muscle mass and 
oxidation [12] which eventually exacerbates PEW.   
 Oxidative stress, defined as an imbalance between the pro- and anti-oxidant system, is 
highly elevated in HD patients as compared to healthy-matched control [11, 13, 14]. Impaired 
oxidative balance in HD patients is partly attributed to increased reactive oxygen species 
production, reduced clearance, and a poor antioxidant defense system [14]. Oxidative stress is 
linked to CVD because of its involvement in oxidative modification of low-density lipoprotein 
(LDL). Oxidized LDL instigates a cascade of reactions including adhesion of circulating 
monocytes on endothelial cells, migration of monocytes into the arterial intima and platelet 
activation, and expression of tissue factor by endothelial cells [14].  
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 Furthermore, advanced CKD patients including ESRD on dialysis also develop 
dyslipidemia characterized by impaired synthesis and activity of high-density lipoprotein (HDL) 
and delayed catabolism of triglyceride-rich apo B containing lipoprotein, which subsequently 
leads to elevated triacylglycerols (TAG) and low plasma HDL cholesterol (HDLC) [15]. 
Accumulating evidence indicates that the concentration of plasma apo-A1 and lecithin-
cholesterol acyl-transferase (LCAT) are decreased [16, 17] which in turn impedes HDL-
mediated reverse cholesterol transport [18], a process for disposing excessive cholesterol from 
extra hepatic tissues and blood vessel walls. As oxidative stress is highly prevalent in ESRD 
patients, byproducts of oxidation reactions can be involved in oxidative modification of 
lipoproteins which consequently can disrupt the protective effects of HDL against atherosclerosis 
[18].   Taken together, a combination of MICS coupled with oxidative stress and dyslipidemia is 
highly conducive to exacerbating atherosclerosis in the HD population.  
Rationale for the current project 
Although much knowledge have been gained in understanding the complex pathophysiology of 
CVD in this population, multifaceted clinical interventions aimed at improving CVD outcome in 
HD patients have been marginally successful. This is evident with from the fact that two thirds of 
dialysis patients die within five years of commencing dialysis predominantly related to CVD 
[19] despite substantial improvement in dialysis therapy. In fact, mortality rates in ESRD 
patients in the US (>20% per year), is worse than many fatal cancers [1, 20]. Some major clinical 
trials that failed to demonstrate beneficial results of improving mortality and CVD outcomes 
include AURORA [21], 4D trials [22] (both studies used lipid lowering therapy approach) and 
HEMO trial (increased dialysis dose)[23, 24]. Interestingly, two clinical trials that used ‘dietary 
intervention’ as a mean to improve cardiovascular outcome showed promising results. Off the 
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two, one study – ‘Secondary Prevention with Antioxidants of Cardiovascular Disease in End 
Stage Renal Disease (SPACE)’ demonstrated that supplementation with 800IU of vitamin E per 
day resulted in reduction of overall mortality and morbidity based on composite cardiovascular 
end points [25]. Additionally, a recent observational study in 1046 diabetic hemodialysis patients 
demonstrated that patients with the lowest tertiles of plasma α-tocopherol had a 79% higher risk 
of stroke and 31% higher risk of all-cause mortality compared to those with the highest  tertiles 
[26], which exemplifies the role of maintaining adequate dietary vitamin E/antioxidant intake. 
Taken together, from the nutritional stand point, an effective yet a safe therapeutic approach is 
needed to reduce comorbid conditions in this population.  Nevertheless, dietary strategies to 
correct these problems have been inconclusive. 
 Recommendation for Omega-3 fatty acids studies in HD population stemmed from the 
fact that these nutrients have been shown to possess anti-inflammatory, anti-oxidative and lipid 
altering properties in vivo, in vitro and also in a clinical setting [27-30]. Furthermore, the fact 
that HD patients have lower plasma and erythrocytes levels of omega-3, (among the lowest as 
compared to the other clinical population [31]) related to dietary monotony [32] and a high 
inflammatory and oxidative milieu, exemplify the needs for dietary intervention studies. 
However, current level of evidence is still controversial to mandate incorporation of this nutrient 
into standard nutritional care of HD patients as a mean to prevent CVD.  
 Similarly, vitamin E tocotrienols (TT) recently have received great scrutiny due to their 
superior biological activity and therapeutic benefits as compared to tocopherols (TP) [33-35].  
TT have been reported to confer antioxidant protection from oxidative damage [36], have anti-
inflammatory properties [37] and are potentially cardioprotective due to their lipid altering 
properties [38]. Taken together, the fact that ESRD patients undergoing HD are at high risk for 
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cardiac mortality related to widely prevalent malnutrition, inflammation, heightened oxidative 
stress and dyslipidemia, therefore, dietary intervention to evaluate the effectiveness of these 
nutrients to reduce the aforementioned co-morbid conditions is recommended [6].  
 However, the global impact of such dietary intervention in a diverse clinical population is 
difficult to interpret, partly due to 1) inter-individual variation in the response against dietary 
intervention; 2) the existence of various confounding factors such as the difference in underlying 
comorbidities, medication profile, genetic makeup and socioeconomic disparities; 3) lack of 
effective approach to accurately account for compliance/non-compliance towards the 
intervention and 4) the nature of traditional biomarkers that are unable to provide a complete 
picture to reflect the effect of such intervention. With the emergence of ‘omics’ technology, a 
comprehensive systematic and simultaneous profiling of the complete set of metabolites is now 
possible [39, 40]. Given that, metabolomics approach has been used in various fields including 
investigating the postdose drug effects vs predose metabolic profiles [41], studying drug toxicity 
and gene function [42], evaluating the progression of disease [43] and determining changes in 
metabolite excretion profiles following dietary changes [39], we therefore sought to apply 
metabolomics to understand a broader spectrum regarding the effects of these nutrients in HD 
patients.       
Specific aims of the current project 
The objective of this study was to investigate the effects of supplementation with nutrients 
having anti-inflammatory and antioxidant properties on nutritional, lipids, inflammatory and 
oxidative status. The central hypothesis of the present study was that supplementation with 
protein as an anabolic nutrient; omega-3 fatty acids and tocotrienol rich fraction (TRF) as anti-
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inflammatory and antioxidant nutrients; will improve nutritional status, lipid profiles, as well as 
inflammatory and oxidative stress markers. The rationale for the proposed studies was that once 
the effects of these nutrients are established, larger clinical trials can be performed to establish 
clinical evidence in order to accommodate incorporation of these nutrients into dietary regimen 
of HD patients as an adjunct therapy to attenuate co-morbid conditions in these patients. 
Accordingly, the following specific aims were established; 
 
Specific aim 1: To document the global effects of protein and omega-3 supplementation on 
nutritional status and inflammatory markers in chronic hemodialysis patients. 
 
Specific aim 2: To document the global effects of TRF supplementation on nutritional indices, 
inflammatory markers, oxidative status and lipid profiles in chronic hemodialysis patients.  
 
Specific aim 3: To determine changes in metabolomics profiles following TRF supplementation. 
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CHAPTER II 
REVIEW OF LITERATURE 
Overview of kidney structures and functions 
The kidneys are a pair of bean shape organs located retroperitoneally between the transverse 
process of T12-L3 vertebrae, with the left kidney located on a slightly superior position than the 
right kidney. Each kidney weighs ~ 150g and 135g in males and females, respectively. Despite 
representing less than 1% of total body weight, the kidneys receive approximately 20% of the 
cardiac output, which is the highest blood flow of all the larger organs in the body, filtering ~ 
1600 L of blood/day. The blood supplies for the kidneys originate from the paired renal arteries 
at the level L2 of the vertebrae. Each kidney comprised of more than a million functional units – 
called nephrons. Each nephron consists of different functional segments with a typical cellular 
appearance; the renal corpuscle (glomerulus and bowman capsule), proximal convoluted tubule, 
descending loop of Henle, ascending limb, distal convoluted tubule and the collecting duct [44, 
45].    
 The kidneys serve important functions, including maintaining homeostatic balance with 
regards to fluids, electrolytes, organic solutes and acid-base balance. In the renal corpuscle, 
perfusion pressure of the glomerulus forces molecules smaller than 6500Da to pass through 
semipermeable membrane of the glomerulus into Bowman capsule as filtrate. About 80% of the 
blood entering glomerulus returns to the blood stream while the remaining 20% become filtrate. 
However, 99% of the filtrate will be reabsorbed via renal tubules and only 1% of the filtrate is 
excreted as urine. This process is achieved via a unique structure of renal tubules with varying 
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permeability between segments and hormonal regulation allowing the kidney to produce a final 
urine with diverse concentration of electrolytes, osmolality, pH and volume [45].  
 Kidneys also play substantial roles (not related to excretion) as in the regulation of blood 
pressure that is achieved via renin-angiotensin mechanism. Granular cells of the juxtaglomerular 
apparatus in the kidneys secrete renin which catalyzes the formation of angiotensin I from a 
plasma globulin, angiotensinogen. Angiotensin I is further converted into angiotensin II, a strong 
vasoconstrictor causing constriction of the blood vessels and subsequently increased blood 
pressure. Angiotensin II also contributes to the increase in blood volume by increasing water and 
sodium reabsorption via stimulation of aldosterone hormone [44, 46].      
 Moreover, renal corticointerstitial cells of the kidneys produce erythropoietin (EPO), 
which plays a vital role in maturation of erythrocytes in the bone marrow and other non-
homopoietic roles such as a neuroprotective agent in the response to neuronal injury in the brain 
[47] and in the wound healing process mainly by improving vascular perfusion [48]. Another 
function of the kidney includes the maintenance of calcium-phosphorus homeostasis. This is 
achieved via a complex interplay of various effector organs (the guts, kidney and bone) and 
hormones (parathyroid hormone, calcitonin and active vitamin D) – the kidney role in this 
process includes activation of vitamin D and excretion of phosphorus and calcium [45]. The 
diverse role of kidney is summarized in Table 2-1.  
Chronic kidney disease and end-stage renal disease 
Definition 
Chronic kidney disease (CKD) is defined as progressive, irreversible abnormalities in kidney 
structure and function, present for more than three months which has implication for health [49].   
Based on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical guidelines, CKD is 
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classified based on cause, glomerular filtration rate (GFR) category and albuminuria category 
[49]. Given the difficulties to accurately measures GFR in clinical settings, it is often estimated 
using mathematical calculation based on serum creatinine levels, demographic and 
anthropometric parameters [50]. Based on the estimated GFR (eGFR) patients with CKD are 
classified from G1 (normal/reduced kidney functions) to G5 (kidney failure). However, it should 
be noted that decrease in GFR alone is not an absolute criterion for kidney damage diagnosis but 
rather should be manifested by either pathological abnormalities or markers of kidney damage 
such as abnormalities in imaging test and composition of the blood and urine [49, 51]. Among 
individuals with CKD, one is typically considered as end-stage renal disease (ESRD) when GFR 
is severely reduced to <15ml/min/1.73 m2 (Table 2-2) and this is accompanied with clinical 
symptoms mandating the need for lifelong renal replacement therapy (RRT) to maintain survival.  
Incidence and Prevalence 
In the United States incident of end-stage kidney disease rose steadily since 1980 to 2001, but 
has leveled off since then to approximately 350 people per million population (pmp) [1]. When 
these data are compared to other well developed nations, ESRD incidents in the US range from 
twice to thrice as much of those in the United Kingdom, France, Denmark, Russia, New Zealand, 
Australia and most European countries (Figure 2-1).    
 In term of ESRD prevalence, United States continues to report one of the highest rates 
(1870 pmp), just behind Taiwan (2584 pmp) and Japan (2260 pmp). In contrast, other affluent 
countries such as the United Kingdom, Sweden, France and Australia have reported prevalences 
rate twice as low as in the US [1].  
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Etiology 
Uncontrolled underlying chronic diseases such as Diabetes Mellitus (DM) and hypertension are 
the most common causes of ESRD. Based on the United States Renal Data System, 41% of 
incident ESRD cases are due to DM (718 cases pmp), follow by hypertension (477 cases pmp), 
glomerulonephritis (274 cases pmp) and polycystic kidney diseases (92 cases pmp). 
Internationally DM is reported as a primary cause of ESRD in more than 60% of the new ESRD 
patients in Mexico, Singapore and Malaysia, while Russia, the Netherland, Norway and Romania 
reported rates below 20% [1]. Other rare causes include autoimmune disease (especially 
systemic lupus erythematous associated nephritis), tubular interstitial nephritis, drug toxicity and 
glomerular diseases caused by hepatitis B, C and HIV viruses.   
 Uncontrolled DM contributes to functional changes in glomeruli including hyperfiltration 
and hyperfusion, subsequently leading to histological alteration of the nephron, increasing 
capillary permeability to macromolecules characterized by micro and macroalbuminuria 
(>300mg/day). This is accompanied by structural changes including glomerular basement 
thickening and hypertrophy, as well as mesangial expansion leading to glumerolosclerosis and 
tubulointerstitial fibrosis. Metabolic processes such as hyperglycemia and hormonal mediators 
including glucagon and growth hormones are implicated in diabetic nephropathy, over time, 
leading to overt proteinuria, azotemia and culminating in ESRD [52].   
Treatment Modalities 
Patients with advanced CKD (stage G4/5) may eventually deteriorate to the degree that the 
remaining kidney functions are unable to keep them off from significant kidney failure 
symptoms. Some of the severe symptoms include excessive fluid overload leading to congestive 
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heart failure, severe nausea, vomiting, confusion/decrease alertness and seizures. Moreover, 
certain electrolytes such as sodium, potassium or bicarbonate could be dangerously elevated, 
affecting functionality of the organ. This is commonly occurring when eGFR is 
<15ml/min/1.73m2, however some patients might be more symptomatic at a higher eGFR [46]. 
Therefore, RRT is needed at this point to limit clinical symptoms and to maintain their survival. 
There are several options of RRT available including different forms of dialysis (e.g. 
hemodialysis, peritoneal dialysis) and kidney transplantation. In-center hemodialysis (HD) is the 
most common type of treatment modality in the US accounting for 98% of the total dialysis 
patient population [1]. 
 In HD procedure, patient’s blood is pump through semipermeable membrane dialyzer in 
the extracorporeal circuit, while dialysate (solution containing sterilized mineral ions, 
bicarbonate and glucose [53]) is flowing in the opposite direction of the blood flow (Figure 2-2-
B). Removal of waste solutes and fluid is achieved by the principle of hydrostatic pressure and 
diffusion across the concentration gradient. Because HD required permanent access to blood 
stream during each treatment, vascular access either via an arteriovenous fistula, arteriovenous 
graft or intravenous catheter has to be created. Patients undergoing in-center chronic HD 
treatment typically attend the clinic for three times a week for three to four hours per treatment. 
During HD procedure, blood is drawn out from the access route at a rate of 200-400 mL/min 
while patient is closely monitored for changes in blood pressure.  
  Meanwhile, peritoneal dialysis use similar principle as HD, except the fact that it uses 
the patient’s own peritoneum membrane to remove waste solute and fluids (Figure 2-2-A). In 
this process, a dialysate fluid is introduced into the abdominal cavity through a permanent 
catheter implanted in the abdomen. This dialysate fluid (containing sterile mineral ions, 
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bicarbonate and glucose) remains in the patient’s abdominal cavity (4-6 hours) to allow waste 
solutes to exchange across the concentration gradient before removal and replacement with new 
ones. This process is repeated at least four times a day for patients undergoing continuous-
ambulatory peritoneal dialysis treatment.  
 Kidney transplantation (Figure 2-2-C) offers a better prospect as compared to dialysis 
provided that the transplanted kidney functions successfully. However, RRT is still dominated by 
HD in large due to shortage of donor kidneys [54]. In this procedure, a compatible kidney from 
living/deceased donor is transplanted into the patient’s pelvis and connection is made into the 
artery and vein, including surgical incision of the transplanted ureter into the bladder. Patient 
receiving a kidney transplant needs to also rely on immunosuppression drugs to avoid rejection.        
Complications 
In CKD, as GFR is decreased the capacity to respond to the intake of minerals, water and other 
solutes become less flexible due to reduced number of functional nephrons, leading to the 
accumulation of solutes and water in the body. Compounds that are normally being excreted 
such as phosphates, sulfates, uric acids and hydrogen ions are subsequently retained in the body 
as the disease progresses. Retention of hydrogen ions results in metabolic acidosis, a clinical 
disturbance characterized by increased plasma acidity that could lead to disturbance of several 
organs system. In addition, toxic compounds such as phenols, guanidine, organic acids, indols, 
polyamines β2-microglobulin and some other trace elements will accumulate leading to 
hormonal deficiency and the inability to respond to stimuli (e.g. insulin resistance, 
eryhthropoietin resistance) [46]. 
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 Accumulation of blood urea and other toxic compounds that normally are being excreted 
by the kidney could leads to uremia. Uremia is a clinical syndrome due to imbalance of body 
fluids, electrolytes, hormones and metabolic abnormalities that occur following dysfunctional 
kidneys [46]. Some common signs and symptoms of uremia includes neural and muscular 
manifestation (e.g. fatigue, peripheral neuropathy, decrease mental acuity, anorexia and nausea, 
restless legs, cramps, decrease sense of smell and taste), endocrine and metabolic affects 
(amenorrhea, reduce body temperature, increased protein-muscle catabolism), while severe 
untreated uremia could lead to seizures, coma and cardiac arrest	  [54]. Uremia could also lead to 
oxidative stress and oxidation of macromolecules as evident by increased levels of reactive-
oxygen species (ROS), oxidized plasma proteins and lipids [55].  
 Anemia (as defined by hemoglobin levels ≤ 13g/dL for men and ≤ 12 g/dL for women 
[32]) is another common complication of ESRD. Hemoglobin <11 g/dL are often associated with 
lower quality of life and increased cardiovascular mortality and morbidity [56]. Anemia in CKD 
and ESRD patients has multifactorial physiopathology but it is generally accepted that it may 
occurs due to the decreased in erythropoietin production as result of the loss of functioning renal 
tubular mass. In dialysis patients, protein-energy malnutrition and chronic infection lead to 
erythropoietin resistance and anemia [57]. Inflammation could also affect mucosal absorption of 
ferum and trigger gastric bleeding which further exacerbates anemia in ESRD [58]. Anemic 
condition leads to prolonged fatigue, decreased immune functions and increased workload of the 
heart resulting in ventricular hyperthrophy, a risk factor for CVD[59]. Chronic anemic patients 
also experience fluid and sodium retention, high cardiac output and reduced oxygen carriage in 
the circulation [60]. Moreover, anemia could also induce a series of cardiovascular and 
neurohormonal compensations including increased plasma norephineprine, renin activity, 
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aldosterone, growth hormone and arterial natriuretic peptide that could have injurious 
cardiovascular complications in long-term [60].  
 Furthermore, ESRD patients often experience bone and mineral disorders characterized 
by hyperphosphatemia, hyperparathyroidism and systemic deficit in activation of vitamin D. A 
cascade of changes in the metabolism of calcium, phosphorus and vitamin D occurs following 
reduction of GFR leading to these disorders. As GFR is reduced, activity of 1α-hydroxylase 
enzyme declines, causing impaired conversion of vitamin D into its active form and subsequently 
limiting calcium absorption from the intestinal tracts. On the other hand, phosphorus levels in the 
blood are increased due to decreased renal tubular functions. Because vitamin D is also needed in 
suppression of the production of parathyroid hormones (PTH), reduced vitamin D levels (the 
active form) together with reduced serum calcium lead to overproduction of PTH in a 
counteregulatory action to release calcium from the bones store [61]. Ironically, increased in 
serum phosphorus levels (hyperphosphatemia) further exacerbate PTH production leading to 
hyperparathyroidism.    
 Although dialysis is an effective treatment to alleviate the adverse effect of uremia, some 
residual uremic toxins remain [62]. This is evidenced by high mortality rate, poor quality of life 
and high hospitalization rates in patients undergoing dialysis despite advancement in dialysis 
technology.  It has been estimated that more than 20% of ESRD patients undergoing HD 
treatment die due to uremia and treatment complications [20].  
ESRD main complication: cardiovascular diseases  
Cardiovascular disease (CVD) is a major complication affecting CKD and ESRD population. It 
has been estimated that cardiovascular death accounts for more than 50% of mortality in ESRD 
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patients undergoing HD treatment [19]. Common forms of CVD occurring in this population 
include acute myocardial infarction and several forms of atherosclerotic vascular diseases (e.g. 
chronic coronary artery disease, stroke and transient ischemic attacks)	  [5].  
 Atherosclerosis is an inflammatory process initiated by several factors including 
accumulation of LDLs in the artery wall [63, 64]. When plasma LDL levels exceeds certain 
threshold, they enter artery faster than they can be removed leading to their accumulation [63]. 
Because accumulated LDLs are prone to oxidation, the oxidative stress milieu in ESRD patients 
exaggerates the acceleration of atherosclerosis in part by modification/oxidation of LDLs [64]. 
The modified LDLs trigger endothelial cells to express a protein known as monocyte 
chemotactic protein-1 (MCP-1), which in turn attracts monocytes into the arterial wall and 
promotes their differentiation to macrophages. Macrophages engulf oxidized LDLs via their 
scavenger receptor and express several cytokines including tumor necrosis factor alpha (TNF-α), 
interleukin-1 (IL-1) which activates endothelial cells to express adhesion molecules (e.g. E-
selection, VCAM-1 and ICAM-1). Formation of lipid-filled foam cells following macrophages’ 
ingestion of LDLs and the binding of monocytes to the endothelium by adhesion proteins marks 
the beginning phase of atherosclerosis [63]. 
 Evidence from autopsy and clinical investigation has demonstrated that coronary artery 
plaques are highly prevalent in patients with advanced kidney disease [64, 65]. Figure 2-3 
summarizes the atherogenesis/ coronary artery plaque development processes. As reviewed by 
Stenvinkel et al [64], during the early phase of atheroma, prolonged inflammatory conditions and 
persistent dyslipidemia result in increased susceptibility to oxidation of lipids and other 
macromolecules.  Fatty streak is developed following recruitment of inflammatory cells and the 
accumulation of foam cells. Degradation of extracellular matrix occurs when the activated 
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leukocytes secreted proteinase, and proinflammatory cytokines stimulated T helper cell type 1 
(Th1) which could limit the synthesis of new collagen, thinning the fibrous cap and making it 
susceptible to rupture. When the rupture occurs, coagulation of the blood on the plaque caused 
the formation of thrombus and manifested as an acute coronary syndrome [64]. 
 Various factors have been postulated to be involved in the increased cardiovascular 
burden in ESRD as illustrated in Figure 2-4. Briefly, ESRD patients undergoing chronic HD are 
exposed to various conditions that increase the cardiovascular diseases burden including 1) 
underlying co-morbid conditions such as diabetes; 2) uremic residuals which triggers 
inflammatory modulation, heightened oxidative stress and influences appetite and food intake; 3) 
dialysis technique related factors that could worsen inflammatory responses and nutrient losses; 
4) undesirable outcome of dietary restrictions (e.g. limited intake of antioxidants due to 
restriction of certain fruits and vegetables) and 5) genetic factors and racial disparities (as 
reviewed by Kalantar-Zadeh & Balakrishnan [66]).  
Dyslipidemia 
A number of factors contribute to the accelerated atherosclerosis in ESRD population. One of 
them is dyslipidemia which in some studies reported the prevalence rate as high as 80% [67, 68]. 
Dysregulation of lipid metabolism in this population is characterized by hypertriglyceridemia, 
elevated very low-density lipoprotein (VLDL) and reduced plasma HDLC. Interestingly, plasma 
levels of total cholesterol and LDLC are usually within normal limits [15].  
 In normal metabolism, liver secretes TAG rich VLDL into the circulation. Lipoprotein 
lipase (LPL), an endothelial enzyme, converts TAG in VLDL into free fatty acid, allowing 
uptake and utilization by peripheral tissue. As VLDL loses its TAG content, it becomes 
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intermediate density lipoprotein (IDL) and eventually LDL that is rich in cholesterol. LDL 
delivers cholesterol to extrahepatic tissue for synthesis and maintenance of cell membrane. HDL 
on the other hand is involved in reverse-cholesterol transport system, by removing excess 
cholesterol from extrahepatic cells via several mechanisms. HDL acquires lipids by: 1) action of 
ATP binding cassette transporter A-1 (ABCA1) that mediate the transfer of phospholipids and 
some unesterified cholesterol; 2) lecithin cholesterol acyltransferase (LCAT) that converts free 
cholesterol on the surface of nascent HDL into cholesteryl ester before sequestering it into the 
core of HDL particle - this step is important to ensure maximum uptake of cholesterol from 
extrahepatic tissue and maturation of HDL particle. HDL can unload its cholesterol either 
through binding with SR-B1 for liver uptake/excretion in bile or by transferring it to VLDL/LDL 
in exchange of TAG, mediated by cholesteryl ester transfer protein (CETP) [63]. However, the 
indirect pathway (i.e. through CETP) is believed to be pro-atherogenic due to the transfer of 
cholesterol from HDL to the pro-atherogenic VLDL/IDL [63]. 
 In ESRD patients, despite having normal or even subnormal plasma total cholesterol, 
they are at high risk of atherosclerotic vascular diseases [69]. This is partly contributed by a 
delayed TAG rich lipoprotein catabolism which is illustrated in Figure 2-5. ESRD induced 
deficiencies of LPL that is responsible for removal of two-third of fatty acids content on VLDL 
for uptake by extrahepatic tissues [70]. This lead to accumulation of ApoB-containing 
lipoproteins (TAG rich) which are highly atherogenic because they are readily oxidizable and 
taken up by macrophages leading to formation of foam cells in the artery walls [69]. 
 Vaziri et al [18, 69] reviewed evidences to explain lower HDL particle and its cholesterol 
contents in ESRD. Based on these evidences, it is summarize that: 1) hepatic expression and 
production of ApoA1, which is the principal protein component of HDL particle is decreased; 2) 
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expression of acyl-CoA:cholesterol acyltransferase-1 (ACAT) is increased – this cause retention 
of cholesterol within the cells due to entrapment of free cholesterol from HDL uptake; 3) hepatic 
production and activity of LCAT is reduced; and 4) HDL uptake by the liver for removal and 
degradation occurs via HDL endocytic receptor (irreversible) instead of SRB1 (reversible). 
Several lines of evidence also indicate that activity of CETP is increased in this population [71]. 
CETP mediates the transfer of cholesterol ester from HDL to VLDL remnants in exchange for 
TAG. In summary, CKD/ESRD induces dyslipidemia which causes increased influx, impaired 
efflux leading to accumulation of lipids in the artery walls which is believed to accelerate 
atherosclerosis in this population.  
Malnutrition, inflammation, oxidative stress and their relation to CVD 
Malnutrition, inflammation and oxidative stress interlink has been recognized as the ‘evil axis’ 
for poor survival rates in dialysis patients [20]. This is based on the fact that up to two third of 
dialysis patients show evidence of protein energy malnutrition, chronic inflammation and 
increased oxidative stress. In fact, nutritional and inflammatory markers such as serum albumin, 
CRP and IL-6 have been identified as the strongest predictor for mortality and morbidity in this 
population [72, 73]. It is believed that there is overlap between malnutrition and inflammation in 
term of their mechanism and their relation to CVD in this population [74]. A brief discussion on 
each of these components follows: 
Malnutrition 
Malnutrition is highly prevalent in ESRD population. It has been reported that, malnutrition 
present in 18-70% of ESRD patients undergoing hemodialysis [75]. Various terms have been 
used to describe a syndrome of adverse changes in body composition, inadequate nutritional 
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intake, and loss of protein/energy stores in this population. These terms include malnutrition, 
protein-energy-malnutrition, malnutrition-inflammation-atherosclerosis syndrome, and uremic 
cachexia [75]. However, the International Society of Renal Nutrition and Metabolism (ISRNM) 
suggests the use of the term - protein energy wasting (PEW) - to describe concurrent losses in 
protein and energy stores and facilitate the diagnosis and identification of this condition [12].  
 Based on the consensus statement by ISRNM, the etiology of PEW in this population is 
multifactorial and not limited to insufficient dietary intake alone [12]. In fact, uremic milieu is 
speculated to be responsible for alteration in appetite-regulating hormone such as ghrelin, 
resulting in chronic anorexia [76]. Moreover, HD patients also experience 12 to 20% increase in 
resting energy expenditure related to HD procedure [77], or the presence of comorbidities. 
Hypercatabolism in this population is also linked to persistent inflammation. Inflammation 
contributes to PEW  by several mechanisms: 1) increase resting energy expenditure that triggers 
starvation response even in well-fed individuals [12, 78]; 2) pro-inflammatory cytokines such as 
tumor necrosis factor (TNF) and interleukin (IL) cause muscle protein breakdown [79] and act 
on the central nervous system to decrease appetite leading to anorexia [80]; and 3) the increase in 
positive acute phase protein (i.e. CRP) leads to decreases in visceral protein stores (e.g. by 
reducing synthesis and half-life of serum albumin) [81]. In addition, dialysis procedure itself is 
also catabolic in nature, contributing to PEW by causing nutrient losses, triggering inflammatory 
response and leading to loss of residual renal function [12]. Potential causes of PEW are listed in 
Table 2-3.  
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Inflammation  
Inflammation can be defined as a complex body response to injury [82], destruction of tissue or 
harmful stimuli characterized by production of cytokines (e.g. interleukins and tumor necrosis 
factor) which in turn stimulate secretion of acute phase protein (C-reactive protein). The initial 
reaction in response to damaging stimuli is normal; however, persistent inflammation is harmful 
as it may result in organ and vascular damage.  
 In ESRD population, inflammation is relatively an old problem that has been reported 
since 1980s [6]. However, only recently has chronic inflammation been recognized as an 
established risk factor that plays a central role in various co-morbidities especially CVD, PEW 
and is an independent predictor for mortality [6]. Pathophysiology of chronic inflammation in 
ESRD patients is complex due to its inter-twined relation with PEW, however each contributes 
independently to mortality risk [11]. Common causes of chronic inflammation that are 
traditionally reported include foreign body exposure (e.g. arteriovenous graft and dialyser), 
depletion of antioxidant, oxidative stress, and pre-existing co-morbid diseases [74, 83]. Some 
other causes include intercurrent clinical events (e.g. periodontal diseases) and dialysis related 
causes (e.g. infection of dialysis access and volume overload) as presented in Figure 2-6. 
 Pro-inflammatory cytokines have been postulated to induce and mediate the lean body 
mass catabolism in dialysis patients, however their exact role is not completely understood. One 
of the mechanisms proposed is through impairment of insulin signaling activity (e.g. suppression 
of insulin receptor-1-associated phosphatidylinositol 3-kinase activity) which subsequently leads 
to stimulation of ubiquitin-proteasome proteolytic system and activation of caspase-3 [84, 85]. 
Similarly, pro-inflammatory cytokines also suppress the expression and function of insulin-like 
21 
	  
	  
growth factor-1, which is an anabolic growth factor [86]. Moreover, IL-1 and TNF-α also have 
been shown to cause anorexia by acting on central satiety center, leading to suppressed food 
intake [85]. Taken together, pronounced catabolic effects of pro-inflammatory cytokines on 
muscle catabolism is due to combined suppression of food intake and increased protein 
breakdown which subsequently leads to overall poor nutritional status [85].   
Oxidative stress – the missing link 
Oxidative stress (OS) is defined as a state of imbalance between oxidant production and their 
degradation by antioxidant system which leads to accumulation of free radicals such as reactive 
oxygen species (ROS) and reactive nitrogen species (RNS). Over 90% of free radical production 
occurs during normal process of metabolism such as during metabolism of oxygen in 
mitochondria when oxygen that is being passing down the electron transport chain leaks away 
and turns into superoxide anion [87]. Additionally, ROS could be synthesized in phagocytic 
cells, at the vascular walls, and other tissues following exposure to a stimulus such as the 
presence of foreign particle or during inflammatory processes [14, 87]. When OS occurs, it 
results in oxidation of various macromolecules such as DNA, lipids and protein [11]. Oxidative 
modifications of lipoprotein particles especially LDL is thought to be an important step in the 
initiation of atherogenesis [63, 69].  
 In HD patients, OS has been recognized as an important factor that serves as a missing 
link between malnutrition and inflammation. OS is highly elevated in HD patients when 
compared to healthy-matched controls [88]. Impaired oxidative balance in HD patients is partly 
attributed to increased ROS production, reduced clearance, and poor antioxidant defense system 
[14]. Several lines of evidence support the notion that OS is linked to CVD based on the fact that 
oxidative modification of LDL, is the initial steps that triggers immune response. Oxidized LDL 
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instigates cascade of reactions including adhesion of circulating monocytes on endothelial cells, 
migration of monocytes into arterial intima and platelet activation, cytokines release and 
expression of tissue factor and by endothelial cells [14]. 
 There are several factors that contribute to the impaired oxidative balance in HD patients. 
These include the underlying disease itself, HD procedures, poor dietary antioxidant intake 
related to malnutrition and persistent inflammation. Evidence indicates that residual uremic 
solutes such as β2m, and homocysteine can become substrate for oxidative modification, thus 
potentiating their pathogenicity	   [11]. HD procedure on the other hand causes solute loss 
including enzymatic antioxidants. Furthermore, malnutrition condition, characterized by 
hypoalbuminemia also contribute to OS. This is because albumin molecules contain thiol groups 
that act as antioxidant in order to maintain plasma milieu in a reduced form. Therefore, 
diminished plasma albumin reduces overall plasma antioxidant capacity. Taken together, 
inflammation and malnutrition condition will have a synergistic effect on the risk of oxidative 
injury in this population	  [11].   
Standard of care for nutrition in HD patients 
Patients undergoing chronic HD require a comprehensive nutritional care given the fact that high 
prevalence of protein energy malnutrition (PEM) is largely contributed by inadequate nutritional 
intake [51]. The goal of the nutritional management for these patients is to maintain a good 
nutritional status through adequate energy, protein, vitamin and mineral intake while minimizing 
complications associated with uremia by maintaining blood chemistry within normal ranges [45]. 
It is also crucial to ensure patient’s adherence on fluid restriction, potassium and sodium intake 
in order to control edema and electrolytes imbalance, given the limited capacity of HD to 
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completely remove fluid and minerals. Often, nutritional management also considers  long term 
complications of HD such as bone mineral diseases (renal osteodystrophy) by monitoring 
phosphorus, calcium and vitamin D intake. All of these are achieved through carefully planned 
dietary regimens and periodic counseling from a renal dietitian.   
 Continuous monitoring of patient’s nutritional status is crucial in order to achieve these 
goals. This process includes assessment of visceral protein status, body composition and 
nutritional intake. The widely used clinical indicator for assessment of visceral protein store in 
HD patients is serum albumin. This is due to the fact that it is readily available and has been 
identified as an independent predictor for hospitalization and mortality [85]. Beside that, serum 
transferrin and prealbumin levels are also frequently used in monitoring nutritional status. It is 
important to note that serum albumin and prealbumin level can fluctuate based upon hydration 
status, infection, inflammation and trauma while ferritin can be influenced by changes in iron 
stores or the presence of inflammation. Since albumin and prealbumin are negative acute-phase 
reactants, it is common to measure C-reactive protein (an acute phase reactant) when their levels 
are low. Beside biochemical profiles, simple anthropometric measurements such as weight and 
BMI along with diet records are also used to monitor changes in body composition and 
nutritional status over time. Furthermore, the use  of composite indices comprised of diagnostic 
measures of body composition and dietary intake coupled with subjective assessment of overall 
well-being is also recommended [85]. One of the commonly used composite indices is 
Malnutrition-Inflammation Score (MIS). MIS is a quantitative scoring system that incorporates 
components relating nutritional status (BMI, serum albumin, serum total iron binding capacity, 
appetite and gastro-intestinal symptoms), functional status and comorbidity [89].   
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 Standard dietary recommendation for HD patients include energy intake of 35 kcal/kg 
body weight (for adult patients <60 years old) and 30-35 kcal/kg body weight for older adults 
(>60 years old), while protein intake should be at least 1.2 g/kg body weight with 50% of the 
protein being of high biological value. This is the maneuver to prevent protein-energy 
malnutrition and to meet the increase in requirement due to the catabolic nature of the HD 
treatment. Moreover, controlling mineral intake particularly sodium (<2.0 g /day), calcium (2.0 
g/day) and phosphorus (0.8-1.0 g/day) should also be emphasized in order to prevent acute 
complications and comorbidities. Standard of care for nutrition in HD patients is summarized in 
Table 2-4. 
Strategies to reduce CVD 
As discussed earlier, inflammation plays a central role in various comorbidities associated with 
ESRD including CVD. Carrero and Stenvinkel [6], have outlined treatment strategies in order to 
control inflammation and reduce the associated comorbidities (Figure 2-6). These multi-modal 
treatment approaches include medical, pharmacological, nutritional and life style interventions. 
First and foremost, comorbidities and potential dialysis related causes should be addressed and 
treated if possible. These include assessment and treatment for intercurrent illnesses such as 
periodontal disease and infectious complications of HD access.  
 When all of the medical issues have been addressed, it is recommended that various anti-
inflammatory strategies in the forms of pharmacological, physical and nutritional intervention be 
considered. Some of the pharmaceutical products reported to have immunomodulating properties 
include statins, pentoxifylline (a nonspecific phosphodiesterase inhibitor with anti-inflammatory 
properties) and angiotensin-converting enzyme inhibitor. Furthermore, given that majority of 
dialysis patients are physically inactive, resistance training and aerobic exercise could also be 
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introduced as several studies indicate beneficial results on inflammation [82, 90, 91]. From the 
nutritional standpoints, there are several nutrients that merit further investigation based on 
evidence from animal and human studies. These nutrients include omega-3 fatty acids, vitamin 
E, and soy isoflavones and genistein. The following discussion will focusing on the two nutrients 
that form the basis of this dissertation project, namely, omega-3 fatty acids and vitamin E 
tocotrienols. 
Potential nutritional agents to reduce co-morbid conditions:  
Omega-3 fatty acids 
Several different system of nomenclature exists for fatty acids.  One of the commonly used is n-x 
system (also known as omega-x), which is based on the location of the first double bonds 
counted from the methyl therminus. Thus a fatty acid that comprised of two or more double 
bonds, one of which is located three or six carbon positions from methyl terminus is called 
omega-3 or omega-6, respectively (Figure 2.3). In general, omega-3 fatty acids can be elongated 
from α-linolenic acid (C18:3) (ALA) to the longer chain fatty acids [eicosapentanoic acid (EPA) 
(C20:5)].  EPA can be further elongated into docosahexanoic acid (DHA) (C22:6) in the 
peroxisomes via several complex steps. Because enzymatic conversion of ALA into EPA and 
DHA is limited in human, this necessitate reliance on dietary sources in order to maintain 
adequate levels of EPA and DHA [92].  
Dietary sources and dietary intake recommendation 
In the US, average dietary intake of omega-3 fatty acids is about 1.6 g/day or equivalent to 0.7% 
of total energy intake [93]. Major dietary source of omega-3 ALA include vegetable oils such as 
soybean, rapeseed, flaxseed and also walnuts. EPA and DHA are predominantly from cold-water 
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fish with varying concentration among species depending on environmental factors and whether 
the fish is farm-raised or wild.  Some of the rich sources of EPA and DHA include sardines, 
Atlantic salmon, and pacific herring which provide more than 1g per serving size (3 oz.) [94].  
 Currently, there is no reference for normative range for blood and tissue concentration of 
omega-3 fatty acid. Nevertheless, American Heart Association has established evidence-based 
guidelines which recommends individuals with documented heart disease to consume about 1g/d 
of EHA+DPA [32, 92].  In the nephrology practice, there is no consensus renal dietary 
recommendation for omega-3 fatty acid intake, however the recent NKF KDOQI guidelines 
recommend for further study to identify the essential fatty acid status in CKD patients [95].  
Absorption and transportation 
Absorption and transportation of omega-3 fatty acids follow the same route as other long-chain 
fatty acids. Upon absorption by intestinal cells, they are resembled into TAG and packaged into  
chylomicrons,  which are then transported into the thoracic duct via the lymphatic system and 
subsequently enter the blood stream for distribution to tissue and finally to be taken up by the 
liver. 
Epidemiology and observational studies in general population 
Earlier epidemiological studies from various population such as Greenlandic Eskimos [96] and 
Japanese coastal fishing village residents [97] indicate that higher fish intake were associated 
with lower risk for cardiovascular diseases.  In the Nurses Health Study, fish intake and omega-3 
fatty acids have been reported to have an inverse association with coronary heart disease (CHD). 
Women who consumed fish 1 to 3 times per month, once per week, 2 to 4 times per week and >5 
times per week had lower risk of CHD death (21%, 29%, 31% and 34%, respectively) when 
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compared with women who rarely ate fish  (less than once per month) [98]. Some 
epidemiological studies however failed to demonstrate any beneficial association of fish 
consumption and CHD / cardiac mortality including Health Professional Follow-up Study 
[99]and the US Physician Health Study [100]. It is speculated that the different in the outcome of 
these studies are due to differences in experimental design, dietary intake estimation, study 
population and variability in the end point studied [94]. It is however beyond the scope of this 
dissertation to discuss literature in the non-kidney disease population. Therefore, the following 
discussion is streamlined towards omega-3 research in dialysis population.   
Omega-3 fatty acids status in dialysis patients  
Recommendation for omega-3 fatty acids supplementation in dialysis patients is stemmed from 
the fact that omega-3 intake in dialysis population is much lower as compared to healthy control, 
partly due to monotony of their diet [32, 92] and non-palatable in taste because of uremia 
associated taste alteration	   [92, 101].  This is also supported by the fact that levels of omega-3 
PUFA plasma and cell membranes of HD patients is significantly lower as compared to healthy 
subjects	  [31, 102].  Furthermore, HD patients who are fish eaters have been shown to have much 
lower mortality as compared to their counterpart	   [92]. In term of its cardiovascular effects, 
omega-3 has been shown to possess lipid altering properties (especially in reducing TAG), 
improved inflammatory markers and improve endothelial function related to its anti-thrombotic 
properties	  [103, 104]. 
Therapeutic effects of omega-3 fatty acids: lipid altering 
The mechanisms involved for the observed effects of omega-3 fatty acids with regards to cardio 
vascular health is not clearly understood [94]. The potential mechanism by which omega-3 
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confers cardio-protective effects is summarized in Table 2-5. The most established effect of the 
omega-3 fatty acids is as a hypotriglyceridemic agent. Majority of the studies reviewed in this 
dissertation reported somewhat effects of omega-3 on lipid profiles with supraphysiologic 
omega-3 supplementation [29, 105, 106] (Table 2-6). In a longitudinal study by Schmitz and 
colleague, 4g daily of fish oil (80% of which containing omega-3 fatty acids) supplementation 
resulted in 53% reduction in TAG after 3 months of the supplementation [105]. In another study, 
Khajehdehi and colleagues reported that supplementation with 2g omega-3 per day in HD 
patients resulted in significant improvement in TC/HDLC, LDLC/HDLC and TAG/HDLC ratios 
[29]. Taken together, in hemodialysis patients, there is consistent evidence indicating the 
effectiveness of omega-3 supplementation on lipid profiles. This is also in concert with a 
comprehensive review of human studies showing that the supplementation of ~ 4g/d of omega-3 
fatty acids from fish oil reduced TAG by 25 to 30 percent [104] .  
 Based on the mechanistic study, it is reported that omega-3 fatty acids can modulate two 
important component in lipid homeostasis, namely peroxisome proliferator-activated receptors 
(PPARs) and sterol regulatory binding protein (SREBP) [107]. This is partly explained due to 
omega-3’s ability to inhibit SREBP conversion from its inactive to active form, affect cellular 
composition of the membrane, and bind to PPAR-α and –γ which promote β-oxidation and 
adipogenesis [107]. 
Therapeutic effects of omega-3 fatty acids: anti-inflammatory 
Inflammation plays a central role in the accelerated atherosclerosis in HD patients. Friedman and 
Moe [92] reviewed several literatures available with regards to omega-3 fatty acids effects in HD 
patients, including on inflammatory markers – some of these studies are presented in Table 2-6. 
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In a case-control study involving 42 HD patients and 16 age-, gender-matched healthy control, 
supplementation with 2.4 g omega-3 fatty acids resulted in reduction of the inflammatory 
markers (TNFα and IL-6) [106].  Similarly, Saifullah and colleagues demonstrated that 
administration of omega-3 fatty acid with modest dose (1.3 g/day) resulted in 24% reduction in 
CRP, a surrogate marker for CVD [108]. In fact, reduction in CRP levels has been found to be 
independent of TAG reduction after 6 month of fish oil supplementation using 2 g fish oil daily 
(containing 1.6 g omega-3 fatty acids) [109]. However, in a systematic review of all fish 
oil/omega-3 fatty acid supplementation in human, it appears that omega-3 fatty acids is 
ineffective in reducing inflammatory markers [110].  This however has been criticized due to the 
inclusion of studies with relatively small number of subjects in healthy population [108], while it 
is generally accepted that the effect of supplementation would be more apparent in population 
with heightened inflammatory response such as in HD patients.  
Mechanistic explanation of the anti-inflammatory effects of omega-3 fatty acids is 
illustrated in Figure 2-8. It is known that arachidonic acid (omega-6 fatty acid) can be converted 
into eicosanoid products (e.g. prostaglandins, leukotrienes, thromboxanes, lipoxins and 
epoxyeicosatrienoates) via cyclooxygenase, lipoxygenase, or cytochrome P450 arachidonic acid 
monooxygenase. Some of these arachidonic acid-derived eicosanoids promote platelet 
aggregation, vascular permeability, vasoconstriction and cytokines release; hence their pro-
inflammatory and pro-thrombotic properties are implicated in the pathogenesis of CVD [92].  
Because omega-3 fatty acids can incorporate into cell membrane phospholipids, this results in 
reduced content of arachidonic acid in the cells. As arachidonic acid is reduced, there is limited 
amount of substrate available for the synthesis of pro-inflammatory eicosanoids. In other words, 
omega-3 fatty acids exert their anti-inflammatory effects by competing with omega-6 fatty acids 
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for the incorporation into the cells and for the enzymes involved in the eicosanoids synthesis 
[92]. Moreover, in HD patients, there is a line of evident indicating that the metabolism of 
arachidonic acid is shifted from cyclooxygenase pathway to the lipooxygenase pathway, leading 
to producing a relatively more pro-inflammatory leukotrines [111]. Therefore, higher levels of 
omega-3 fatty acids particularly EPA and DHA could block the lipooxygenase pathway of 
eicosanoid production leading to less inflammatory eicosanoids [106, 111]. Reduced pro-
inflammatory eicosanoids may alleviate inflammation by decreasing production of 
proinflammatory cytokines, and cell surface molecules such as intercellular cell adhesion 
molecules (ICAM) and vascular adhesion molecules (VCAM) that play a critical step in foam 
cell formation in the atherogenesis process [92, 112].  In summary, the molecular aspect of 
omega-3 fatty acids action on inflammatory response is well understood, however, this is yet to 
be translated into a positive outcome in clinical population.  
Potential nutritional agents to reduce co-morbid conditions:  
Vitamin E tocotrienol 
Vitamin E is a group of compounds that possess a chromanol ring with a long chain attached to 
its 2-position. There are eight known naturally occurring vitamin E isomers namely α-, β-, δ-, γ- 
tocopherol (TT) and tocotrienols (TP) that differ in the number and position of methyl group in 
the chromanol ring (three methyl groups in α- isoforms; two methyl groups in β- and γ- isoforms; 
one methyl group in δ- isoforms). Vitamin E is a generic term used to describe all TT and TP 
isomers that qualitatively exhibit the biological activity of α-tocopherol. TT and TP exhibit 
similar chemical structures except the fact that TT possess a farnesyl (unsaturated chain) rather 
than a saturated isoprenoid C16 chain [113], characterized by the presence of three trans double 
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bonds (Figure 2-4). This explained the fact that TT has greater fluidity and superior cell 
accessibility thus confers a distinct biological activity than TP [34, 114].  
Dietary Sources 
Natural sources of vitamin E are lipid-rich plant products and vegetable oils. The plants 
accumulate vitamin E in oily seeds and fruits to prevent lipid peroxidation and protect from 
oxygen toxicity [113]. TP are widely available at high concentration in many type of fruits and 
vegetable (>0.5mg/100mg edible portions) while TT are limited to certain fruits and vegetable at 
a level that usually less than 0.1mg/100mg edible portion [115]. A good sources of TT can be 
found in cereal grains such as oat, barley and rye, while the richest natural sources of TT are 
found in annatto, palm and rice bran oil [33, 34, 116] (Figure 2-10). Given that, TP particularly 
γ-TP is the most abundant vitamin E in the US diet [117]. 
Absorption and transportation of vitamin E 
Absorption mechanism of all vitamin E isomers are fundamentally similar as in other lipid 
molecules (reviewed in Rigotti 2007 [118]). Upon digestion, vitamin E is incorporated into 
mixed micelles and taken up by enterocytes. The uptake of vitamin E from the mixed micelles is 
hypothesized to occur via a simple passive diffusion as well as through intestinal scavenger 
receptor class B type I (SR-B1) [118]. However, the detailed cellular mechanism for intracellular 
trafficking of vitamin E is remained to be elucidated [118]. Once in the enterocytes, vitamin E is 
packed into chylomicron and secreted into the lymphatic system. Several studies indicate that 
there is no selective preferential between TP and TT forms – they are absorbed and secreted into 
chylomicrons in similar proportion of those occurring in the diet [118, 119]. Anwar and 
colleague [120] demonstrated that, an alternative pathways of intestinal vitamin E absorption 
32 
	  
	  
exist – this is occur through HDL-dependent mechanism in which vitamin E is directly secreted 
by intestinal epithelial cells into HDL. It is important to note that there is interindividual 
variability in intestinal absorption of vitamin E which range from 20 to 80%. This is partly due to 
intrinsic differences in expression and activity of SR-B1 and ABCA1, and influenced by the 
amount and quality of dietary fat in a meal [118, 121, 122]. Lipoproteins are the major 
transporter of lipid soluble antioxidants including vitamin E.  Following a meal, chylomicrons 
deliver vitamin E to the liver parenchymal cells, while LDL and HDL transport most of vitamin 
E under fasting condition for hepatic uptake [118].  
Regulation of vitamin E concentration 
Biological half-life of TT is relatively shorter than TP (by 4.5 to 8.7 fold); α-, γ-, δ-TT have 2.3, 
4.4 and 4.3 hours, respectively vs 20 hours for α-TP [33, 123]. This is explained by the fact that 
following hepatic uptake of vitamin E, there is selective preferential for α-TP to being re-
secreted into the plasma due to differential affinity for various vitamin E forms in α-Tocopherol 
Transfer Protein in the following order: α-TP (100%) > α-TT (12%) > γ-TP (9%) > δ-TP (2%) 
[124, 125].  
 Since TP discovery some decades ago by Evans & Katherine Bishop, a vast majority of 
studies have been focusing on the therapeutic role of TP [33]. The other forms of vitamin E 
compound is remained poorly understood in part due to the abundance of α-TP in human plasma 
and lack of bioavailability of the other vitamin E isomers [113]. However, TT have recently 
gained increasing scientific attention as current research indicates that they possess a different 
therapeutic role than TP due to their eminent anti-oxidative, neuroprotective, anti-
hypercholestrolemic and confers a distinct molecular target [33, 34, 113]. The following 
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discussion will be emphasizing on TT.  Potential therapeutic effects of TT are summarized in 
Table 2-7. It should be noted that, a vast majority of the literature pertaining to the clinical 
intervention of vitamin E in HD population are in the form of TP supplementation – this is 
summarized in Table 2-8. 
Therapeutic effects of tocotrienol: Antioxidant 
Imbalance between the generation of reactive species and antioxidant defense system lead to 
oxidative stress and subsequently macromolecules damage including DNA, lipids and protein 
[11]. Oxidative stress has been shown to involve in the pathogenesis of various chronic diseases 
such as cancer and atherosclerosis. As reviewed earlier in this chapter, oxidized LDL play an 
important role in the development of atherosclerosis, by attracting accumulation and 
differentiation of monocytes, followed by massive deposition of cholesterol and formation of 
lipid-filled foam cells on the artery wall. The differentiated monocytes (i.e. macrophages) in turn 
express various cytokines which trigger the inflammatory response. Therefore, it is postulated 
that antioxidant including vitamin E tocotrienol can prevent DNA damage and lipid peroxidation 
by neutralizing free radical and halt further propagation of atherosclerosis [34].   
 It is well established that, TT, as TP, exhibit antioxidant activity due to phenolic group in 
the chromane ring which neutralizes peroxyl radicals by conversion to relatively stable phenoxyl 
radicals [126, 127]. These less reactive radicals can be reduced back to its original form by 
vitamin C or other thiol antioxidants [116].   However, Yu et al [128] reported that 
polyunsaturated phytol side chain of TT also exhibit antioxidative activity. Furthermore, TT also 
has a higher recycling efficiency from chromanoxyl radicals due to its position closer to the 
membrane surface area as demonstrated in the study using nuclear magnetic resonance 
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spectroscopy [129]. This is consistent with other reported publication that TT have a superior 
antioxidant activity when compared to TP [36, 129, 130]. For example, in vitro experiment 
demonstrated that that α-TT is 40 times more effective against lipid peroxidation in rat liver 
microsomal membranes and is 6.5 times more efficient in protecting cytochrome P-450 from 
oxidative damage when compared to α-TP [34, 36]. In vivo, TT has been shown to be at least as 
equally effective as TP considering physiological processes (e.g. absorption, distribution, 
metabolism and excretion) that may limit its antioxidative properties [116]. Recent study using 
type-2 diabetic rats supplemented with tocotrienol-rich fractions (TRF) showed that the activity 
of antioxidant enzymes (i.e. superoxide dismutase, glutathione peroxidase) were restored and 
malondiadehyde (MDA), an oxidative stress marker, were reduced when compared to the 
untreated group. The antioxidant activity of TT has been postulated to confer protection against 
diabetic nephropathy in these rats [131]. 
 In human, data on the antioxidative role of tocotrienols in chronic diseases is scarce. In a 
study by Chin and colleagues, supplementation with 160 mg of TRF for 6 months in healthy 
adults failed to improve erythrocyte antioxidant enzymes (i.e. superoxide dismutase and 
glutathione peroxidase) and MDA levels [132]. In summary, despite a clear anti-oxidative effect 
of TT has been shown in cell and animal studies, this has yet to be demonstrated in clinical 
population.  
Therapeutic effects of tocotrienol: Anti-inflammatory properties  
As discussed earlier, inflammatory mediator such as cytokines are implicated in the development 
of atherosclerosis in part by promoting expression of cell adhesion molecules and generation of 
free radicals [11, 64]. Therefore, dietary compound possessing anti-inflammatory properties such 
as TT has received a greater scrutiny recently.  TT has been shown to reduce arachidonic acid, a 
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primary substrate for the synthesis of pro-inflammatory eicosanoids, in hereditary 
hypercholestrolemic swine [133]. In a recent systematic review by Frank and colleagues, they 
illustrated that TT could alleviate pro-inflammatory eicosanoids from arachidonic acid based on 
two pathway; 1) through inhibition of glutame-induced production of   phospholipase A2, which 
is the enzyme that catalyzes production of arachidonic acid from the cell membrane 
phospholipids, and 2) through inhibition of cyclooxygenase-2 and c-Src kinase resulting in 
reduced production of pro-inflammatory eicosanoids (Figure 2-11) [116]. This is also consistent 
with the lowering of the ‘end-point’ of the eicosanoid products such as TNFα, and interleukins in 
lipopolysacharides-induced human monocytic cells following incubation with TRF [37]. 
Moreover, several lines of evidence suggest that TT could block activation of NFκB [37, 134], a 
family of transcription factors that plays a central role in regulation of genes critical for 
inflammation and immunity. Interestingly, such effects were not seen with TP [134].  
In hemodialysis population however, there is no study on TT as yet. Nevertheless, several 
studies in general population indicate a positive effect on inflammatory markers. In a study by 
Heng et al [135], subjects were recruited based on two different age group (young adults with 
average age of 32 and old adults with average age of 52), and TRF was administered for 6 
months. They found that TRF supplementation in older adults resulted in lower CRP levels, 
which has been regarded as a prognostic indicator for cardiovascular events and mortality in 
ESRD patients [6, 7].  
Therapeutic effects of tocotrienol: Lipid altering properties 
TTs have been consistently demonstrated in the literature to possess lipid altering effects 
especially in cell and animal studies. In a study using chicken, TC and LDL-C levels were 
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reduced by 22% and 52%, while HDLC-LDLC ratios were improved by 123-150% in the animal 
that were fed a small doses of tocotrienol-rich fraction for four weeks [136]. Furthermore, the 
same authors also indicate that each of the TT isomer has variable impact on the serum lipids, 
with γ- and δ-TT considered as the most potent. In the experimentally induced hyperlipidemic 
rats, supplementation with a range of TRF concentration resulted in decreased in lipid parameters 
(TAG, LDLC) in dose-dependent manner with the optimum dose identified at 8mg TRF/kg/day 
[137].  
 It is generally accepted that the hypocholestrolemic effect of TRF can be explained by 
suppression of mevalonate pathway that serves as the basis for cholesterol biosynthesis. Sterol-
inhibitory activity of TT is contributed by the side-chain unsaturation with ability to increase 
cellular farnesol which signals the proteolytic degradation of HMG-CoA reductase (HMGR), a 
rate-limiting enzyme of the cholesterol biosynthetic pathway [34, 138]. Therefore this lipid 
altering properties is unique for TT but not TP. Furthermore, in cell study, Song & Debose-Boyd 
[139] mechanistically explained that δ-TT suppressed cholesterol biosynthesis by stimulating 
ubiquitination and degradation of HMGR, and blocks processing of sterol regulatory element-
binding protein (SREBPs), the transcription factors that involved in synthesis of enzyme 
involved in sterol biosynthesis. They also showed that TP neither accelerate HMGR degradation 
nor block SREBPs processing, in concert with the notion that lipid-altering effect is the unique 
properties of TT. Another mechanistic study from HepG2 liver cell line, hycholesterolemia 
induced-mice and borderline hypercholestrolemic patients summarized that the lipid lowering 
effect of TT, particular γ- and δ- are due to: 1) suppression of the upstream regulators of lipid 
homeostasis genes (i.e. ApoB100, SREBP, HMGCR and diaclyglycerol O-acyltransferase 2) 
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resulting in reduced TAG, cholesterol and VLDL biosynthesis; and 2) enhancement of LDL 
efflux via induction of LDL receptor expression [140].  
 However, the effects of TT particularly in lipids in human are rather ambiguous. In a 
double-blind, cross-over clinical study, Qureshi and colleagues demonstrated that 
supplementation with TRF in hypercholestrolemic human subject resulted in 31% decreased in 
serum cholesterol during 4 week period when they were given 200mg γ-TT/day as compared to 
the time when the same subjects were given 300mg corn oil/day [141]. Furthermore, the same 
authors demonstrated that TTs supplementation in patients who took statins reduced statins-
related side effects [142]. On the other hand, Mensink et al [143] provided TRF supplementation 
(140mg TT, 80mg TP per day) to 20 men for 42 days showed no improvement in lipoprotein 
profiles despite changes in plasma TP and TT concentration. Similarly, administration of 200mg 
TT/day for 28 days in healthy hypercholestrolemic volunteers failed to show any effects on 
blood lipids [144]. In a dose escalation study involving 32 normal healthy men, supplementation 
with variable doses of TRF ranged from 80mg/day to 320mg/day also did not showed any 
changes in lipid profiles [145].   Taken together, the lack of consistency in human results may be 
due to: 1) variability in absorption of TT (e.g. with meal/ without meal); 2) different in doses; 
and 3) different clinical population [35]. Table 2-9 summarized studies reporting the global 
effects of TT supplementation (lipids, inflammation and anti-oxidative effects) in healthy 
volunteer. As of now, there is no study reporting the effects of TT supplementation in HD 
patients.  
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Applying metabolomics for nutrition research in ESRD population 
Metabolomics definition 
‘Omics’ is a general term referring to interdisciplinary system biology to denote studies on a 
large-genome wide scale including genomics, transcriptomics, proteomics, and metabolomics. 
The ‘omics’ science has emerged since several decades ago, much attention has been focused on 
sequencing the human genome and annotating the human proteome; however, the current focus 
is on its application in finding a novel insight to understand the processes in cellular metabolism 
in relation to health and diseases [146, 147].  
 Metabolomics is the latest of the omic sciences that utilized cutting edge analytical 
instruments to quantitatively measures metabolites and detect their changes in biological fluids 
and tissues in conjunction with pattern recognition approach and bioinformatics [147]. In other 
words, metabolomics approach in human scrutinize the human metabolome – that is the 
complete collection of human metabolites comprising of a diverse small molecules chemical 
entities such as peptides, amino acids, nucleic acids, carbohydrates, vitamins, drugs and organic 
acids that are part of biochemical and cellular processes or can be ingested by humans [146]. 
Because of a diverse role of metabolites in serving as building block of various macromolecules, 
fueling all cellular processes, and acting as messengers and buffers in intracellular/extracellular 
events following environmental insults, they together with genome and proteome define what 
and who we are [146].  
 However, in contrast to the genome and proteome, metabolome is not well defined due to 
the fact that it does not dictate by the genome alone because it can be affected by various factors 
such as environmental insults (exogenous factor) or even the indigenous microflora in the gut 
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(endogenous factor) [146, 148]. For example, a disease process altered biochemical imbalance in 
the body that is transpires in peculiar metabolites that can be measured in biological fluids and 
tissues. On the other hand, organism’s genome is constant while the change in transcriptome and 
proteome does not always translate as phenotypic alteration. Given that, compared to the other 
omics platform, metabolomics has a greater potential to impact clinical health practices due to 
the fact that metabolites represent integrative information of the phenotype in response to genetic 
and environmental changes [149]. Taken together, a comparative analysis of metabolite profile in 
disease vs non-disease states enable disease etiology, stages of progression and diagnostic 
biomarkes to be ascertained [149], exemplifies its application in clinical medicine for prognostic 
or  predictive interpretation of the disease status.  It is important to note that despite a number of 
advantages offer by metabolomics over conventional analyses, our knowledge on the 
composition of the metabolome is currently  incomplete [150], thus may limit overall application 
in understanding the disease pathophysiology,  diagnosis and treatment. 
Metabolomics methodology 
Metabolomics comprised of two generalized experimental strategies namely: 1) non-targeted 
metabolic profiling and 2) targeted metabolic profiling [150]. Non-targeted metabolites profiling 
is referring to a holistic study, an unbiased approach of data analysis without prior knowledge 
about the data set/ the represented metabolites. This approach usually leads to discovery of new 
ideas on the disease process, hypothesis-generating and a potential new ways of diagnosis [146, 
150].  
However, potential issues arise with the non-targeted metabolite profiling / pattern 
recognition is the fact that metabolic profile may not be specific to a disease condition while 
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confounders may not be accounted for, leading to problems in understanding the overall disease 
process [151, 152]. Therefore, a second strategy, a targeted metabolite profiling is often used to 
focus on quantitative changes of metabolite of interest with priori knowledge pertaining to their 
involvement in the disease process. This closed profiling approach is also being used to validate 
a biomarker after it is being discovered [152].  
One of the common multivariate data analysis uses for metabolomics is a principle 
component analysis (PCA). In PCA, a new smaller set of uncorrelated variables, known as 
principle component (PC) is formed from a large set of related variables (e.g. NMR spectra from 
the plasma of HD patients), which represent the largest variation from the original data set. 
Using a multidimensional space, each of this PC is compared on a score plot, in which one score 
representing one observation (i.e. NMR spectrum from the respective individual). The 
contribution of each variable to the PC can also be calculated and visualized as a loading plot. 
Loading plot indicates variables (i.e. a part of the NMR spectrum) that responsible for the 
clustering and separation that correspond to the score plot [153].  Other statistical algorithm such 
as partial least square (PLS) is also commonly used when analyzing human metabolome. Unlike 
PCA, PLS is a supervised method of analyses which is an extension of PCA in which Y variables 
are added to connect with the information provided by X variables. Y variables represent 
additional information of the data set such as different group of intervention (intervention vs 
placebo) or different time of measurement (e.g. baseline vs end of study), biochemistry or 
clinical data [154]. In other words, PLS method helps to identify correlation between the 
measured bioassay (y-axis) with NMR spectra data (x-axis).  PLS-discriminant analysis (PLS-
DA), another method that commonly used, is a modification of PLS. PLS-DA is focused on 
maximum separation (discrimination) rather than maximum variation [155]. 
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Metabolites profiling by nuclear magnetic resonance spectroscopy 
Analytical tools that are available for metabolomics study are nuclear magnetic resonance 
(NMR) spectroscopy, and mass spectrometry (MS) such as liquid chromatography-MS (LC-MS) 
and gas chromatography-MS (GC-MS). GC-MS and LC-MS are robust and mature technology 
offering superb sensitivity in detecting metabolome [146]. However, both of the latter techniques 
have some drawbacks including relatively slower process, requires sample preparation/ 
separation (GC-MS), sample not recoverable (both LC-MS and GC-MS) and may suffer from 
alteration due to sample collection and handling, hence requiring stringent quality assurance 
[152].  On the other hand, NMR is more of a favorite tool for metabolomics due to its ability to 
provide a high resolution spectra, requires relatively less sample preparation hence more rapid 
analysis and more importantly non-destructive to the sample [146].  NMR techniques is based on 
the properties of the magnetic spin of the nuclei to determine chemical structures and 
concentration of a compound, thus nuclei having odd spin number such as 1H, 13C, 31P and 15N 
are commonly used. However, it is important to note that, the number of metabolites detectable 
using NMR techniques is relatively smaller when compared to LC-MS or GC-MS partly due to 
dependency on the magnetic strength to detect the chemical shift for metabolite identification, 
throughput and sensitivity [152].  
Metabolomics application   
Metabolomic approach has been used in various field including cancer, diabetes mellitus, and 
cardiovascular diseases. In cardiovascular research, metabolomics is used predominantly in 
elucidating etiology and identifying various biomarkers in the diseases pathophysiology [152].  
Sebatine and colleagues demonstrated that a non-targeted approach of metabolomics were able to 
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differentiate the metabolomics profiles of those who had clear-cut inducible ischemia than those 
who did not (all patients underwent stress test for evaluation of possible myocardial ischemia) 
[156]. This has allowed them to analyzed metabolic disturbance before and after stress testing to 
identify potential novel biomarkers of coronary ischemia. Patients with clear-cut inducible 
ischemia showed abnormality in the levels of gamma aminobutyric acid, uric acid, citric acid and 
some other unidentified metabolites [156].    
As far as ESRD patients is concerned, there are very limited studies that utilized the 
metabolomics approach to study the disease process or potential biomarkers identification to help 
in diagnosis and treatment. Recently, Ando and colleagues conduct an explorative study to assess 
metabolic response in ESRD patients undergoing chronic HD in a time course manner - before, 
during and after the HD treatment using plasma and dialysate sample using 1H NMR 
spectroscopy [157].  They found a good correlation of creatinine in the plasma and dialysate 
which indicating that dialysate solution could be used as a non-invasive measurement of 
metabolic profile in HD patients in the future. Interestingly, they also found that additional 
metabolites were formed during HD procedure [157], suggesting the catabolic effect of the HD 
treatment.  
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TABLE 2-1. Overview of kidney functions 
Function Descriptions 
Waste elimination • Removal of metabolic waste products (urea, creatinine, uric 
acid) 
• Elimination and detoxification of drugs and toxins 
Fluid balance • Involve in removal and reabsorption of water to maintain fluid 
balance (via action of antidiuretic hormone, atrial natriuretic 
peptide, aldosterone) 
Acid-base regulation • Involve in secretion, excretion and reabsorption of H+, HCO3-, 
NH4+, PO4++ to maintain blood pH 
Electrolytes balance • Involve in excretion and reabsorption of electrolytes such as 
sodium, potassium, chloride, and bicarbonate to maintain 
homeostasis. 
Mineral metabolism • Control of mineral metabolism through endocrine synthesis 
(1,25-dihydroxycholecalciferol and 24,25-
dihydroxycholecalciferol) and excretion of phosphorus. 
Endocrine functions • Regulation of systemic blood pressure (renin, angiotensin, 
prostaglandin, nitric oxide, sodium homeostasis) 
• Production of erythropoietin 
Metabolic process • Regulation of metabolic processes (gluconeogenesis, lipid 
metabolism) 
• Degradation and catabolism of peptide hormones (insulin, 
glucagon, parathyroid hormone) and low molecular weight 
protein (β2-microglobulin and light chain) 
(Adapted from Himmelfarb et al 2010 [46]) 
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TABLE 2-2. Current CKD staging based on GFR used by KDIGO 
GFR Category GFR (ml/min/1.73 m2) Terms 
G1 ≥ 90 Normal or high 
G2 60-89 Mildly decreased* 
G3a 45-59 Mildly to moderate 
G3b 30-44 Moderately to severe 
G4 15-29 Severely decreased 
G5 <15 Kidney failure 
(Source: KDIGO, 2012 [49]) 
 
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate 
* Relative to young adult level 
In the absence of evidence kidney damage, neither GFR category G1 nor G2 fulfill the criteria for CKD 
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TABLE 2-3. Potential causes of protein energy wasting in CKD/ESRD population. 
Causes Notes 
1. Decreased protein and 
energy intake 
a.Anorexia 
  - Dysregulation in circulating appetite mediators 
  - Hypothalamic amino acid sensing 
  - Nitrogen-based uremic toxins 
b.Dietary restrictions 
c.Alterations in organs involved in nutrient intake 
d.Depression 
e.Inability to obtain or prepare food 
 
2. Hypermetabolism a.Increased energy expenditure 
   - Inflammation 
   - Increased circulating proinflammatory cytokines 
   - Insulin resistance secondary to obesity 
   - Altered adiponectin and resistin metabolism 
b.Hormonal disorders 
   - Insulin resistance 
   - Increased glucocorticoid activity 
 
3. Metabolic acidosis  
4. Decreased physical activity  
5. Deceased anabolism a.Decreased nutrient intake 
b.Resistance to GH/IGF-1 
c.Testosterone deficiency 
d.Low thyroid hormone levels 
 
6. Comorbidities and lifestyle Comorbidities (diabetes mellitus, CHF, depression, 
coronary artery disease, peripheral vascular disease) 
7. Dialysis a.Nutrient losses into dialysate 
b.Dialysis-related inflammation 
c.Dialysis-related hypermetabolism 
d.Loss of residual renal function 
(Source: Carrero et al 2013 [12]) 
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TABLE 2-4. Dietary recommendations for patients undergoing chronic hemodialysis. 
Nutrients Recommended Intake 
1. Calories (kcal/kg body weight) 30 – 35* 
2. Protein (g/kg body weight) 
    Protein (% of total calories) 
1.2-1.4 
15-25 
3. Carbohydrate (% of total calories) 50-60# 
4. Fat (% total calories) 25-35 
5. Cholesterol (mg/day) <200 
6. Saturated fat (% of total calories) <7 
7. Sodium (g/day) <2.0  
8. Calcium (g/day) 2.0 
9. Phosphorus (g/day) 0.8 – 1.0 
    (Adapted from: Ikizler 2010 [85]) 
Note: *35 kcal/kg body weight/day if <60 years old and 30-35 kcal/kg body weight/day if >60 years old. 
# Carbohydrate intake should be provided at a reduced amount for patients with hypertriglyceridemia. 
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TABLE 2-5. Potential mechanism of actions of omega-3 fatty acids on cardiovascular disease 
Omega-3 fatty acids properties Remarks 
1. Hypotriglyceridemic • Reduce fasting and postprandial TAG 
2. Anti-inflammatory • ↓ inflammatory cytokines (TNF-α, IL-1β, 
IL-6, IL-8) 
• ↓ generation of reactive oxygen species 
• ↓ arachidonic acid derived eicosanoids 
3. Antithrombogenic • ↓ paletelet agregation 
4. Retard growth of the atherosclerotic plaques • ↓ adhesion molecules expression (e.g. 
VCAM-1, ICAM-1) 
5. Anti-arrhythmias • Prevent calcium overload  
• Inhibit voltage-gated sodium channel 
6. Mildly hypotensive • Unknown mechanism 
(Adapted from Connor 2000 [158]; Kris-Etherthon et al 2002 [94]) 
Abbreviations: TAG, triacylglycerol; TNF- α, tumor necrosis factor alpha; IL-1β, interleukin 1 beta; IL-6, 
interleukin 6;  IL-8, interleukin 8; VCAM-1, vascular cell adhesion molecule 1; ICAM-1, intercellular 
adhesion molecule 1. 
Note: This figure shows potential mechanism of omega-3 fatty acids in reducing risk for cardiovascular 
diseases. This is contributed by hypotriglyuceridemic, anti-inflammatory, antithrombotic, antiarrythmias 
and anti-atherosclerotic properties of omega-3.  
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TABLE 2-6. Selected studies reporting the effects of omega-3 supplementation in HD patients 
Study Design Groups Dose Therapy 
Duration 
Outcome  
Measures 
Khajehdehi et al 
[29] 
 
 
Randomized, 
placebo-
controlled trial 
4 different treatment 
groups (n=60) 
1. Fish oil 
2. Corn oil 
3. Sesame oil 
4. Placebo 
 
1.5 g omega-3 
/day 
8 weeks Ratios of 
HDLC/LDLC, 
TC/HDLC and 
TAG/HDLC 
decreased 
significantly in fish 
oil and corn oil 
treated groups. 
 
Kalantar-Zadeh 
et al [159] 
Concurrent 
control 
Hypoalbuminemic 
HD patients:  
1. intervention 
(n=20)  
2. control (n=20) 
0.46 g EPA 4 weeks ↑ in albumin in 
intervention group 
Non-significant 
reduction in CRP 
Perunicic-
Pekovic et al 
[106] 
Case-series pre-
post test 
1. Age, sex matched 
control (n=16) 
2. HD patients 
(n=42) 
2.4 g omega-3 
/day 
8 weeks ↓ in IL-6, TNF-α 
↑ in HDLC & 
albumin 
Schmitz et al 
[105] 
Randomized, 
placebo-
controlled 
1. Omega-3 (n=12) 
2. Placebo (n=12) 
4 g omega-3 
/day 
12 months ↓ in TAG by 53% 
Lower incidence of 
thrombosis in the 
treatment group 
(17% vs 75%) 
Saifullah et al 
[108] 
Randomized, 
placebo-
controlled 
1.Omega-3 (n=18) 
2.Placebo (n=9) 
1.3 g omega-3 
/day 
12 weeks No significance 
changes in TAG 
Decreased in CRP 
Tayyebi-
Khosroshahi et 
al [160] 
 
Non-
randomized, 
placebo-
controlled 
1.omega-3 (n=37), 
2.control (n=38) 
3 g omega-3 
/day 
8 weeks MDA significantly 
reduced in omega-3 
group.  
No changes in 
antioxidant enzymes 
(SOD, FRAP) 
Poulia et al[161] 
 
 
Single blinded, 
randomized, 
cross-over trial 
HD patients (n=25) 0.9g EPA + 
0.8g DHA + 
8mg α-TP, 
OR α-TP 
alone 
 
4 weeks on 
each 
treatment, 2 
weeks 
washout 
period. 
No effects on serum 
lipids and CRP.  
      
Abbreviations: EPA, eicosapenthanoic acids; DHA, decosahexanoic acids; TP, tocopherols, TAG, 
triacylglycerols; CRP, C-reactive protein; IL-6, interleukin-6; TNF-α; tumor necrosis factor alpha; MDA, 
malondialdehyde; SOD, superoxide dismutase; FRAP, ferric reducing ability of plasma. 
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TABLE 2-7. Potential therapeutic effects of tocotrienols.  
Tocotrienols properties Remarks 
1. Antioxidant • TTs are more potent radical scavenger and has 
greater antioxidant activity again lipid peroxidation 
in liposome than TPs. 
• TT is more effective in the protection of 
cytochrome P450 against oxidative damage when 
compared to TP.  
• This is due to faster cellular uptake; faster recycling 
from the respective chromanoxyl radical forms in 
liposomal membrane and lipoproteins; higher inter-
membrane mobility. 
 
2. Anti-inflammatory • ↓ inflammatory cytokines (CRP, TNF-α, IL-4, IL-6, 
IL-8, NFκB) 
• ↓ generation of reactive oxygen species 
• ↓ arachidonic acid derived eicosanoids 
3. Lipid altering effects • Hypocholestrolemic effects is unique to TT not TP 
• This is due to post-transcriptional suppression of 
HMG-CoA reductase protein; enhance 
ubiquitination of HMG-CoA reductase.  
4. Effects on suppression, regression 
and progression of atherosclerosis 
• Suppression of atherosclerosis is related to 
reduction in oxidative stress, total cholesterol, 
increased in HDL-C; ↓ adhesion molecules 
expression (e.g. VCAM-1, ICAM-1) 
• Do not regress atherosclerosis in experimental 
animals 
• Conflicting results in progression of atherosclerosis. 
5. Antithrombogenesis • δ-TT is a potent inhibitor of platelet aggregation. 
• TT reduced serum levels of thromboxane-B2 and 
platelet factor 4 
(Reviewed in Frank et al 2012 [116], Prasad 2011	  [35] and Vasanthi et al 2012 [34]) 
Abbreviations: TT, tocotrienol; TP, tocopherols; CRP, C-reactive protein; IL, interleukin; TNF- α, tumor 
necrosis factor alpha; VCAM-1, vascular cell adhesion molecule 1; ICAM-1, intercellular adhesion 
molecule 1; NFκB, nuclear factor kappa B; HDLC, high density lipoprotein cholesterol.  
Note: This figure shows potential mechanism of tocotrienols in reducing risk for cardiovascular diseases. 
This is contributed by antioxidant, anti-inflammatory, lipid altering, anti-atherosclerotic and anti-
thromogenic properties of tocotrienols.  
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TABLE 2-8. Selected studies reporting the effects of oral vitamin E (α-tocopherol)     
supplementation in HD patients 
Study Design Groups (n) Dose Therapy 
Duration 
Outcome Measures 
Boaz et 
al.[25] 
Randomized, 
double-blind 
placebo-
controlled 
1. HD pts α-TP (97) 
2. HD pts placebo (99) 
800IU/day 519 days 
(median) 
No oxidative stress 
measures 
↓ Cardiovascular end 
points (sudden death; 
myocardial 
infarction) 
 
Bayes et 
al.[162] 
Open label, 
untreated healthy 
control 
1. HD pts (16) 
2. Healthy control 
untreated (30) 
400mg	  α-TP 
/ dialysis 
session 
3 months ↓ plasma MDA 
↓ autoantibodies to 
oxLDL 
Galli et 
al.[163] 
Open label, 
untreated healthy 
control 
1. HD pts (19) 
2. Healthy control 
untreated (30) 
800mg α-
tocopheryl/d 
3 weeks ↓ plasma TBARS 
↑ nitric oxide 
↑ plasma TP 
↑ plasma GSH 
Giray et 
al[164] 
Open label, 
untreated healthy 
control 
1. HD pts (36) 
2. Healthy control 
untreated (36) 
600mg α-
TP/d 
14 weeks ↓ plasma TBARS 
↑ plasma GPX and 
SOD activity 
Badiou et 
al.[165]  
Open label, 
treated healthy 
control 
1. HD pts (14) 
2. Healthy control 
treated (6) 
500mg α-
TP/d 
6 months ↓ plasma TBARS 
↓ copper induced 
oxidation 
↑ plasma lipoprotein 
α-TP 
Diepeveen et 
al.[166] 
Randomized, 
double-blind, 
placebo-
controlled 
(factorial design) 
1. HD pts given 
artovastatin + placebo 
α-TP (13) 
2. HD pts given α-TP 
+ placebo artovastatin 
(10) 
3. HD pts given 
artovastatin + α-TP 
(11) 
4. HD pts given 
placebo artovastatin + 
placebo α-TP (10) 
800IU 
(536mg) α-
TP/day 
12 weeks ↓ in vitro LDL 
oxidazibility 
No effect on plasma 
oxLDL levels 
↑ serum α-TP 
Uzum et 
al.[167] 
Randomized, 
placebo-
controlled, with 
treated PD pts, 
untreated healthy 
control 
1. HD pts α-TP 
2. HD pts placebo 
3. Healthy control 
untreated 
300mg/day 20 weeks ↓ erythrocytes 
osmotic fragility 
levels in HD & PD 
↓ MDA in HD 
↑ serum α-TP 
(Adapted  from: Coombes & Fassett 2012 [24]) 
Note: This table shows a list of vitamin E intervention (Tocopherols) studies and their outcome measures 
in hemodialysis patients. 
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TABLE 2-9. Selected studies reporting the effects of tocotrienols in healthy volunteer and other 
clinical population 
Study Design Groups Dose Therapy 
Duration 
Outcome Measures 
Radhakrishnan 
et al. [168] 
 
 
Randomized, 
placebo-
controlled 
trial 
1. Healthy 
volunteer – TRF 
(n=16) 
2. Healthy 
colunteer α-TP 
(n=15) 
3. Control – 
placebo (n=17) 
200mg of 
either TRF or 
α-TP 
8 weeks No different in immune 
cells modulation (i.e.T-
helper, NK cells, B-
lymphocytes, CD4:CD8 
ratio) 
Rasool et al. 
[145] 
 
 
Randomized, 
blinded-end 
point, 
placebo-
controlled 
trial  
 
Healthy 
volunteer – 4 
groups of dosage 
(n=36) 
1. Placebo 
2. 80mg/d 
3. 160mg/d 
4. 320mg/d 
 
Various 
dosage: 
80mg/d,  
160mg/d, 
320mg/d 
 
8 weeks No changes in TAS, 
ASBP, TC or LDLC. 
Group 160mg/d and 
320mg/d showed 
significant improvement 
ASBP 
Patel et al. [169] 
 
 
Open label  Healthy 
volunteer (n=80) 
 
400mg α-TP 
400mg TT 
20 weeks 
(mean) 
1-96 weeks 
(range) 
TT are transported into 
vital organs 
Chin et al. [132] 
 
 
Randomized, 
placebo-
controlled 
trial 
1. Healthy 
volunteer – 
placebo (n=30) 
2. Healthy 
volunteer TRF 
(n=32) 
160 mg TRF 6 months Erythrocytes antioxidant 
enzymes (SOD, GluProx) 
Lipid profiles- significant 
improvement in HDLC in 
older adult group.  
 
 
Abbreviations: TRF, tocotrienol-rich fractions; TP, tocopherols; TAS, total antioxidant status; TC, total 
cholesterol; LDLC, low density lipoprotein cholesterol, ASBP, aortic systolic blood pressure; SOD, 
superoxide dismutase; GluProx, glutathione peroxidase.  
Note: This table shows a list of vitamin E tocotrienol intervention studies and their outcome measures in 
healthy volunteer and other clinical population.  
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FIGURE 2-1. International comparisons for incidents of end-stage kidney disease. 
 
 
 
 
 
 
 
 
 
 
 
 
(Source: USRDS, 2012 [1]) 
 
Note: This figure shows incident rates of the reported ESRD cases worldwides in 2011. Mexiro reported 
the highest incident rate followed by the United States, Taiwan and Japan. Rates less than 100 per million 
population were reported in Scotland, Finland, Russia and Bangladesh.  
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FIGURE 2-2. Different types of treatment modality option for patients with end stage kidney 
disease. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Source: NKUDIC, 2013; Kidney Health Australia, 2013) 
Legend: A- Peritoneal dialysis, B-Hemodialysis, C-Kidney transplantation 
Note: (A) Peritoneal dialysis use patient’s own peritoneum membrane to filter out fluids and other 
dissolved substances. (B) In hemodialysis modality, patient’s blood is pump to pass through a dialyser 
membrane allowing diffusion of fluid and other waste substance across a semipermeable membrane. This 
dialysis modality is the most common in the US. (C)  A new kidney from a donor is transplanted in iliac 
fossa, in the recipient’s contra lateral side.   
A B 
C 
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Co-morbid 
conditions 
Kidney 
Failure Fluid overload Dialysis 
technique 
 
	   Diet restrictions 
Survival selection: C
K
D
 à
 ESR
D
 
Anorexia,  
↓food intake 
Genetic 
Polymorphism 
polymorphism	  
Diet 
↓antioxidant 
Race/ racial 
disparities 
Cultural/ social 
factors  
Malnutrition-
Inflammation 
Complex (MICS) 
↑ pro-inflammatory 
cytokines 
↓ body fat 
↑ Vascular 
calcifications 
Endothelial 
dysfunction 
↑CVD burden, ↑Mortality, ↓QOL 
Oxidative 
Stress 
	  
↑Circulating 
endotoxins 
↑oxidation 
lipoprotein 
↑pro-inflam. 
cytokines 
FIGURE 2-3. Schematic diagram of the increased cardiovascular burden in ESRD. 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
(Adapted from: Kalantar-Zadeh & Balakrishnan 2006 [66]) 
Abbreviations: CKD, chronic kidney disease; ESRD, end-stage renal disease; QOL, quality of life. 
Note: This figure shows a proposed pathophysiology of cardiovascular disease in ESRD patients. 
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FIGURE 2-4. Schematic view of the atheroma’s development 
 
 
 
 
 
 
 
 
 
 
(Source: Stenvinkel et al 2003 [64]) 
 
Abbreviations: Th, T-helper cell; CRP, C-reactive protein; VCAM, vascular cell adhesion molecules; 
ROS, reactive oxygen species; MMPs, matrix metalloproteinases; AngII, angiotensin II; oxLDL, oxidized 
low-density lipoprotein.  
Note: This figure shows atheroma’s development processes. Normal human artery is comprised of three 
layers of cells – endothelial, the intima layer and the underlying tunica media. During early 
artherogenesis, fatty streak is developed as a result of recruitment of inflammatory cells and foam cells 
(from accumulated lipids). When dyslipidemia and inflammatory conditions persist, lipid pool grows. 
Activated leukocytes secrete proteinase which caused degradation of the extracellular matrix and 
ultimately cells death. Meanwhile, Th1 activity is stimulated by the present of inflammatory cytokines 
that limit the synthesis of new collagen which may thin fibrous cap which make it susceptible to rapture. 
Accute chronory syndrome occurs following plaque rupture due to thrombus formation from the 
coagulated blood that block the circulation. On the other hand, higher Th2 activity leads to a more stable 
plaque and less susceptibility to rupture. 
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FIGURE 2-5. Plasma lipid transport in hypertriglyceridemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Source: Barter 2005 [63]) 
Abbreviations: CE, cholesterol ester; CETP, cholesteryl ester transfer protein; FC, free cholesterol; FFA, 
free fatty acid; HDL, high density lipoprotein cholesterol, LCAT, lecithin cholesterol acyl transferase; 
LDL, low density lipoprotein cholesterol;  LPL, lipoprotein lipase; TAG, triacylglycerol; VLDL, very low 
density lipoprotein cholesterol. 
Note: This figure shows overview of lipoprotein metabolism with a highlight on dyslipidemia in 
CKD/ESRD. In the normal metabolism, the liver secretes VLDLs that rich in TAG. LPL hydrolyze TAG 
to FFA and promotes extrahepatic cellular uptake. In CKD/ESRD, dyslipidemia is highly prevalence 
characterized by delayed TAG rich lipoproteins catabolism (i.e. ↑ VLDL/IDL) and low HDLC due 
suppressed apoA1 production, increased CETP, and reduced LCAT activity.  
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FIGURE 2-6. Proposed treatment strategies to treat inflammation and minimize risk for CVD in 
hemodialysis patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Source: Carrero & Stenvinkel 2010 [6]) 
 
I. Evaluate and treat intercurrent events and co-morbidities that cause inflammation 
  Volume overload 
  Infectious complications 
  Periodontal disease 
  Inflammatory diseases 
  Silent ischemic heart disease 
II. Evaluate and handle potential dialysis related cause of inflammation 
 Central dialysis catheter 
 Unpure dialysate 
 Thrombosed fistula or graft 
 Volume overload 
 Bioincompatible membrane 
 Infection of dialysis access 
III. Consider possible anti-inflammatory treatment strategies 
Non-specific Immuno-
modulation 
 Statins 
 Vitamin D 
 ACEs / ARBs 
Physical training Anti-cytokine therapy 
(future treatment) 
 IL-1 receptor 
antagonist 
  Antibodies 
against TNF 
Nutritional 
Intervention 
 Omega-3 fatty 
acids 
 Vitamin E 
 Soy Isoflavones 
 Genistein 
58 
	  
	  
 
FIGURE 2-7. Omega-3 molecular structures 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ALA, α-linolenic acid; EPA, eicosapentanoic acid; DHA, docosahexanoic acid.  
Note: This figure shows omega-3 fatty acids molecular structures – ALA (C18:3), EPA (C20:5) and DHA 
(C22:6). Omega-3 fatty acids have double bond beginning at the third carbon atom from the end of the 
carbon chain. 
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FIGURE 2-8. Different effects of omega-3 and omega-6 in relation to eicosanoids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Source: Friedman & Moe 2006 [92]) 
Abbreviations: COX, cyclooxigenasae; LOX, lipoxygenase; TxA, thromboxane; LT, leukotriene. 
Note: This figure shows synthesis of eicosanoids from omega-6 and omega-3 fatty acids. Eicosanoids are 
a group compounds that exert a complex control particularly in the intensity and duration of inflammatory 
response. Eicosanoids derived from omega-6 are proinflammatory by promoting platelet aggregation, 
vascular permeability and cytokines release. On the other hand, eicosanoids produced from omega-3 is 
less inflammatory in nature. Because eicosanoids derived from omega-3 use the same enzymatic pathway 
as those derived from omega-6, high concentration of EPA results in a shift towards non-inflammatory 
eicosanoids.  
 
Arachidonic Acid 
(n-6) 
Eicosapentanoic Acid 
(n-3) 
n-6 derived eicosanoids 
(TxA2, LTA4, LTB4, 
LTD4) 
n-3 derived eicosanoids 
(TxA3,  LTB3) 
• ↑ Platelet 
aggregation 
• ↑ Vascular 
permeability 
• ↑ Cytokine release 
• Vasoconstriction 
• Chemotaxis 
Pro-inflammatory 
products 
Less inflammatory/ 
anti-inflammatory 
products 
• ↓Platelet 
aggregation 
• ↓ Cytokines 
production 
• ↓ Cytokines release 
• Vasodilation 
• ↓ Chemotaxis 
Competition for 
eicosanoid enzymes 
(COX, LOX) 
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FIGURE 2-9. Vitamin E molecular structures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Source: Aggarwal et al 2010 [33]) 
Note: This figure shows eight known vitamin E isomers, named as α-, β-, δ-, γ- tocopherol (TT) and 
tocotrienols (TP) based on the number of methyl group in the chromanol ring. TT are different from TP 
due to the present of unsaturated chain rather than saturated.  
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FIGURE 2-10. Dietary sources of tocotrienols 
 
 
(Adapted from: Aggarwal et al 2010 [33]) 
Note: This figure shows natural dietary sources of tocotrienol, expressed as µg per gram of the item. 
Tocotrienol is abundant in palm oil, rice bran, barley, oat and wheat germ while safflower, soybean and 
olive oil are minimally contain tocotrienol.   
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FIGURE 2-11. The role of tocotrienols in suppression of the synthesis of pro-inflammatory 
eicosanoids from arachidonic acid.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from: Frank et al 2012 [116]) 
 
Abbreviations: TT, tocotrienols; 12-HPETE, 12-hydroperoxy-eicosatetraenoic acid; COX-2, 
cyclooxygenase-2. 
Note: This figure shows the role of tocotrienols in alleviating production of pro-inflammatory eicosanoids  
from arachidonic acids. The first pathway is through inhibition glutamate-induced production of 
phospholipase A2, which is the enzyme that catalyzes production of arachidonic acid from the cell 
membrane phospholipids. The second pathway involved inhibition of COX-2 and c-Src kinase resulting 
in reduced production of pro-inflammatory eicosanoids.  
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CHAPTER III 
METHODOLOGY 
General study design 
This dissertation is comprised of three experiments from two different studies. General aim of 
these studies is to document the effects of supplementation with anti-inflammatory, lipid altering 
and antioxidant agents (i.e. omega-3 fatty acids and tocotrienols) in hemodialysis patients. These 
studies were designed as randomized, double-blinded, parallel, placebo-controlled trials using 
the same cohort of patients undergoing chronic hemodialysis at Great Lake Dialysis Clinic, 
Detroit MI. There was seven months wash out period between the two studies (Figure 3.1).  
 In the first experiment (Specific Aim 1), chronic hemodialysis patients were 
supplemented with omega-3 fatty acid for 24 weeks to evaluate the feasibility of the 
supplementation using ‘directly observed treatment’ and to document the global effects omega-3 
on nutritional, lipid profiles and inflammatory markers. Following the proven feasibility of the 
study using ‘directly observed treatment’, second study (Specific Aim 2) was conducted using 
similar study design but with some modification to improve compliance and delivery of effective 
doses to the subjects. In the second study, HD cohort was supplemented with tocotrienols-rich 
fractions (TRF) for 16 weeks to evaluate the global effects of TRF on nutritional status, lipid 
profiles, inflammatory markers and oxidative status. Further investigation was carried out to 
elucidate the effect of TRF on lipid metabolism following positive results on lipid profiles. In the 
third experiment, the author investigated the changes in patients’ metabolomics profile following 
supplementation (Specific Aim 3).  
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 This chapter will describe general methods that were the same between the omega-3 and 
TRF studies. Specific methods/assays for each study will be described in specific chapter for the 
particular study (Chapter IV, V and VI).  
Ethics and human subjects issues 
The Omega-3 study (Specific Aim 1) recruited 63 patients from the Great Lake Dialysis Clinic. 
The protocol for the Omega-3 study was approved by the Human Investigation Committee of 
Great Lake Dialysis Clinic (IRB# 00007308) and Wayne State University (HIC #125709A). 
Informed written consent from the patients was obtained beforehand.  Similarly, the protocol for 
the TRF study (Specific Aim 2a/b) was approved by the Human Investigation Committee of 
Great Lake Dialysis Clinic (IRB #00007308) and Wayne State University (IRB# 067411A). The 
study recruited 81 patients of the same cohort and informed consents were obtained from the 
patients before the study start. Any serious adverse events (e.g. death, inpatient hospitalization, a 
life-threatening adverse experience, a persistent/significant disability) or unexpected adverse 
experiences related to the use of these supplements were promptly reported to the Human 
Investigation Committee using the specify form within five working days.   
 The Great Lake Dialysis Clinic is an outpatient dialysis facility that is affiliated with 
Delta Renal Group. The dialysis facility has 24 hemodialysis stations. The hemodialysis patients 
are distributed equally among seven hemodialysis shifts. Each patient attends hemodialysis 
session either on Monday-Wednesday-Friday or Tuesday-Thursday-Saturday rotation at a 
designated time. Each rotation day comprised of three dialysis session namely; Shift 1 runs from 
5.15 am to 8.45 am, shift to from 10.15am to 1.45pm and night shift hours of operation are from 
5 pm to 4.30 am. Hemodialysis patients are under exclusive care of the nephrologist and a 
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certified nurse-practioner. A full time registered dietitian provides routine nutritional care and 
dietary counseling to those patients. Anemia management is performed by the clinical director of 
the clinic.  
General aspects of collection and handling of blood samples 
In general, blood was collected from the patients prior to the dialysis session into two 10mL 
Vacutainer tubes with EDTA and heparin preservatives (BD, Franklin Lakes, NJ, USA). Blood 
samples were transported to Wayne State University’s laboratory within 2 hours after the 
collection. Additional blood was collected into tubes without anticoagulant for standard renal 
profiles measurement (ser. Alb, Hb, Kt/V) and were sent to an external laboratory (Ascend 
Clinical Laboratory Services, Redwood City, CA, USA). Blood samples collected in the EDTA 
tubes were designated for analyses of lipid profiles and NFκB while lithium heparin tubes were 
used for analyses of oxidative status and inflammatory markers. Plasma was separated by 
centrifugation at 2800 rpm for 20 minutes at 4oC (GS-6KR Centrifuge, Beckman-Coulter, USA) 
and aliquots were stored at -80oC until further analysis.  Blood sample for nuclear factor kappa B 
(NFkB) were processed immediately to obtain mononuclear cell extract using Ficoll-Paque 
method (GE Health Care, Piscataway, NJ, USA), and the nuclear extract were kept at -80oC until 
use. 
Anthropometry measurements 
The anthropometrics measurements carried out in both studies included estimated dry weight and 
height at the baseline and the end of the study. Height was measured to the nearest 0.1cm (Tanita 
Wall Mounted Height Rod, Tanita, USA). Body weight was measured to the nearest 0.1kg after 
each HD session (Tronix Flush-Mounted In-Floor Scale, Scale-Tronix, USA). Body mass index 
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(BMI) was calculated from the measurements of weight and height using Quetelet ‘s Index [ 
BMI (kg/m2) = weight (kg) / height (m2)][170] and compared to WHO (2000) BMI 
classification chart [171].  
Biochemical analyses 
Biochemical analyses performed in both studies included 1) Renal profiles (ser. Alb, Hb, Kt/V) 
(performed by external laboratory) 2) Lipid profiles (TC, TAG, HDL-C) and 3) Inflammatory 
markers (C-RP, NFκB). Brief descriptions of each assays performed in these studies are 
described as follow: 
Lipid profiles 
TC and TAG in the plasma was determined using commercial enzymatic assay per manufacturer 
protocol (Pointe Scientific, Canton, MI). Briefly, 10µL of unhemolyzed plasma samples were 
transfer into test tubes, followed by addition of 1.0mL of TC/TAG reagent (pre-warmed to 37oC) 
and gently mixed by vortexing. The tubes were incubated for 10 minutes in the dark and the final 
color intensity of the solution was recorded at 500nm within 30 minutes (DU 640 
Spectrofotometer, Beckman-Coulter, USA). TAG concentration for each sample was calculated 
by comparing to the standard absorbance (abs unknown/ abs standard X concentration standard) 
and the results were expressed as mg/dL. All samples were assayed in duplicate.  
 HDL-C was measured in the supernatant fraction following precipitation of ApoB 
containing lipoprotein using dextran sulfate and magnesium ions (Pointe Scientific Inc., Canton, 
MI). In short, 150µL of plasma was transferred to microtube followed by the addition of 30µL of 
Mg/Dextran Sulfate and 10 minutes incubation at room temperature. The solution was spun at 
10,000 rpm for 5 minutes to precipitate ApoB containing lipoprotein. Supernatant fraction 
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(50µL) was transferred to the test tubes in duplicates followed by the addition of 1.0mL of pre-
warmed TC reagent. After 10 minutes incubation, the color intensity was measured using 
spectrophotometer at 500nm. HDL-C concentration for each sample was calculated by 
comparing to the standard absorbance (abs unknown/ abs standard X concentration standard) and 
the results were expressed as mg/dL. LDL-C was calculated using the Friedewald’s equation by 
difference (LDLC = TC minus HDLC minus TAG/5)[174].   
Inflammatory markers 
CRP (Cayman Chemical, Ann Arbor, MI) levels were measured using commercial kits based on 
enzyme-linked immunoabsorbent assay (ELISA) method as per the manufacturer’s protocol 
(Cayman Chemical, Ann Arbor, MI).  Plasma samples were diluted in the assay buffer into 
1:15,000 and 100µL of each sample was placed into 96-wells microplate that has been coated 
with a monoclonal antibody specific for human CRP and were incubated for an hour. The plate 
was then rinsed for four times with wash buffer before addition of HRP-labeled CRP monoclonal 
antibody. Two antibodies were added and formed a sandwich by binding to different location of 
CRP molecule. CRP concentration in the plasma samples were measured at 450nm after addition 
of chromogenic substrate TMB (tetramethylbenzidine) that formed a distinct yellow color. 
Standard curve was prepared using a known concentration of CRP with data being expressed as 
mg/L. A general principle of sandwich ELISA method is presented in Figure 3-2.  
 NFκB assay was performed based on three steps: 1) Isolation of mononuclear cells from 
the blood, 2) Extraction of nuclear and cytoplasm extract, and 3) Measurement of NFκB 
expression/concentration in the nuclear extract. Isolation of the mononuclear cells from the blood 
was performed using Ficoll-Paque PLUS solution (GE Healthcare Life Science, Pittsburgh, PA, 
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USA). Briefly, 5mL of fresh blood that were collected in EDTA tube were diluted with an equal 
volume of 1 X phosphate buffer saline solution. The diluted blood were then transferred into a 
15mL Corning centrifuge tube (Corning Life Science, Tewksbury, MA, USA) containing 10 mL 
of Ficoll-Paque solution  by carefully overlaying it using 9” Pasteur pipette (Thermo Scientific, 
USA). This was followed by a centrifugation at 1,400 rpm, 20oC for 30 minutes to separate 
peripheral blood mononuclear cells (PBMC). PBMC was harvested using Pasteur pipette, 
transferred into a new 15mL Corning centrifuge tube, followed by an addition of three volumes 
of 1 X PBS. The solution containing PBMC was centrifuge again at 1,000 rpm, at 4oC for 10 
minutes to eliminate contaminant (e.g. platelet). The washing processes were done two times 
before the PBMC were harvested and stored at -80oC until further use. Nuclear and cytoplasm 
extract were obtained from PBMC using kits purchased from PIERCENET (Thermo Scientific, 
Rockford, IL, USA) per manufacturer’s protocol. For a 40mg packed cell volume, 400µL of 
cytoplasmic extraction reagent I (CER-I) was added into the cell pallet followed by a vigorous 
vortexing for 15 seconds and incubation on ice for 10 minutes. CER-II solution (22 µL) was 
added into the tube followed by vortex and centrifugation for 5 minutes at 16,000g, 4oC. The 
cytoplasmic extract was harvested from the supernatant while the insoluble pallet was used to 
extract the nuclear extract by the addition of the nuclear extraction reagent (NER). Protein 
content of the nuclear extract were determined based on Bradford’s method using a commercial 
reagent purchased from PIERCENET (Thermo Scientific, Rockford, IL, USA) per 
manufacturer’s protocol. Upon the quantification of the protein content, each sample was 
standardized for the protein concentration by a dilution with NER solution. NFκB p65 in the 
nuclear extract was determined using TransAM NFκB (Active Motif, Carlsbad, CA, USA) based 
on ELISA method as discussed earlier on.  
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Statistical analysis 
Upon the completion of the study, data were keyed-in in Microsoft Excel, checked for their 
integrity and missing values before transferring into SPSS. Statistical analyses were carried out 
using SPSS version 16.0 (IBM, Chicago, IL). Continues data were presented as mean±SD (in 
tables) and mean±SEM (in figures), while data that were not normally distributed were presented 
as median±IQR.  Categorical data were presented as absolute number and percentage.  
 Independence t-test were applied to normally distributed continuous data to check 
differences in mean between the two groups, while paired t-test were used to check differences 
between time points. For continuous data that were not normally distributed, equivalent non-
parametric tests were used to test differences in mean of the two groups and between the time 
points. Chi-square test was used to test differences in categorical data. Pearson-correlation 
coefficient test was used to evaluate correlation of the studies’ parameters.   
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FIGURE 3-1. General study design. 
 
 
 
 	    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: Ser. Alb, serum albumin; Hb, hemoglobin; MIS, malnutrition-inflammation score; CRP, 
C-reactive protein; NFκB, nuclear factor kappa B; IL-6, Interleukin-6; TNF-α, tumor necrosis factor 
alpha; TAP, total antioxidant power; MDA, malondialdehyde; TC, total cholesterol; TAG, triacylglycerol; 
HDLC, high-density lipoprotein cholesterol; CETP, cholesteryl ester transfer protein; ApoA1, 
apolipoprotein A1. 
OMEGA-3 STUDY 
(n=60) 
TRF STUDY 
(n=81) 
Specific aim 1 parameters: 
• Nutritional indices  
(Ser. Alb, Hb, MIS score) 
• Inflammatory markers 
(CRP, NFκB) 
• Lipid profiles 
(TC, TAG, HDLC) 
 
 
Supplementation duration: 
24 weeks 
(on dialysis days only – 
3x/wk)  
Washout period:  
24 weeks  
Supplementation duration: 
16 weeks 
(on daily basis – 2x/day)  
Specific aim 2 parameters: 
• Nutritional indices  
(Ser. Alb, Hb, 24-hr diet analysis) 
• Inflammatory markers 
(CRP, IL-6, TNF-α, NFκB) 
• Oxidant status 
(TAP, MDA) 
• Lipid profiles 
(TC, TAG, HDLC) 
• Lipids  
(CETP, ApoA1) 
 
 
 
Specific aim 3: 
• Metabolomics analysis 
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FIGURE 3-2. Principle of sandwich ELISA  
 
 
 
 
(Illustration by: Genway Biotech Inc, 2013) 
1. A 96-well microplate is pre-coated with desire antibody by the manufacturer (e.g. human 
CRP, IL-6). 
2. Plasma sample is added to the each well in the microplate in duplicate. Any antigen found in 
the plasma is bound to the capture antibody. 
3. Biotin labeled detection antibody is bound to the antigen.  
4. HRP is added and binds the biotin labeled antibody. 
5. TMB substrate is added and converted by HRP into detectable color solution. The 
concentration of the antigen is quantified using spectrophotometer. 
 
Note: This figure shows principle of sandwich ELISA that has been used to measure CRP, IL-6, TNF-α 
and NFκB in this project.  
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CHAPTER IV 
SPECIFIC AIM 1: 
 EFFECTS OF PROTEIN AND OMEGA-3 SUPPLEMENTATION ON NUTRITIONAL 
STATUS, LIPID PROFILES AND INFLAMMATORY INDICES 
Published in: Vascular Health and Risk Management. 2012; 8:187-195 [175]. 
Daud ZAM, Tubie B, Adams J, Quainton T, Osia R, Tubie S, Kaur D, Khosla P, Sheyman M. 
 
Introduction 
Cardiovascular disease (CVD) represents the major source of morbidity and is a leading cause of 
death in uremic patients on chronic hemodialysis [164]. From non-traditional cardio-vascular 
disease risk factors in dialysis patients, a malnutrition-inflammation complex syndrome has been 
postulated to play a role in the etiology of premature CVD in hemodialysis patients [7]. Thus, 
there is considerable interest in finding appropriate interventions for the malnutrition-
inflammation complex syndrome (MICS) in this population.  
 Protein energy malnutrition (PEM) is highly prevalent in dialysis populations which 
negatively impacts prognosis. PEM is implicated in a complex syndrome caused by nutritional 
and non-nutritional factors such as deficient food ingestion secondary to uremia, dietary 
restriction, chronic inflammatory state and increased catabolism related to treatment modalities, 
nutrients loss in dialysate and metabolic acidosis [74]. Numerous studies have demonstrated that 
protein supplementation alone may improve protein metabolism, nutritional parameters and 
therefore improve clinical outcomes [176-178]. Meanwhile, causes of inflammation are 
multifactorial comprising of dialysis and non-dialysis factors such as exposure of blood with 
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dialyzer membranes or tubing, infection on vascular access, reduced antioxidants and increased 
oxidative stress [74, 179]. Therefore, in order for a nutritional intervention to be most effective, 
it should be targeted at improving protein status and have anti-inflammatory properties to 
improve inflammatory status [159]. 
 There is a growing scientific interest on the application of omega-3 fatty acids as a means 
to prevent CVD in dialysis population. Omega-3 fatty acids have been postulated to reduce a 
pro-inflammatory response, confer antithrombotic properties, improve lipid levels particularly 
triglycerides and improve endothelial functions in several studies [98, 104, 180, 181]. To date, 
there is no well-established recommendation on omega-3 fatty acid supplementation for the 
dialysis population despite the fact that the dialysis population has lower omega-3 intake [32] 
and plasma levels [102]. Some of the studies published used supraphysiological doses of omega-
3 (>3 g/d) which required the high number of capsules and may be difficult to consumed long 
term [92]. Moreover, there may be barriers to compliance with this type of nutritional 
intervention especially when the study population includes non-Caucasian races, low-income 
groups and unemployed [182]. Some of the clinical studies only rely on subjective method such 
as pill counting to measure compliance [109, 161] which could be the important limitation for 
the likely type of non-compliance population.  
 Therefore, we performed a pilot study to investigate the technical feasibility of  “directly 
observed treatment” of nutritional supplementation administered during regular dialysis sessions. 
Secondary outcomes included observations on nutritional and inflammatory status of 
hypoalbuminemic patients undergoing hemodialysis. We hypothesized that a combination of 
protein and omega-3 supplementation would be more effective than protein supplementation 
alone in improving nutritional and inflammatory status. 
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Methods 
Patients 
One hundred-and-five patients who were undergoing routine hemodialysis treatment in the Great 
Lake Dialysis Clinic in Detroit, Michigan were screened. Selection criteria for patients included 
serum albumin levels not meeting the outcome goal of K/DOQI guidelines [183]  (≤3.9 g/dL), 
age greater than 18 years old and ongoing dialysis treatment for at least 3 months prior to the 
study. Patients who were residents of nursing homes or receiving intradialytic parenteral 
nutrition, tube feeding, undergoing 8 hours of dialysis treatment, nocturnal dialysis, serum 
albumin > 3.9 g/dL, or fish allergies were excluded. 
Study design and procedures 
The present study was approved by the Human Ethics Committees of Wayne State University 
and the Human Investigation Committee of Great Lakes Dialysis. Informed written consent was 
obtained from all patients. Eligible subjects (n=63) were randomized into two groups - placebo 
+protein supplement (Placebo, n=32) and omega 3 + protein supplement (Omega3, n=31). 
Patients, care givers and investigators were blinded from group assignments. This study lasted 6 
months. 
Nutritional intervention and compliance 
The nutritional intervention provided comprised of two components. Both treatment groups 
received a blend of 30 mL liquid protein supplement (Proteinex) (Llorens Pharmaceuticals Inc, 
Miami, FL) in 60 mL of apple juice providing 100 kcal, 18g protein and 8 gram carbohydrate 
[specifically, 30mL of Proteinex provides 18g of protein hydrolysate (72 kcals), with 1440mg of 
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L-Arginine, 540mg of L-Leucine, 420mg of L-Phenylalanine, 132mg of L-Histidine, 780mg of 
L-Lysine, 360mg of L-Isoleucine, 132mg of L-Methionine and 66mg of L-Tryptophan]. 
Additionally, subjects were given 4 capsules of either omega-3 or placebo, formulated by Twin 
Rivers Technologies (MA, USA). Each one of the omega-3 capsule contained 150 mg of DHA 
and 450 mg of EPA (total DHA 600 mg, total EPA 1800 mg), while the other capsule was a 
placebo comprised of olive oil. Analysis of omega-3 and placebo capsule is presented in Table 1.  
Both protein and capsules were given to the patients 3 times a week after their regular dialysis 
session for a total duration of 6 months. Compliance was ascertained by administering the 
supplements during the patient’s dialysis session with close monitoring by nurses. Tolerability 
and side effects for supplements were recorded by registered nurses and hospitalization rates 
were also monitored.  
Blood sampling and laboratory measures 
The study flow chart is shown in Figure 1. Approximately 20 mL of fasting blood sample were 
taken prior to the dialysis session. Plasma samples intended for lipid analysis were isolated from 
blood by centrifugation at 3000 rpm for 20 minutes at 4oC and were kept at 4oC to be analyzed 
on the following day. Blood samples for NFκB were processed immediately to obtain 
mononuclear cell extract using Ficoll-Paque method [184] and the extract was kept at -80oC 
until further analysis. Serum samples for common renal profiles (serum albumin, BUN, 
creatinine, hemoglobin, etc) were sent to Satellite Laboratory Services (Redwood City, CA) for 
analysis and were measured using standard automated laboratory techniques. 
Lipids analysis 
Total cholesterol, HDL cholesterol and triacylglycerol (TAG) in the plasma were determined by 
enzymatic reaction using kits purchased from Pointe Scientific Inc. (Canton, MI). LDL 
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cholesterol was calculated using the Friedwald equation (LDL-C = TC minus HDL-C minus 
TAG/5) [174]. LDL-C to HDL-C ratio was calculated by dividing LDL-C by HDL-C values.  
Inflammatory markers 
Serum CRP was analyzed by an independent laboratory (DMC Laboratory, Detroit, MI) using 
immunoturbidimetric method. Activated NFκB was measured from the nuclear extracts using 
TransAm chemiluminescent (p65) kit purchased from Active Motif (Carlsbad, CA) using the 
procedure described by the manufacturer.  
Nutritional indicators 
Serum albumin was measured by bromcresol green method using standard automated laboratory 
techniques. Normalized protein nitrogen appearance (nPNA) was calculated according to 
K/DOQI guidelines (2000) [183]. Malnutrition-inflammation score (MIS) questionnaire [89] was 
also administered prior to (baseline), during (month-2) and at the end of the study (month-6). 
MIS is a quantitative scoring system that comprised of 10 components related to patients’ 
medical history, physical exam, body mass index and laboratory parameters, which has been 
reported to be a useful tool to predict dialysis outcome, malnutrition and inflammatory status 
[185-187]. MIS was performed and calculated by a single person, a registered dietitian, to 
minimize inter-observer variability.  
Statistical analysis 
The minimum sample size for each group was n=31, which was estimated at a power of 80% and 
α=0.05 for a two-arm parallel study to detect a 0.2g/dL difference in serum albumin. Results 
were analyzed using intention to treat principle. All study participants were maintained in the 
treatment groups to which they were randomized regardless of post-randomization withdrawal 
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and any missing values reported accordingly. Categorical data are reported as number and 
percentage, while continuous data are reported as mean±SD or as otherwise stated. Independent 
t-test was used to determine differences in the variables of interest between the two groups at 
baseline. Difference between baseline and month-2 and between baseline and month-6 for each 
group were tested using paired t-test. Data that were not normally distributed were tested using 
non-parametric test. Statistical significance was set at α=0.05. All statistical tests were performed 
using SPSS v. 16. As there was no significant difference between baseline and the 2-month 
values in any of the parameters measured, these are not discussed further (data not shown). 
 
Results 
Demographic profiles 
Sixty-nine patients met the inclusion criteria, and 63 agreed to participate. Subjects were 
randomized based on albumin levels, and with the exception of gender distribution, there were 
no significant difference in age, duration on dialysis, BMI and prevalence of existing co-morbid 
(diabetes mellitus) or indicators of dialysis adequacy (Kt/v) between the two groups (Table 2). 
The study population was homogenously comprised of African-American ethnicity with no 
difference in income between groups.  
Tolerability, side effects and compliance 
Over the course of the study, four patients passed away due to a) cerebrovascular accident (one 
subject, P group), b) diabetic infection (one subject, Omega3 group) and c) CVD (two subjects, 
one from each group). There were no other adverse events reported (i.e. a life-threatening 
adverse experience, inpatient hospitalization or prolongation of existing hospitalization, or a 
persistent or significant disability/incapacity), over the course of the study. No discernible 
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“fishy” smells were reported by any of the patients with regards to capsule assignment. Two 
patients complained they couldn’t swallow the pills (P group) and withdrew from the study 
(Figure 1). Twenty-one patients (33%) were able to take 100% of the supplement provided (no 
missing day) during the 6-month study period. Sixty-seven percent of the patients (n=22 for 
Omega3 group and n=21 for P group) were able to take greater than 80% of the supplements. 
The principal reason for “lack of compliance” was subjects who missed their scheduled dialysis 
sessions.  
Effects on lipid profiles 
One subject was excluded from the analysis due to high TAG levels (478 mg/dL) as Friedwald 
equation for LDL-C estimation is not reliable when TAG levels exceed 400mg/dL [188]. Total 
cholesterol was significantly reduced over the 6 months intervention in both groups (p<0.001) 
(Table 3). At the end of 6 months, the reduction in TC in the Omega-3 group (-37±32 mg/dL) 
was approximately fifty percent greater than the reduction seen in the P group (-21±26 mg/dL, 
p=0.057). While HDL-C levels were increased at month-6 compared to the baseline in both 
groups (t=-4.077, p=0.000 and t=-3.410, p=0.004, respectively), there was no significant 
difference between groups (p=0.531). LDL-C was reduced in both groups (Omega3 group: 
t=6.083, p=0.000, P group: t=4.200, p=0.000) at month-6 as compared to the baseline, however, 
no significant differences between the two groups were noted at the end of the study (p=0.092). 
The LDL-C/HDL-C ratios were significantly improved in both groups as compared to baseline 
(Omega3 group: t=5.875, p=0.000, P group: t=4.683, p=0.000). After 6 months, the Omega3 
group had a significantly larger reduction in LDL-C/HDL-C ratios as compared to the P group (-
1.3±1.1 vs -0.7±0.8, p=0.043). As compared to baseline, TAG levels did not change in the P 
group (p=0.561), while there was a tendency for a decline in the Omega3 group (p=0.064) 
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Effects on nutritional parameters 
Serum albumin and other nutritional indices are presented in Table 4. Serum albumin at the end 
of the study was comparable to the values observed at baseline in both the Omega3 (t=-1.895, 
p=0.070) and P (t=-0.314, p=0.756) groups. Comparison between both groups showed no-
significant difference (p=0.295). Similarly, no changes were observed in MIS score, nPNA and 
BMI following the intervention within or between the groups. Additionally, hemoglobin levels 
were not changed following intervention in both groups (Omega3 group: t=1.100, p=0.282, P 
group: t=-0.731, p=0.471). 
Effects on inflammatory indicators 
The NFκB levels observed after 6 months in the Omega3 and P groups were similar to their 
baseline values (Table 5). Additionally, mean differences (month-6 minus baseline) between 
Omega3 and P groups were not significantly different (p=0.134). With regards to CRP levels,  
mean values showed a significant elevation in CRP levels in the P group (t=-2.158, p=0.040) but 
not the Omega3 group (t=-0.582, p=0.565) over the 6 months.  However these differences were 
not apparent when median CRP values were compared. Additionally, there was a significant 
inverse association between CRP and albumin levels across both groups (r= -0.261, p=0.049). 
Discussion 
Our study tested the potential of a combination of protein and omega-3 supplementation to 
improve nutritional and inflammatory markers in chronic hemodialysis patients. To increase 
compliance the supplements were administered during patient’s routine dialysis session, three 
times per week (“directly observed treatment”). Directly observed treatment allowed for 2/3rds 
of the subjects to receive more than 80% of the stated overall dose over a six months period. 
While compliance was excellent in patients who came in for regular dialysis sessions, the 
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significant comorbidities within this patient population resulted in a large number of missed 
dialysis treatments (and hence missed supplementation). 
We observed that serum albumin, one of the markers of nutritional status, was not 
improved significantly in either group following the intervention. This finding was in contrast to 
what has been reported in previous studies [189-191]. This may be explained by the fact that 
only a small number of patients were able to take all of the supplement provided to them (no 
missing day) during the study course (n=21, 33.3%). Patients missed days of supplementation 
mostly due to frequent hospitalization or failed to show up for their routine dialysis treatment, 
ranging from 1-44 days. Therefore, this could potentially upset the effect of omega-3 and protein 
supplementation per se. Further analysis on a pool of patients who substantially completed the 
supplementation course (i.e. taking >80% of the supplements) showed marginal improvement in 
serum albumin at month-6 as compared to the baseline (3.6±0.3 g/dL vs 3.7±0.3 g/dL, p=0.079) 
but no improvement were noted in those who took <80% supplements (3.7±0.2 vs 3.7±0.4, 
p=0.939). Interestingly, nPNA, an indicator of protein intake, remained constant in both group 
despite protein supplementation. A similar study by Morretti et al. [192] also noted a similar 
trend, in which there were no changes in nPCR despite improvement in serum albumin in the 
protein group for the second 6 months.  
Reduced protein intake and an increase in inflammatory response are two important 
factors that lead a decrease in serum albumin [193]. However, Kaysen et al [194] had noted that 
low serum albumin in dialysis population may be attributed to systemic inflammation rather than 
nutritional inadequacy as a causative factor per se. In relation to that, we also observed a 
significant inverse correlation between serum albumin and CRP which may indicate the 
influence of inflammatory process in serum albumin levels. Friedman and Fadem [195] 
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suggested that serum albumin should be taken as a marker of illnesses rather than nutrition. This 
is due to the fact that serum albumin has a strong ability in predicting mortality but rather limited 
prediction for nutritional status due to significant influence of non-nutrition causes (such as 
inflammation).   
Many of the omega-3 fatty acid supplementation studies in dialysis population have 
described various potential outcomes such as attenuating dyslipidemia, inflammation and 
providing cardio-protective effect. Moreover, there is substantial evidence for reducing TAG 
levels [27, 28, 30] even at a dosage as low as 1.5g/day [29]. As for plasma TAG, we saw a 
tendency for a reduction in TAG levels in both groups although in the O3PP group statistical 
significance was marginal (p=0.064). The large variation in the difference in TAG changes 
observed in the PPP group (-7±61 mg/dL, p=0.56, Table 3) could be attributed to one subject 
with very high triacylglycerols concentrations. Upon removal of this subject the difference in 
TAG between the 6 month and baseline value was 1±44 mg/dL, p=0.89. Thus collectively these 
data suggest no change in TAG over 6 months in the placebo group, while there was a tendency 
for a reduction in TAG in the Omega3 group (-20±44 mg/dL, p=0.064). Previous studies [106, 
161] which administered a higher amount of omega-3 per week, with varying percentage of 
EPA/DHA but with a shorter duration (4 – 8 weeks) also reported no changes in TAG levels. 
However, Bouzidi et al (2010) reported that a supplementation of 2.1g omega-3 daily for 3 
months among CKD patients reduced TAG levels by 48% [196]. However, it is important to note 
that the baseline TAG levels in their study were much higher than the current study (275±58 
mg/dL vs 123±60 mg/dL in omega-3 group). We postulate that, the baseline TAG levels (O3PP: 
123±60 mg/dL and PPP group: 104±69  mg/dL) were within the normal levels and thus may not 
have been sufficiently elevated to achieve a significant reduction.  Skulas-Ray et al reported that 
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the extent of TAG lowering with omega-3 is a function of baseline TAG levels [197]. Omega-3 
supplementation resulted in better improvement in LDL-C/HDL-C ratios as compared to placebo 
which appeared to be due to a greater improvement in non-HDL-C.  As for inflammatory 
markers, our results for CRP were inconclusive. While mean values in the P group increased 
over the 6 month period, this was not the case in the Omega3 group, in which CRP levels stayed 
the same.  Thus Omega-3, if not effective in attenuating inflammation, may be beneficial in 
preventing further increases in inflammatory status. However when the data were evaluated 
using median CRP values, these differences were no longer apparent suggesting the need for a 
larger sample size to definitively resolve this issue. Only a small number of studies have 
investigated the effects of omega-3 on inflammatory marker in hemodialysis population. It is 
important to note that, most of these studies are not comparable due to difference in study design, 
supplement dosage, EPA/DHA ratios and study duration. Saifullah et al showed that, a 
supplementation of 1.3 g of oral EPA and DHA daily over the period of 3 months could 
modestly reduced CRP levels [108]. However, a recent study using a larger dosage (2.08g/day) 
but a shorter duration (10 weeks) showed no effects on serum systemic inflammation markers 
(CRP, IL-6, TNFα) and oxidative stress (MDA, TAC) [198].  In a prospective cohort study by 
Noori et al (2011), the authors showed that, a lower omega-6 to omega-3 ratios (~6) was 
associated with decreased inflammation and overall mortality in hemodialysis population which 
indicate the importance of n-6/3 PUFA ratios in the diet [32]. However, our study was not 
designed to investigate the effects of the ratio per se. 
NFκB, a key player in pathogenesis of inflammation, is stimulated by pro-inflammatory 
agents such as cytokines and CRP. Studies have shown that, NFκB activation and subsequent 
activation of mononuclear cells trigger a process that cause myocardial inflammatory damage in 
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hemodialysis patients [199, 200].  Interestingly, our data for translocation of activated NFκB to 
the nucleus showed no significant changes following the intervention within and between both 
groups even though we saw an increase in CRP levels in the placebo group. The latter may have 
been due to the fact that the baseline CRP values in the placebo group were lower than those 
assigned to the omega-3 group.  
Limitations of the study 
We were restricted in our patient population to one dialysis clinic for this pilot study. While the 
lipid data suggested benefits of Omega3, the data for inflammatory markers was less clear-cut. 
One plausible explanation for variation in inflammatory markers in the current study may be 
related to insufficient dosage/frequency of Omega-3 supplementation as well as compliance (due 
to frequent hospitalization resulting subjects missing dialysis sessions and therefore 
supplementation). There are several similar studies that also failed to report significant changes 
in inflammatory markers [161, 201-203]. Studies that demonstrated a significant effect of 
omega-3 supplementation on inflammation indices are those with a higher dosage and more 
frequent administration of the supplement (9.1 to 21 g/week vs 7.2g/week DHA + EPA in the 
current study) as well as reported better patients’ compliance [204-207]. Another factor that 
could potentially explain the contradictory finding in our study with those studies is baseline 
levels of inflammatory markers. Omega-3 supplementation appears to be more effective in 
studies reporting higher baseline CRP (>13.8 mg/dL) than those which did not [109, 198, 204]. 
  Notwithstanding some of the limitations discussed above, ours is one of the few studies 
to report on the use of “directly observed treatment” of oral nutritional supplementation with 
protein and omega-3 in a cohort of hemodialysis patients. Our results suggest that “directly 
observed treatment” is technically feasible in hemodialysis patients and does not disrupt the 
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normal dialysis schedule. The relatively large number of missed dialysis sessions due to 
hospitalizations, however, suggests that “directly observed treatment” should be used in the 
setting of both outpatient and in-patient dialysis sessions in order to optimize compliance. In 
addition, while emphasizing the huge progressive inflammatory burden in hemodialysis patients 
over time; this pilot study suggests that “directly observed treatment” with a combination of 
omega-3 and protein based supplement (as opposed to a pure protein supplement) could have 
some benefical effects on lipid profile and CRP progression. Further studies using a combination 
of out-patient “and” in-patient “directly observed treatment” of fish oil based nutritional 
supplementation are warranted. 
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Tables and figures 
TABLE 4-1. Selected fatty acid composition of omega-3 and placebo capsule.   
 Omega-3  
(g/100g as FA) 
Placebo  
 (g/100g as FA) 
C16:0 0.96 13.86 
C16:1 0.35 1.44 
C17:0 0.14 0.07 
C17:1 - 0.11 
C18:0 4.66 2.73 
C18:1n9 8.88 66.64 
C18:2n6 2.00 11.42 
C18:3n3 0.77 0.69 
C20:0 0.50 0.43 
C20:1n9 - 0.26 
C20:5n3 35.36 - 
C21:5n3 1.70 - 
C22:5n3 4.95 - 
C22:6n3 24.31 - 
   
SAFA 7.02 17.26 
MUFA 15.21 70.63 
PUFA 77.77 12.11 
   Omega-3 67.08 0.69 
 
Abbreviations: SAFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids; FA, fatty acids. 
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TABLE 4-2. Clinical and demographic characteristics of the study population.   
 Omega-3  
(n=31) 
Placebo  
 (n=32) 
 
P value 
Demographics    
Age (years)  59±13 58±13 .845 
Ethnicity    
     African American (n, %) 30 (97) 32 (100) - 
     Caucasian (n, %) 1 (3) 0 (0) - 
Gender (males, %) 20 (62.5) 12 (38.7) .059 
Income ($ per month) 1015±576 1148±761 .552 
    
Clinical    
Time on dialysis (years) 3.6±2.9 3.3±3.8 .784 
BMI (kg/m2) 28.4±8.3 26.9±7.8 .468 
Diabetes mellitus (n, %) 20 (62.5) 20 (64.5) .868 
Kt/v 1.58±0.29 1.63±0.32 .536 
Statin usage (n, %) 11(35.5) 9 (28.1) .530 
C-reactive protein (mg/dL) 5.8±9.2 4.9±5.6 .134 
 
Abbreviations: BMI, body mass index; Kt/v, index of dialysis adequacy. 
	  
Notes: Differences in age, time on dialysis, BMI, Kt/v and income were tested using independent t-test. 
Baseline CRP levels is reported in median±interquartile range. Differences were tested using Mann-
Whitney rank-sum test.	  Differences in gender, Diabetes mellitus and statin treatment were tested using 
chi-square. P<0.05 is considered significant. 
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TABLE 4-3. Means and standard deviations of lipid profiles (TC, HDLC, LDLC, and TAG) at 
baseline and month-6. 
 Placebo(n=26)  Omega 3 (n=28)  P 
overall  Baseline Month 6 Diff. P  Baseline Month 6 Diff. P 
Lipid profiles          
TC  
(mg/dL) 
159±49 138±42 -21±26 .000  176±36 139±29 -37±32 .000 .057 
HDLC 
(mg/dL) 
44±13 49±11 +5±8 .004  41±14 47±16 +6±8 .000 .531 
LDLC 
(mg/dL) 
94±42 69±35 -25±27 .000  108±34 71±29 -39±33 .000 .092 
TAG  
(mg/dL) 
104±69 96±68 -7±61 .561  123±60 102±53 -20±55 .064 .405 
LDL-HDL 
ratio 
2.2±1.0 1.5±0.9 -0.7±0.8 .000  3.0±1.6 1.7±1.0 -1.3±1.1 .000 .043 
           
 
Abbreviations: TC, total cholesterol; HDLC, high density lipoprotein cholesterol; LDLC, low density 
lipoprotein cholesterol; TAG, triacylglycerides; Diff, Mean difference of month-6 minus baseline.  
 
Notes: All values are presented as mean±SD. P values for each group derived from paired t-test between 
baseline versus month-6 comparison. Overall P values derived using independent t-test, tested for mean 
differences of lipid profiles parameters between omega-3 and placebo groups (bold face).  
Data excludes values from 7 subjects (Placebo, n=4; Omega-3, n=3) who passed away (n=4, 2 from each 
group) or were hospitalized (n=3), during the course of the study. One subject (placebo) was excluded 
due to extremely high TAG levels (478mg/dL) as the Friedwald equation is not reliable when TAG levels 
exceed 400mg/dL.   
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TABLE 4-4. Means and standard deviations of nutritional status indicators (Ser. Alb, Hgb, MIS 
score, nPNA and BMI) at baseline and month-6. 
 Placebo (n=27)  Omega-3 (n=28) P 
overall  Baseline Month 6 Diff. P  Baseline Month 6 Diff. P 
Nutritional status          
Ser. Alb 
(g/dL) 
3.7±0.2 3.8±0.4 0.0±0.3 .756  3.6±0.3 3.7±0.3 0.1±0.3 .070  .295 
Hgb  
(g/L) 
11.0±1.0 11.3±1.7 0.2±1.7 .471  10.4±1.1 10.8±1.5 0.3±1.4 .282 .866 
MIS 
score 
7.6±3.6 8.1±4.0 0.6±4.0 .215  9.0±3.6 9.1±3.4 0.4±2.2 .408 .730 
nPNA 
 
0.96±0.38 0.91±0.22 -0.01±0.23 .810  0.99±0.29 0.87±0.25 -0.07±0.45 .471 .598 
BMI 
(kg/m2) 
25.4±5.6 25.1±6.1 0.3±1.8 .327  28.1±7.0 28.1±7.2 0.1±1.0 .699 .500 
           
 
Abbreviations: Ser.Alb, serum albumin; Hgb, hemoglobin; MIS, malnutrition inflammation score; 
nPNA, normalized protein equivalence of nitrogen appearance; Diff, mean difference of month-6 minus 
baseline. 
Notes: All values are presented as mean±SD. P values for each group derived from paired t-test between 
baseline versus month-6 comparison. Overall P values derived using independent t-test, tested for mean 
differences of lipid profiles parameters between omega-3 and placebo groups (bold face).  
 
Data excludes values from 7 subjects (Placebo, n=4; Omega-3, n=3) who passed away (n=4, 2 from each 
group) or were hospitalized (n=3), during the course of the study.	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TABLE 4-5. Means and standard deviations of inflammatory indicators at baseline and month-6. 
 Placebo (n=27)  Omega-3 (n=28) P overall 
 Baseline Month 6 P  Baseline Month 6 P  
         
NFkB (fold 
diff) 
2.48±1.03 2.54±1.14 .703  2.52±1.19 2.15±0.4 .129 .134 
 
CRP (mg/dL)* 6.6±8.3 11.0±13.9 .040  13.1±17.5 14.6±19.7 .565 .259 
 
CRP (mg/dL)** 4.9±5.6 4.6±12.0 .034  5.8±9.2 6.1±14.0 .412 
 
.326 
 
Abbreviations: CRP, C-reactive protein; NFkB, Nuclear factor kappa-light-chain enhancer of activated B 
cells. 
Notes: NFkB value is presented as mean fold difference (relative to control) ±SD. CRP value is presented 
as *mean±SD and **median±IQR.  P values for each group derived from either paired t-test (NFkB 
)/Wilcoxon rank sum test(CRP) between baseline versus month-6 comparison. Overall P values derived 
using either independent t-test/Mann-Whitney rank sum test, tested for mean differences of inflammatory 
parameters between omega-3 and placebo groups (bold face).  
Data excludes values from 7 subjects (Placebo, n=4; Omega-3, n=3) who passed away (n=4, 2 from each 
group) or were hospitalized (n=3), during the course of the study. 
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FIGURE 4-1. Omega-3 study’s flow chart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: MIS, Malnutrition-Inflammation Score. 
Notes: All patients at the Great Lake Dialysis clinic (n=105) were screened for eligibility. Sixty-nine 
patients met the inclusion criteria but 6 of them declined to participate. The remaining 63 patients were 
randomized into omega-3 and placebo groups and underwent intervention for 6 months. Seven additional 
subjects (Placebo, n=4; Omega-3, n=3) were excluded from data analysis due to death (n=4, 2 from each 
group) or hospitalization (n=3). Two patients voluntarily dropped out as they were unable to swallow the 
capsules but their data were included in the analysis (intent to treat).  
Assessed for eligibility 
(n=105) 
Randomization 
(n=63) 
Excluded (n=42) 
-­‐ Did not met exclusion 
criteria  (n=36) 
-­‐ Declined to participate 
(n=6) 
 
Allocated to Omega-3 
group (n=31) 
Allocated to placebo 
group (n=32) 
Baseline: blood 
collection, MIS, 
anthropometric data. 
Month-2: blood 
collection, MIS, 
anthropometric data. 
Month-6: blood 
collection, MIS, 
anthropometric data.	  
Analyzed  
(including drop out) 
(n=28) 
Analyzed 
(including drop out) 
(n=28) 
Voluntary drop-out  
(Unable to swallow the 
capsule) (n=2) 
Passed away 
(n=2) 
Passed away 
(n=2) 
91 
	  
	  
 
CHAPTER V 
SPECIFIC AIM 2: 
 EFFECTS OF TOCOTRIENOL-RICH FRACTION SUPPLEMENTATION ON 
NUTRITIONAL INDICES, INFLAMMATORY MARKERS, OXIDATIVE STATUS AND 
LIPID PROFILES IN CHRONIC HEMODIALYSIS PATIENTS 
This is an expanded version of the paper published in:  
Vascular Health and Risk Management. 2013; 9:747-761 [208]. 
Daud ZAM, Tubie B, Sheyman M, Osia R, Adams J, Quainton T, Tubie S, Khosla P. 
 
Introduction 
End-stage renal disease (ESRD) patients on chronic hemodialysis (HD) experience a higher risk 
for atherosclerotic vascular disease; cardiac death accounts for approximately 50% of all-cause 
mortality [209], which is 15-30 times higher than an age-matched general population [3, 5]. The 
increased cardiovascular risk in this setting however cannot be exclusively explained by 
traditional cardiovascular risk factors alone. Instead, a combination of various factors especially 
malnutrition-inflammation complex syndrome, oxidative stress and dyslipidemia are implicated 
[11, 12, 210].  
 Patients on HD treatment often present with malnutrition-inflammation complex 
syndrome characterized by coexistence of protein-energy malnutrition and inflammation 
pertaining to dialysis related factors, disease processes, various comorbidities, nutrient loss and 
poor nutritional intake [74]. Chronic systemic inflammation which is commonly found in 30-
50% of ESRD patients exacerbates oxidant production. This is aggravated by low intake of 
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antioxidants, secondary to malnutrition and dietary restrictions in this population [211]. In fact, 
low circulating plasma levels of antioxidants have been shown to correlate with carotid 
atherosclerosis in ESRD patients [212]. Equally noteworthy, unadjusted analyses of 4D (Die 
Deutsche Diabetes Dialyse Studie) study revealed that HD patients in the lowest plasma vitamin 
E (α-tocopherol) quartile had a 79% higher risk of stroke and 31% higher risk of all-cause 
mortality as compared to their counterpart in the highest quartile; however, this was confounded 
by malnutrition [213].  
 Additionally, in ESRD patients on dialysis, dyslipidemia is highly prevalent due to 
delayed catabolism of triglyceride-rich apolipoprotein B containing lipoproteins, which 
subsequently leads to elevated triacylglycerol (TAG) and low plasma HDLC [15]. In a study of a 
large cohort of incident dialysis patients (n= 21, 893), it has been shown that dyslipidemia 
present in 82% of the population was predominantly manifest as elevated TAG (52%) and very 
low density lipoprotein (VLDL) (52%), and decreased HDL (51%) [214].  Furthermore, 
accumulating evidence indicates that the concentration of plasma apo-A1 and lecithin-cholesterol 
acyl-transferase (LCAT) are decreased [16, 17] which in turn impedes HDL-mediated reverse 
cholesterol transport [18], a process of disposing excessive cholesterol from extrahepatic tissues 
and blood vessel walls. Taken together, a combination of oxidative stress, lipid disorders and 
inflammation in this population is highly conducive for atherogenesis by promoting LDL 
oxidation, monocyte activation, endothelial injury and consequently accumulation of lipids in the 
artery wall [18].   
 Dietary intervention may be potentially beneficial in improving inflammatory status, 
correcting oxidative stress and the observed dyslipidemia. However, there is paucity of 
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information regarding the impact of dietary interventions with nutrients possessing antioxidant, 
anti-inflammatory or lipid altering properties to correct these problems in the HD population.   
 Tocotrienols (TT) are dietary compounds that have gained increasing scientific scrutiny. 
TT are members of the Vitamin E family which also includes Tocopherols (TP). Vitamin E is 
comprised of 8 different isomers (four TP and four TT) designated α-, β-,γ- and δ, characterized 
by a different number and position of methyl group attached on the chromanol ring. TT are the 
unsaturated members of the vitamin E family, found primarily in palm fruit oil, rice bran and 
annatto. In the US diet however, TP particularly γ-TP is the most abundant form of vitamin E, 
derived primarily from plant seeds and vegetable oils [117].  
 Comparisons of antioxidant activities amongst vitamin E family members in rat liver 
microsomes revealed that TT exhibited 40- to 60- fold higher activities against lipid peroxidation 
(Fe2+ + ascorbate and Fe2+ + NADPH induced) and greater radical scavenging potency than TP 
[129, 130].  However, in vivo, antioxidative properties of TT could be limited by physiological 
process (e.g. absorption, distribution, metabolism and excretion), but TT have been found to be 
as equally potent as TP [116, 215]. More importantly, TT also play a role beyond their known 
antioxidant activity – i.e. they possesses an anti-inflammatory property which has been shown to 
inhibit lipopolysaccharide-induced secretion of interleukin-6 (IL-6) and tumor necrosis factor 
(TNF) in macrophages [37], and decreased C-reactive protein (CRP) in human volunteers [135].  
Additionally, TT may also confer cardioprotective effects by improving lipid profiles (reduced 
total cholesterol and TAGs) [142, 216], and lower oxidation of LDL cholesterol [137]. 
 To our knowledge, there are no reported TT studies in HD patients, whereas 17 TP trials 
have been reported, albeit with inconclusive results [24]. Majority of these studies were open 
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label aimed at improving oxidative stress while only three studies used a randomized controlled 
trial (RCT) design that included 95 patients cumulatively. Of the three studies, Diepeveen et 
al[166] provided 800IU/day for 12 weeks (~536mg) of α-TP in combination with 40mg/day of 
atorvastatin but failed to show any effects on plasma-oxidized LDL. On the other hand, Uzum et 
al[167] provided 300mg TP/day for 20 weeks and showed decreased plasma oxidative stress 
markers (MDA and erythrocyte osmotic fragility).  
 Despite the lack of TT studies in ESRD population, several studies have shown beneficial 
effects of TT supplementation in the general population. Cardioprotective effects of TT in these 
studies have been primarily attributed to its anti-oxidative, anti-inflammatory and lipid lowering 
properties. In a study by Heng et al [135], TT supplementation in healthy volunteers resulted in 
lower CRP levels, which has been regarded as a prognostic indicator for cardiovascular events 
and mortality in ESRD patients [6, 7].  In addition, supplementation with TT-rich fraction from 
palm oil (200mg/day for 8 weeks) plus statin in hypercholesterolemic human subjects resulted in 
improved  lipid profiles while minimizing the side effects of statins [142]. A recent study showed 
that palm oil derived TRF increased plasma HDL-C in the elderly following 6 month of 
supplementation [132]. Lipid altering effects of TT was attributed to their ability to suppress, and 
stimulate ubiquitination and degradation of HMG-CoA reductase as well as to block the 
processing of SREBPs as demonstrated in cell culture studies [139, 217]. 
  Given that HD patients experience oxidative stress, chronic inflammation and 
dyslipidemia and that TT are potent antioxidant and anti-inflammatory agents with the potential 
to improve lipid profiles, we hypothesized that TT supplementation would be of benefit to HD 
patients by improving one or more of the above conditions. The results from this pilot study form 
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the basis of the current report. To the best of our knowledge, this is the first study to report the 
role of TT in HD patients.  
Methods 
Patients 
All patients (n=118) from the Great Lake Dialysis Clinic (Detroit, MI, USA) were screened for 
eligibility. Patients were eligible for enrolment if they were at least 18 years of age, and had been 
on dialysis treatment for at least 3 months prior to the study. Patients who were residents of 
nursing homes or receiving nutritional support (tube feeding/ intradialytic parenteral nutrition) 
were excluded. None of the patients in the unit were known to have AIDS or to be on active 
treatment for cancer. All patients were undergoing dialysis with the same high-flux dialyzer 
membrane (Fresenius Optiflux Dialyzer, Fresenius Medical Care, Waltham, MA, USA).  
Study design and procedures 
The present study was approved by the Human Investigation Committees of Wayne State 
University and Great Lake Dialysis, LLC. Written informed consent was obtained from all 
patients. A total of 88 patients met the inclusion criteria, but, seven patients refused to participate 
leading to a final number of 81. Based on the final number of participants, randomization was 
made in blocks in order to keep the sizes of the treatment groups similar and groups were 
uniformly distributed by key-outcome measures. Block sizes were randomly selected to reduce 
the potential for selection bias. This process was performed using the Random Allocation 
Software version 1.0 [218]. A total of 81 patients were randomly allocated into TRF (n=41) and  
placebo (n=40) groups. All clinical investigators and laboratory personnel as well as the study 
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participants were blinded from group allocation and treatment until the end of the study. A 
summary of the study’s flowchart is shows in Figure 5-1. 
Nutritional intervention and compliance 
TRF and placebo capsules were formulated by Carotino Sdn. Bhd. (Johor, Malaysia). TRF soft 
gel capsules used were commercially available, each consisted of 90mg TT (comprising 30.18 
mg α-, 5.30 mg β-, 41.66 mg γ-, and 12.86 mg δ-TTs) and 20.00 mg α-TP. Placebo capsules 
contained negligible amounts of TT (0.12 mg α-, 0.06 mg β-, and 0.06 mg γ-TT) and TP (0.29 
mg α-, 0.04 mg β-, and 0.11 mg γ-TP-) (Table 5-1). Patients were provided with two TRF or 
placebo capsules during each of three weekly dialysis sessions. They were also supplied with a 
pill organizer that contained TRF or placebo capsules for non-dialysis days. Patients were 
instructed to consume two capsules during main meals (one during lunch and one during dinner).   
Compliance was ascertained by “directly observed treatment” [175] – which involved nurses 
directly observing patients taking their supplement capsules during designated days of dialysis. 
Supplementation adherence on the non-dialysis days was measured by pill counting as described 
elsewhere [219]. Briefly, patients returned the pill organizer each week and received refills - the 
left over soft capsules in the pill organizer were counted and recorded.    Potential changes in diet 
pattern were ascertained by collecting 24-hour diet recalls from all subjects (at baseline and week 
16) by the same Registered Dietitian. Energy, macro- and micronutrients intake were analyzed 
using Nutritionist-Pro (First Databank, Chicago, IL) based on the USDA database. Because TT 
were not included in USDA database, their content was estimated based on published values 
[115, 220, 221]. 
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Anthropometry, blood sampling and laboratory measures 
Anthropometry measurements comprised height and weight. Patients’ weights were recorded to 
the nearest 0.1kg (Tronix Flush-Mounted In-Floor Scale, Scale-Tronix, White Plains, NY, USA) 
after each HD session to determine estimated dry body weight. Height was measured to the 
nearest 0.1cm using a Tanita Wall Mounted Height Rod (Tanita, Arlington Heights, IL, USA). 
BMI was calculated based on the Quetelet’s Index [170]. 
 Approximately 15mL of fasting (for ~10 hrs) midweek predialysis blood samples were 
collected from existing access sites of each study participant into two blood collection tubes. 
Blood samples were collected into tubes (Becton Dickson, Franklin Lakes, NJ, USA) containing 
either EDTA (for lipid analyses) or lithium heparin (for inflammatory markers and oxidative 
status analyses) at baseline and wks-8 (lipid analyses only), 12 and 16.  Plasma was isolated by 
centrifugation at 2800rpm for 20 minutes at 4oC, divided into aliquots and immediately stored at 
-80oC until further analysis.  Serum samples for standard renal profiles (serum albumin, BUN, 
creatinine) were analyzed using standard automated laboratory techniques by an external 
laboratory (Ascend Clinical Laboratory Services, Redwood City, CA, USA).  
 Plasma Total cholesterol (TC), and TAG was determined by enzymatic reaction (Pointe 
Scientific Inc., Canton, MI, USA). HDLC was measured in the supernatant after precipitation of 
apoB-containing lipoproteins by dextran sulfate and magnesium ions (Pointe Scientific Inc., 
Canton, MI). LDLC was calculated using the Friedewald equation by difference (LDLC = TC 
minus HDLC minus TAG/5).   
 CRP levels were measured using commercial kits based on enzyme-linked 
immunoabsorbent assay (ELISA) method as per the manufacturer’s protocol (Cayman Chemical, 
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Ann Arbor, MI, USA).  Plasma samples were diluted in the assay buffer into 1:15,000 and 
100µL of each sample was placed into a 96-well microplate that had been coated with a 
monoclonal antibody specific for human CRP and incubated for an hour. The plate was then 
rinsed four times with wash buffer before addition of horseradish peroxidase-labeled CRP 
monoclonal antibody. Two antibodies were added and formed a sandwich by binding to different 
locations on the CRP molecule. CRP concentration in the plasma samples were measured at 
450nm after addition of chromogenic substrate tetramethybenzidine that formed a distinct yellow 
color. IL-6 (Thermo Scientific, Rockford, IL, USA) , ApoA1 (Immunology Consultants Lab. 
Inc., Portland, OR, USA) and TNFα in the plasma was also measured using similar principles per 
manufacturers’ protocol. NFκB p65 levels were measured in the nuclear extract of peripheral 
blood mononuclear cells as described in details in Chapter III.  
 Total antioxidant power (TAP) of the plasma was measured using commercial kits based 
on a cupric reducing antioxidant capacity spectrophotometric method (Oxford Biomedical, 
Oxford, MI, USA).  Briefly, 200µL of diluted plasma samples (1:40 of plasma/dilution buffer) 
were placed in a 96-well microplate followed by the addition of copper solution (50µL) and stop 
solution (50µL). The reduction potential in the plasma sample converts Cu2+ into a reduced form 
of copper (Cu1+) which in turn formed a stable 2:1 complex with the chromogenic reagent. This 
color complex was quantified with an absorption maximum at 450nm. Standard curve was 
prepared using a known concentration of trolox with data being expressed as mM trolox 
equivalents.  
 Malondialdehyde (MDA) in the plasma was measured indirectly based on the reaction of 
a chromogenic reagent, 2-thiobarbituric acid with MDA using a spectrophotometric method 
(Oxford Biomedical, Oxford, MI, USA). Plasma samples were deprotinized with trichloroacetic 
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acid (Fisher Scientific, Fair Lawn, NJ, USA) and the supernatant was obtained by centrifugation. 
Total MDA in the deprotinized  plasma samples were determined by the addition of indicator 
solution followed by incubation at 65oC for 30 mins and the color complex was quantified with 
an absorption maximum at 540nm. Standard curve was prepared using a known concentration of 
MDA stock solution supplied in the kit.  
Statistical Analysis 
All results were analyzed using intention-to-treat principle in which all data were counted 
regardless of post-randomization withdrawal and any missing values were reported accordingly. 
Statistical analyses were carried out using SPSS v.16 (IBM, Chicago, IL, USA). Data for 
categorical variables were reported as number and percentage, while continuous data were 
reported as mean±standard deviation or median±interquartile range for skewed variables. 
Between group difference in the change in parameters at particular time points were tested using 
independence t-test (or respective non-parametric test for non-normality distributed variables). 
One way repeated measures ANOVA were used to test time effects (the change from baseline) 
for variables of interest in each group. χ2 statistics was used to evaluate differences in categorical 
variables. Correlations between selected variables were calculated using Pearson’s correlation 
coefficients test. P values of <0.05 is regarded as statistically significant. 
Results 
Characteristics of the study population 
A total of 81 patients were randomized into placebo (n=40) and TRF (n=41) groups and were 
provided either TRF or placebo capsules for 16 weeks. Two patients in the placebo group died 
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due to cardiac arrest during the course of the study. An additional two patients (1 placebo; 1 
TRF) were excluded due to transplantation and catheter dysfunction, respectively.  
 Table 5-2 shows the clinical and demographics characteristics of the study population. 
There were no significant differences in all demographic and clinical variables at baseline. Our 
study population was homogenously comprised of African-American ethnicity. Average body 
mass index for placebo (28.7±8.2 kg/m2) and TRF (30.3±8.1 kg/m2) groups were in the category 
of overweight based on WHO (2000) classification [171]. Over 60% of the patients in both 
placebo and TRF groups had diagnosed Diabetes Mellitus. Moreover, ten patients (5 placebo; 5 
TRF) was positive for hepatitis C antibody test (RIBA Reflex Siemens Centaur 
chemiluminescent assay). Lipid lowering drugs (statins) were used by 28 patients (11 in placebo; 
17 in TRF), aspirin were prescribed to 47 patients (22 placebo; 25 TRF) and 69 patient were 
prescribed one or more type of antihypertensive drugs (35 placebo; 34 TRF). However, there 
were no differences in term of drug distribution between the two groups based on χ2 test. In term 
of dialysis parameters, both placebo and TRF groups had comparable dialysis treatment 
adequacy as measured by Kt/V (K – dialyzer clearance of urea, t- dialysis time, and V- volume 
of distribution of urea). In term of vascular access route, both groups had a similar proportion of 
patients using either an arteriovenous fistula (18 placebo; 15 TRF), an arteriovenous graft (13 
placebo; 16 TRF) or venous catheter (9 placebo, 10 TRF).  
Dietary intake, tolerability, side effects and compliance 
Dietary analysis based on 24-hr dietary recall during baseline and wk-16 of the study showed 
that there were no changes in energy and macronutrients, between the two groups at a given 
particular time point. There were no differences in vitamin E (TP and TT) intake at baseline and 
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wk-16.  Similar results were also seen in vitamin C, β-carotene and other micronutrients 
(potassium, phosphorus) intake within and between the groups (Table 5-3). Meanwhile, a total 
of 62% of our study population [58% placebo (n=23) and 66% TRF (n=27)] were taking dietary 
supplements that comprised of Renalcaps (18% placebo; 18% TRF), Nephrocaps (3% placebo; 
3% TRF), vitamin C (0% placebo; 2% TRF) and multivitamins (2% placebo; 2% TRF). 
Nephrocaps and Renalcaps comprised of 100mg vitamin C, 1.5mg Thiamine, 1.7mg Riboflavin, 
20mg Niacin, 10mg Vitamin B6, 1 mg Folate, 6µg vitamin B12, 150µg Biotin and 5mg 
pantothenic acid (Figure 5-2).  
 TRF and placebo supplements were well tolerated by the subjects. During the first week 
of the study, one patient from the placebo group reported of diarrhea but this was not related to 
supplementation and subsequently resumed the study. No other adverse effects were reported 
from subjects in either groups to justify removal from the study. In the current study, compliance 
was ascertained by direct and real-time observation of subjects taking the supplements during 
dialysis sessions (three times a week) as well as pill counting method on non-dialysis days. 
Compliance during non-dialysis days was more than 70% for each week except during wk-14 
and wk-15 due to holidays (Thanksgiving). There were no differences in capsule consumption 
(% of capsule disappearance) between placebo and TRF groups during the course of study 
(Figure 5-3).  Compliance of supplementation at home was relatively good considering that the 
study population was comprised of low income and low literacy group which typically is 
associated with poor compliance [175, 222].  
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Effects on nutritional, inflammatory and oxidative markers 
Nutritional, inflammatory and oxidative indices are presented in Table 5-4. Data for CRP and 
IL-6 are reported in median±IQR because they were skewed. Median CRP levels at baseline was 
16.6±28.8 and 13.0±20.5mg/L for the placebo and TRF group, respectively. There were no 
difference in CRP levels between TRF and placebo at each time point. No significant changes 
were noted in the CRP levels in both groups per repeated measures one-way ANOVA. Similarly, 
there was no difference in mean IL-6 between or within groups at all time points.  
 Similarly, there were no significant changes (repeated measures one-way ANOVA) 
observed in NFκB p65 levels over the time in both groups. It is important to note that, at 
baseline, NFκB p65 levels in TRF group is significantly higher than placebo (91.7±9.8 vs 
54.2±10.5 pg/µL, p<0.05, respectively). Upon normalization into the baseline value (week-12 
minus baseline), TRF group showed marginal difference (p=0.08) when compared to placebo (-
16.7±13 vs 15.1±11 pg/µL) (Figure 5-4).  Another inflammatory marker, TNFα, also 
demonstrated similar results in which there were no significant difference noted within and 
between groups as measured at baseline and week-12 of the intervention (Figure 5-5). 
 Measurement of TAP showed that the TRF group had significantly higher TAP (p<0.05) 
at wk-12 as compared to placebo (626±98 vs 564±95 mM Trolox equivalent). However, no 
changes were observed within the TRF and placebo groups when compared to the baseline.   
This was also in concert with indirect measurement of MDA, a marker for oxidative stress, in 
which TRF group had a marginally lower MDA (2.60±2.28 µM MDA) at week-12 as compared 
to placebo group (4.68±5.72 µM MDA) (p=0.055). There were no significant changes in MDA 
values within the TRF and placebo groups when compared to the baseline. In terms of nutritional 
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indicators (serum albumin, hemoglobin, BMI), no changes were observed within or between 
groups.   
Effects on lipid profiles 
Plasma TAG levels was significantly reduced in TRF group after 12 weeks of supplementation 
as compared to baseline values (144±91 vs 113±47 mg/dL plasma, p<0.05) and remained 
significantly reduced at wk-16 (144±91 vs 103±45 mg/dL plasma, p<0.05). In contrast, TAG 
levels remained the same in the placebo group. Interestingly, both groups showed a progressive 
decline in plasma TC and a significant improvement in HDLC when compared to the baseline 
values starting at wk-8. Hence, this also resulted in a reduction of LDL-C and the ratio of 
TC/HDLC (Table 5-5).  
 As TAG levels were somewhat higher in the TRF group at baseline, values were 
normalized to these baseline values.  Normalized plasma TAG were reduced in the TRF group as 
compared to placebo at wk-12 (-33±84 vs 6±66 mg/dL, p=0.032), and at wk-16 (-36±79 vs -
8±47 mg/dL, p=0.072) (Figure 5-6). Plasma HDLC was significantly higher in the TRF group as 
compared to placebo at both wk-12 (22±15 vs 9±11 mg/dL, p<0.0001) and wk-16 (16±14 vs 
10±9 mg/dL, p<0.05, respectively) (Figure 5-7).  
 Measurement of ApoA1 concentration in the plasma, a major protein component of HDL 
particles,  revealed that it was significantly higher in TRF group as compared to placebo at wk-
12 (1.56±0.59 vs 1.27±0.34 mg/mL, p<0.05, respectively) consistent with  the higher HDL-C  
concentrations (Figure 5-10). However, no difference was noted between groups at wk-16.  
 Measurement of CETP activity, a plasma protein that facilitates the transfer of cholesteryl 
ester from HDL in exchange for triacylglycerols from TAG-rich lipoprotein, was significantly 
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lower in the TRF group at wk-16 as compared to placebo (96±18 vs 129±43 pmol/mL plasma/hr, 
p<0.001, respectively), which reflected the higher HDL-C value in TRF group. Interestingly, 
CETP activity was slightly higher in TRF group during wk-12 (95±19 vs 84±19 pmol/mL 
plasma/hr, p<0.05, respectively). Pearson’s correlation test between HDL-C levels and ApoA1 
concentration during wk-12 and wk-16 showed a significant correlation between the two 
variables. Similarly, significant correlations were observed between plasma TAG and CETP 
(Figure 5-11).  
Correlation between biochemical parameters 
Table 5-6 depicted Pearson’s correlation coefficient test between nutritional indicators, 
inflammatory markers and oxidative status parameters based on pool data (baseline + week-12 + 
week-16). MDA as indicator of oxidative stress has an inverse relationship with TAP (r= -0.273, 
p<0.01) indicating that higher total antioxidant capacity in the plasma confers some protective 
effect against the reactive species – MDA. Moreover, MDA levels were also significantly 
correlated with CRP (r=0.501, p<0.01), exemplifies the complex relationship of inflammation 
and oxidative stress as discussed in Chapter II. Serum albumin was also positively correlated 
with TAP suggesting the antioxidant role of albumin (by localized thiol moieties) as previously 
reported elsewhere [11]. Furthermore, serum albumin was inversely correlated with CRP levels 
(r= -0.163, p<0.05) due to the fact that it is a negative-acute phase protein while CRP is the 
positive-acute phase protein. Increased in CRP is therefore lead to a decreased in serum albumin.  
 The summary of Pearson’s correlation coefficient test between lipid profiles (TC, TAG, 
HDLC, LDLC and TC-HDLC ratios) is presented in Table 5-7. In brief, CRP was positively 
correlated with TAG (r= 0.159, p<0.05) while had an inverse relationship with HDLC (p= -
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0.163, p<0.05) suggesting the protective role of HDLC. Similarly, LDLC showed a positive 
relationship with MDA (r= 0.138, p<0.05). Interestingly, when compared to dietary intake 
parameters, total fat and cholesterol intake were inversely correlated with HDLC, while 
cholesterol and vitamin E intake had a positive relationship with TAG levels.  
Discussion 
The present study, to the best of our knowledge, is the first to report the extent of vitamin E 
tocotrienol-rich fraction supplementation effects on inflammatory markers, oxidative status and 
lipid profiles in HD subjects. This study highlights some important findings especially in the 
lipid altering properties of TT which could potentially have clinical implications. Patients in both 
placebo and TRF group had comparable demographics, percentage of smoking cigarettes, 
dialysis and clinical parameters distribution. In addition, baseline inflammatory markers, 
oxidative status and lipid profiles in both groups were not statistically different. Thus any 
potential comorbidities and confounding factors were minimized by being randomly distributed 
across the two groups.  
 In this study, we observed that baseline median CRP levels in both groups were relatively 
higher as compared to commonly reported values in the literatures [223, 224]. However, this is in 
accordance with our previous results [175] despite methodological differences between the two 
studies. The fact that gradual increments in CRP levels were seen in both groups might suggest a 
progressive inflammatory burden in this population. Results from the present study indicated that 
short term TRF administration was unable to improve CRP levels in HD patients. This is in 
contrast with recent TRF trial that has been conducted in healthy volunteers which showed 
reduction in CRP levels in older subjects [135]. We speculate that this is partially due to high 
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interindividual variability in CRP levels, which is often associated with transient intercurrent 
clinical events and the dynamic response of immune system [225]. Despite  the high predictive 
power of mortality in a single CRP measurement [73], given the fact that CRP fluctuates 
dramatically upon acute inflammation [226] or even in the absence of changes in other 
biochemical measures or health status [226-228], CRP measurement alone may not adequately 
capture immunomodulatory changes following therapeutic intervention, thus necessitating 
measurement of other inflammatory biomarkers. Similar observations were also seen in IL-6, 
NFκB p65 and TNFα values. In term of oxidative status parameters, no significant improvements 
were seen in TAP and MDA values in either TRF or placebo group over time, but the TRF group 
had higher TAP and marginally lower MDA at week-12 but these was not seen at week-16. 
Taken together, TRF supplementation failed to improve inflammatory and oxidative status 
markers in the current study.  
 Interestingly, TRF supplementation resulted in improvement in plasma TAG and HDLC. 
The improvement in lipid profiles was less anticipated due to mixed results in previous human 
trials. For example, Mustad et al [144] administered 200mg TT/day for 28 days in healthy 
hypercholestrolemic volunteers but failed to show any effects on blood lipids. Similarly, 
supplementation with a TT-rich vitamin E concentrate (140mg TT, 80mg TP per day) to 20 men 
for 42 days showed no improvement in lipoprotein profiles despite changes in plasma 
tocopherols and tocotrienols concentration [143]. We speculate that the earlier studies in human 
volunteer did not show a positive result in blood lipids due to a shorter duration, a smaller dose 
and sample size. A recent study which administered TT for a longer period (6 months) in healthy 
older adults showed significant improvement in lipid profiles (increased HDL-C and improved 
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TC/HDLC ratios) [132], which strengthen the speculation that TT effects on blood lipids could 
be a function of time and may depend on subject’s clinical status. 
 Because dyslipidemia is implicated in the pathogenesis of cardiovascular diseases, 
therefore, it has become more common for dialysis patients with dyslipidemia to receive statin 
treatment [229], albeit with conflicting evidence [69]. In our study population, 11 patients in 
placebo group and 17 patients in TRF group were on statin treatment. Statin induced inhibition 
of HMG CoA reductase leads to depletion of hepatic cholesterol pools and subsequently 
decreases production of apoB-containing VLDL particles and upregulates LDL receptors. 
Because VLDLs are the major TAG-trafficking lipoprotein in fasting plasma, therefore statins 
reduce TAG by enhancing clearance of VLDL and reuptake of LDL via LDL receptors. In the 
present study, TAG levels were significantly reduced in TRF groups at wk-12 but not at wk-16 
(p=0.07) partly due to high variability in both groups. We postulated that this variability may 
partly be due to statin users in the placebo group. Additional analysis among statin users revealed 
that the TAG reduction observed in the placebo group was indeed due to statin administration 
(Figure 5-8). Interestingly, in TRF group, both the statin and non-statin users showed a 
reduction trend in TAG, which strengthens the speculation that TRF may be directly involved in 
the TAG reduction process. Similar findings has been shown in a randomized, placebo-
controlled clinical trial by Zaiden et al [140]  in which supplementation with 120mg of γ-,δ-
tocotrienols (γ-,δ-T3)  for 8 weeks resulted in an ~ 28% reduction in TAG as compared to 
baseline. This improvement in TAG was partly explained by suppression of the upstream 
regulators of lipid homeostasis as demonstrated in an in-vitro study [140]. 
 The increase in HDL-C levels in the plasma can be attributed in part to increased 
production of HDL particles, delayed catabolism of HDL particles or higher cholesterol contents 
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in HDL particles. To elucidate the mechanism of TT effects on TAG and HDL-C during wk-12 
and wk-16, ApoA1 and CETP were measured. Our results showed that the ApoA1 level was 
significantly higher in the TRF group during wk-12, which coincided with higher HDL-C in the 
TRF group. Because ApoA1 is the major protein component of HDL particles (70%), increased 
HDL-C levels at wk-12 in the TRF group may be explained by an increase in HDL particles 
(mirrored by higher ApoA1 concentration). Pearson’s correlation test between HDL-C levels and 
ApoA1 concentration during wk-12 and wk-16 confirmed significant correlation between the 
two variables.  
 Animal studies have established that about one third of ApoA1 is catabolized by the 
kidney and the rest by the liver - humans are assumed to have similar pathway of ApoA1 
catabolism [230, 231]. In the context of ESRD patients, because kidney functions are impaired, 
this also hypothetically leads to reduction of ApoA1 catabolism. Conversely, a recent study 
showed that ESRD patients on HD have higher prevalence of autoantibodies to ApoA1 (anti-
ApoA1 IgG) which correlates with dialysis vintage [232]. Similarly, in a comparative study 
between healthy control and hemodialysis patients, Pahl et al [233] found that plasma HDL-C is 
markedly reduced in HD patients which was mirrored by reduced ApoA1 plasma concentration. 
Taken together, these may partially explain low HDL-C observed in ESRD/HD patients.   
 In the context of our study, the TRF supplemented group had significant increase in 
HDL-C which was reflected by higher plasma ApoA1 concentration. In concert with the current 
study, Heng et al [135] demonstrated that supplementation with 150mg/day TRF in a healthy 
population resulted in increased expression of ApoA1 precursor. The effect on ApoA1 may not 
be unique to TT per se because α-TP supplementation also increased pro apoA1 and apoA1 
concentration [234]. Literature on molecular explanation of TRF effects on ApoA1 expression is 
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scarce, thus further investigation in this area is warranted. It is possible that TRF and tocopherol 
exhibit antioxidant like mechanism which implicates several transcription factors such as MAP, 
PPARα and PPARγ in the upregulation of proapoA1 [234].  
 CETP activity was lower in TRF group during wk-16, consistent with the higher HDLC 
value.  CETP mediates the transfer of cholesterol ester from HDL to VLDL remnants in 
exchange for triacylglycerols [18]. Because HD patients usually experience delayed catabolism 
of TAG rich lipoprotein, therefore, we speculate that CETP activity may be increased to facilitate 
TAG-Cholesterol transfer between HDL and apoB100 lipoproteins. A recent study that 
compared HDL-associated enzymes in HD vs healthy control subjects confirmed that HD 
patients have higher CETP as compared to control [71], while another study reported no changes 
in CETP [18]. In our study Pearson’s correlation test between CETP activity and TAG 
concentration during wk-12 and wk-16 confirmed significant correlation between the two 
variables.  
 Hemodialysis patients are frequently hospitalized due to concurrent comorbidities. In the 
current study, we monitored missed dialysis sessions for each patient and the primary reason was 
recorded. Cumulative numbers of missed dialysis session for each group were calculated (Figure 
5-12). The total days of hospitalization was 122 vs 180 days for the TRF and placebo groups, 
respectively. This is an intriguing observation. It should be noted that in a recent study in end 
stage liver disease (ESLD) patients Patel et al reported that supplementation with 400mg TT/day 
in ESLD patients slowed the rise in MELD scores (a standardized scoring system that is 
clinically used to determine severity of liver failure and priority for transplantation) in 50% of 
the patients receiving TT supplementation [169]. Coupled with our initial observation, it is 
possible that TT therapeutics may provide benefit due to their ability to penetrate vital organ 
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tissues. However, this hypothesis is purely speculative at present and warrants further 
investigation in a larger cohort. 
 It is important to emphasize that the comparisons here are made to the studies that either 
used α-TP in HD patients or studies that used TT/TRF in healthy volunteers of different clinical 
population. Given that TT possesses the distinct functions from TP in the context of its 
antioxidant and anti-inflammatory properties; therefore there are no comparable vis-a-vis studies 
in HD patients.   
Limitations of the study 
The present study highlights beneficial treatment effects of TRF on lipids. Nevertheless, the 
results of this study should be interpreted with caution. Firstly, the study was homogenously 
comprised of a single race, and the majority of the patients were in low-income, low-literacy 
group. Therefore, the positive outcome of TRF on lipids may not be generalizable to a more 
diverse HD population. Secondly, compliance may have been a factor.  However our study 
design enabled us to directly monitor and observe patients taking their supplement during regular 
dialysis days, while we were able to estimate consumption on non-dialysis days by the pill 
counting method. Dietary changes were monitored by a single 24-hr dietary recall at baseline and 
at the end of the study. We acknowledge the limitation of this method to adequately capture 
dietary changes, however given the fact that diet monotony of dialysis patients plus limited 
contribution of TT-rich food sources to our patients’ diet, we believe that variation in dietary 
contribution of TT is clinically less important in contributing to the outcome of the present study. 
Finally, the number of subjects in our cohort did not allow us to separate the effects of the 
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various medication regimens (e.g. statins, anti-hypertensive drugs, aspirin) from the effects of TT 
per se. 
 We did not measure TT in the blood, as the focus of the study was to observe the global 
effects following oral supplementation, and not to look at the pharmacokinetics of tocotrienol 
supplementation per se.  It is known that TT are transported in circulating lipoproteins,[124, 235, 
236] albeit with a short half-life[123] but recent data shows that they are indeed delivered to vital 
organs.[169] Correlating plasma TT following supplementation in HD patients will be of 
importance in the future as dose-escalation studies are contemplated to ascertain the optimal dose 
of TT required in this population.  
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Tables and figures 
 
TABLE 5-1. TRF and placebo capsule composition 
Content (mg) TRF  
 
Placebo  
  
Tocopherol (TP)   
    α-TP 20.00 0.29 
    β-TP  - 0.04 
    δ-TP - - 
    γ-TP - 0.11 
Tocotrienol (TT)   
    α-TT 30.18 0.12 
    β-TT  5.30 0.06 
    δ-TT 41.66 - 
    γ-TT 12.86 0.06 
   
 
Notes: TRF capsules were formulated from oil palm fruits while placebo capsules from wheat germ oil. 
Other ingredients include the same amount of medium chain triglycerides in both capsules. 
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TABLE 5-2. Baseline clinical and demographic characteristics of the study population. 
 
 Placebo 
(n=40) 
TRF 
(n=41) 
P value 
Demographics    
Age (yrs) 58±13 59±12 0.565 
Age > 65 yrs (n, %) 12 (30) 14 (34) 0.689 
Ethnicity    
     African American (n, %) 40 (100) 40 (97.5) - 
Gender (males, %) 23 (57.5) 20 (48.8) 0.432 
Smoking cigarettes (n, %) 10 (25.0) 10 (24.3)  
    
Clinical    
Diabetes Mellitus (n, %) 26 (65) 25 (61) 0.708 
Hepatitis C (n, %) 5 (12.5) 5 (12.2) 0.967 
Time on dialysis (months) 37±18 34±19 0.446 
BMI (kg/m2) 28.7±8.2 30.3±8.1 0.768 
Systolic B/P (mmHg) 150±24 153±23 0.651 
Diastolic B/P (mmHg) 81±15 83±14 0.506 
Kt/v 1.48±0.26 1.45±0.20 0.516 
Statins (n, %) 11 (27.5) 17 (41.4) 0.124 
Aspirin (n, %) 22 (55.0) 25 (61.0) 0.297 
Anti-hypertensive, one or more type 
(n,%) 35 (87.5) 34 (82.9) 0.562 
Vascular access   0.732 
    Arteriovenous fistula (n, %) 18 (45) 15 (36.6)  
    Arteriovenous graft (n, %) 13 (32.5) 16 (39)  
    Venous catheter (n, %) 9 (22.5) 10 (24.4)  
 
Abbreviations: BMI= Body Mass Index; B/P=blood pressure;  Kt/V=Index of Dialysis Adequacy. 
 
Note: Data are reported as mean±SD for continuous variables and number (percentage) for categorical 
variables. P values are comparison between groups at baseline obtained from independent t-test or 
Pearson χ2 test wherever appropriate, 
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TABLE 5-3.  Energy, macronutrients and micronutrients intake during the course of the study. 
 Baseline Week-16 
 All 
(n=81) 
Placebo 
(n=40) 
TRF 
(n=41) 
P 
value 
All 
(n=71) 
Placebo 
(n=34) 
TRF  
(n=37) 
P 
value 
Energy 
(kcal/day) 
1995±977 2132±1243 1868±633 N.S. 1544±580 1505±545 1580±616 N.S> 
Protein 
(gm/day) 
94±59 99±80 88±31 N.S. 75±40 75±36 76±44 N.S. 
Carbohydrate 
(gm/day) 
209±106 204±100 213±111 N.S. 178±79 177±71 180±85 N.S. 
Fat 
(gm/day) 
90±68 105±90 76±37 N.S. 60±32 57±23 63±39 N.S. 
Vit A 
(IU/day) 
7371 ± 
19372 
5524 ± 
7415 
9172 ± 
26273 
N.S. 6015 ± 
9645 
6377 ± 
12115 
5718 ± 
7193 
N.S. 
Vit C 
(mg/day) 
98±84 89±82 108±86 N.S. 90±105 102±112 80±98 N.S. 
Vit E 
(mg/day) 
9±10 9±9 10±12 N.S. 6±4 5±3 6±5 N.S. 
Tocotrienols 
(mg/day) 
2.5±3.8 2.3±3.8 2.6±3.8 N.S. 1.6±2.3 1.6±1.5 1.6±2.8 N.S. 
Potassium 
(mg/day) 
2350±872 2329±1266 2371±2334 N.S. 2015±919 1962±961 2058±894 N.S. 
Phosphorus 
(mg/day) 
1183±652 1181±722 1186±585 N.S. 996±469 953±431 1031±500 N.S. 
 
Abbreviations: N.S., not significant 
 
Note: Energy, macronutrients and micronutrients intake were estimated based on 24-hr dietary recall. 
Reported tocotrienols values are from diet only and does not include contribution from supplementation.  
All values are presented as mean±SD. P values derived using independent t-test, tested for mean 
differences of micronutrients intake between TRF and Placebo groups between baseline and wk-16.  
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TABLE 5-4. Inflammatory, oxidative and nutritional markers during baseline, week-12 and 
week-16. 
 Placebo 
(n=38) 
TRF 
(n=40) 
Inflammatory markers   
C-reactive protein (CRP) (mg/L)   
    Baseline 16.6±28.8 13.0±20.5 
    Week-12 25.1±36.5 15.5±18.0 
    Week-16 17.9±39.5 14.3±28.0 
Interleukin-6 (IL-6) (pg/mL)   
    Baseline 4.6±5.9 4.9±3.5 
    Week-12 5.2±3.5 4.9±2.3 
    Week-16 5.2±2.1 5.9±3.1 
Oxidative Status   
TAP (mM Trolox equivalent)   
     Baseline 640±207 669±127 
     Week-12 564±95a 626±98b 
     Week-16 697±166 759±246 
TBARS (µM MDA)   
      Baseline 3.39±5.12 3.01±4.65 
      Week-12 4.68±5.72 2.60±2.28 
      Week-16 3.85±3.90 2.89±3.65 
Nutritional indicators   
Serum albumin (g/dL)   
     Baseline     3.9±0.3 3.9±0.3 
     Week-12 3.9±0.3 3.9±0.3 
     Week-16 4.0±0.4 3.9±0.5 
Hemoglobin (g/L)   
     Baseline 10±2 10±2 
     Week-12 10±1 10±2 
     Week-16 10±1 10±2 
Body Mass Index (kg/m2)   
     Baseline 28.7±8.2 30.3±8.1 
     Week-12 29.1±8.1 30.4±8.2 
     Week-16 29.1±8.3 30.5±8.2 
Abbreviations: TAP,total antioxidant power; TBARS, thiobarbituric acid reactive substances; MDA, 
malondialdehyde. 
  
Note: Values are reported as median±IQR (CRP, IL-6) or mean±SD (TAP, TBARS, Alb, Hb, BMI). 
Statistical analysis were conducted using one-way repeated measures ANOVA to test the difference in the 
parameters overtime as compared to the baseline in each group – significant difference (p<0.05) for this 
test denoted as *symbol. Independent t-test (TAP, TBARS, Alb, Hb, BMI) and Mann-Whitney U test 
(CRP, IL-6) were used to test the mean differences between TRF and placebo groups at particular time 
point – significant difference (p<0.05) for these tests denoted as different alphabetical letters. At week-12, 
there was marginal difference (p=0.055) in TBARS (µM MDA) between placebo and TRF groups.   
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 TABLE 5-5. Lipid profiles of the subjects at baseline, week-8, week-12 and week-16. 
 
 Placebo 
(n=38) 
TRF 
(n=40) 
Triacylglycerols (mg/dL)   
    Baseline 109±63 144±91 
    Week-8 106±51 139±86 
    Week-12 100±57 113±47* 
    Week-16 95±48 103±45* 
   
Total cholesterol (mg/dL)   
    Baseline 179±42 183±49 
    Week-8 153±32* 158±36* 
    Week-12 140±31* 142±43* 
    Week-16 149±38* 145±45* 
   
High-density lipoprotein cholesterol (mg/dL)   
    Baseline 44±12 42±13 
    Week-8 51±14* 51±15* 
    Week-12 54±13*a 63±18*b 
    Week-16 54±12* 58±18* 
   
Low-density lipoprotein cholesterol (mg/dL)   
    Baseline 112±38 112±46 
    Week-8 81±31* 79±35* 
    Week-12 70±32* 58±38* 
    Week-16 75±34* 66±42* 
   
TC/HDLC ratio   
    Baseline 4.25±1.36 4.59±1.80 
    Week-8 3.19±1.08 3.29±1.07 
    Week-12 2.80±1.13 2.38±0.87 
    Week-16 2.88±1.07 2.66±1.03 
   
 
Note: Values are reported as mean±SD. TAG, TC and HDLC were measured using standard enzymatic 
assay, whilst LDLC were calculated by different using Fridewald equation.  One-way repeated measures 
ANOVA was used to test the difference in the parameters overtime as compared to the baseline in each 
group – significant difference (p<0.05) for this test denoted as *symbol. Independent t-test was used to 
test the mean differences between TRF and Placebo groups at particular time point – significant 
difference (p<0.05) for these tests denoted as different alphabetical letters.  
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TABLE 5-6. Pearson correlation coefficient between selected nutritional, inflammatory and 
oxidative status markers based on pool data (baseline + week 12 + week-16). 
 
 Oxidative 
Status 
Inflammatory  
Markers 
Nutritional  
Indicators 
 TAP MDA IL-6 CRP TNFα NFκB Alb Hgb Ferr 
TAP 1         
MDA -.273** 1        
IL-6 n.s. n.s. 1       
CRP n.s. .501** .148* 1      
TNFα n.s. n.s. n.s. n.s. 1     
NFκB n.s. n.s. n.s. n.s. n.s. 1    
Alb .144* n.s. n.s. -.163* n.s. n.s. 1   
Hgb n.s. n.s. n.s. n.s. n.s. n.s. n.s. 1  
Ferr n.s. n.s. n.s. n.s. n.s. n.s. .190* -.168* 1 
 
Abbreviations: TAP, total antioxidant power; MDA, malondialdehyde; IL-6, interleukin-6; CRP, C-
reactive protein; TNFα, tumor necrosis factor alpha; NFκB, nuclear factor kappa B; Alb, serum albumin; 
Hgb, hemoglobin; Ferr, ferritin; n.s., not significant. 
 
Notes: This figure shows Pearson correlation coefficients of selected nutritional, inflammatory and 
oxidative status markers based on pool data (n=155 for TNFα and NFκB;  n=226 for all other). Data are 
presented as Pearson correlation r values. Symbol * and ** indicates correlation is significant (p<0.05 and 
p<0.01, respectively).  
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TABLE 5-7. Pearson correlation coefficient between lipid profiles and selected nutritional, 
inflammatory and oxidative status markers based on pool data (baseline + week 
12 + week-16). 
 
 Lipid Profiles 
 TC TAG HDLC LDLC TC/HDLC 
Oxidative Status      
  TAP n.s. .146* n.s. n.s. n.s. 
  MDA .148* n.s. n.s. .138* n.s. 
Inflammatory Markers      
  CRP n.s. .159* -.163* n.s. n.s. 
  IL-6 n.s. n.s. n.s. n.s. n.s. 
  TNFα n.s. n.s. n.s. n.s. n.s. 
  NFκB n.s. n.s. n.s. n.s. n.s. 
Nutritional Indices       
  Alb n.s. n.s. n.s. n.s. n.s. 
  Hgb n.s. n.s. n.s. n.s. n.s. 
  Ferr n.s. n.s. n.s. n.s. n.s. 
  Calorie/kg body weight n.s. n.s. n.s. n.s. n.s. 
  Protein/kg body weight n.s. n.s. n.s. n.s. n.s. 
  Fat intake (g) n.s. n.s. -.194* n.s. n.s. 
  Cholesterol intake (mg) n.s. .306* -.208* n.s. .183* 
  Vitamin E intake (mg/day) n.s. .226** n.s. n.s. n.s. 
 
Abbreviations: TAP, total antioxidant power; MDA, malondialdehyde; IL-6, interleukin-6; CRP, C-
reactive protein; TNFα, tumor necrosis factor alpha; NFκB, nuclear factor kappa B; ALB, serum albumin; 
HGB, hemoglobin; FERR, ferritin; n.s., not significant; TC, total cholesterol; TAG, triacylglycerol; 
HDLC, high density lipoprotein cholesterol; LDLC, low density lipoprotein cholesterol.  
 
Notes: This figure shows Pearson correlation coefficients between lipid profiles and selected nutritional, 
inflammatory and oxidative status markers based on pool data (n=155 for TNFα, NFκB and dietary data;   
n=226 for all other). Data are presented as Pearson correlation r values. TC, TAG and HDLC were 
measured in the plasma using commercial kit while LDLC were calculated by difference using 
Friedewald formula. Dietary data (calorie/kg body weight, protein/kg body weight, fat, cholesterol and 
vitamin E intake were estimated based on two 24-hr diet recall (baseline and wk-16). Symbol * and ** 
indicates correlation is significant (p<0.05 and p<0.01, respectively).  
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FIGURE 5-1. TRF study’s flow chart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: All patients (n=118) were screened for eligibility. A patient was excluded if he/she was <18 years 
age, undergoing dialysis treatment <3 months, resident of nursing homes, undergoing 8 hours of dialysis 
treatment or receiving intradialytic parenteral/enteral feeding. Data were analyzed according intention-to-
treat regardless of post-randomization withdrawal.  
Screened for eligibility 
(n=118) 
Randomization 
(n=81) 
      Excluded (n=37) 
• Did not met inclusion criteria 
(n=30) 
• Declined to participate (n=7) 
Allocated to TRF 
(n=41) 
Allocated to Placebo 
(n=40) 
Analyzed  
(including drop out) 
(n=37) 
Analyzed 
(including drop out) 
(n=40) 
Died (n=1)  
(Cardiac arrest) 
Underwent 
transplantation (n=1) 
Excluded (catheter 
dysfunction) (n=1) Week 1 
Week 3 
Week 12 
Died (n=1)  
(Cardiac arrest) 
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FIGURE 5-2. Dietary supplements intake among study’s subjects. 
 
 
Note: This figure shows dietary supplements intake as reported by the study’s subjects. Values are 
presented as percentage of patients taking particular supplements during the study period. Neprhocaps and 
Renalcaps (generic) contain the same amount of vitamins as follow: 100mg vitamin C, 1.5mg Thiamine, 
1.7mg Riboflavin, 20mg Niacin, 10mg Vitamin B6, 1 mg Folate, 6µg vitamin B12, 150µg Biotin and 
5mg pantothenic acid. 
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FIGURE 5-3. Percent of capsule ‘consumption’ in placebo (n=38) and TRF (n=40) group during 
the course of the study. 
 
 
Note: This figure shows percent of capsule consumption (disappearance) for non-dialysis days, measured 
by pill counting method for 16 weeks of the study.  Values are expressed as mean±SEM. No significant 
differences for each week between the two groups were noted as tested by independent t-test.  
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FIGURE 5-4. NFκB p65 value at baseline and week-12. 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: NFκB, nuclear factor kappa B; Diff, mean difference in [NFκB] (wk-12 minus baseline). 
Note: This figure shows NFκB p65 concentration measured in the nuclear extract using ELISA-based kit. 
Values are reported as mean±SEM.  Independent t-test was used to test the mean differences between 
TRF and Placebo groups at each time point (baseline, wk-12, diff). Symbol * indicates significant 
difference (p<0.05) while # indicates marginal difference (p=0.08) when compared to the placebo group. 
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FIGURE 5-5. TNFα value at baseline and week-12. 
 
 
 
 
  
 
 
 
 
 
 
 
Abbreviations: TNFα, tumor necrosis factor alpha; Diff, difference. 
Note:  This figure shows TNFα concentration measured in the plasma using ELISA-based kit. Values are 
reported as mean±SEM.  Independent t-test was used to test the mean differences between TRF and 
Placebo groups at each time point (baseline, wk-12, diff). No different was noted between placebo and 
TRF groups at all time points.  
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FIGURE 5-6. Mean changes in plasma TAG normalized to the baseline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: TAG, triacylglycerols. 
 
Note: Values are presented as mean±SEM. TAG data are calculated by different from baseline values. 
Symbol * indicates significant difference (p<0.05) as compared to placebo at each time point based on 
independent t-test. At week-16 the there was a marginal different between TRF and placebo groups 
(p=0.072). 
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FIGURE 5-7. Mean changes in plasma HDLC normalized to the baseline.  
 
 
 
Abbreviation: HDLC, high-density lipoprotein cholesterol 
 
Note: Values are presented as mean±SEM. HDLC data are calculated by different from baseline values. 
Symbol * indicates significant difference (p<0.05) as compared to placebo at each time point based on 
independent t-test.  
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FIGURE 5-8. Change in TAG levels among statin and non-statin users in placebo and TRF 
groups. 
 
 
 
 
Note: Changes in TAG and HDLC were calculated by deducting baseline values. Data are reported as 
mean±SEM. Difference alphabet denote marginal difference (p<0.08), tested by independent t-test.   
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FIGURE 5-9. Comparison of ApoA1 (A) and CETP activity (B) during week-12 and week-16.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ApoA1, apolipoprotein A1; CETP, cholesteryl ester transfer protein 
 
Note: Data are presented as mean±SEM. Symbol * indicates significant difference (p<0.05) as compared 
to placebo at each time point, tested by independent t-test.  Figure A shows plasma ApoA1 concentration 
during week-12 and week-16 in both groups as measured by ELISA method. Figure B shows CETP 
(cholesteryl ester transfer protein) activity during week-12 and week-16in both groups as measured in the 
plasma using flourometric assay kit. 
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FIGURE 5-10. Pearson’s correlation coefficient in lipid parameters during week-12 and week-
16.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: HDLC, high-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; TAG, 
triacylglycerols; CETP, cholesteryl ester transfer protein.  
Note: (A) (B) Correlation between ApoA1(mg/mL plasma) and HDLC (mg/dL plasma) at wk-12 and wk-
16, respectively. (C) (D)  Correlation between CETP activity (pmol/µL plasma/hr) and TAG (mg/dL 
plasma) at wk-12 and wk-16, respectively.   
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Placebo 
r=0.375, p<0.002 
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r=0.359, p<0.04 
r=0.475, p<0.001 
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FIGURE 5-11. Cumulative days of missed treatment in placebo (n=38) and TRF (n=40) group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: This figure is for illustrative purpose only. Data are presented as absolute number of days of missed 
dialysis session during each month of study course.  The total number of days missed was 122 vs 180 
days for the TRF and placebo groups, respectively.  
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CHAPTER VI 
SPECIFIC AIM 3:  
CHANGES IN METABOLOMIC PROFILES FOLLOWING TRF 
SUPPLEMENTATION 
Introduction 
ESRD patients on chronic HD have alarmingly higher risk for cardiovascular mortality when 
compared to the age-matched general population (i.e. 15-30 times higher risk) [3, 5]. In fact, 
cardiac death account for more than 50% of all-cause mortality in this population [209]. It is 
believed that malnutrition-inflammation complex syndrome, oxidative stress and dyslipidemia 
are implicated in the pathogenesis of cardiovascular diseases in this population [11, 12, 210]. 
Therefore, it is of interest to examine dietary impact of nutrients possessing antioxidant, anti-
inflammatory or lipid altering properties to alleviate these problems in the HD population.  One 
of the dietary compounds that have gained increasing scientific scrutiny is tocotrienols (TT). TT 
have been shown to confer cardio protection via its antioxidative, lipid-lowering, anti-
inflammatory and anti-atherosclerotic properties in animal model as well as in human [34, 35, 
37, 114].  
 However, the impact of such dietary intervention in a diverse clinical population is 
challenging to interpret partly due to intra- and inter-individual variability in response to the 
intervention, underlying comorbidities and the implication of compliance/non-compliance to the 
overall study’s results. Moreover, the nature of traditional biomarkers such as lipid profiles 
(plasma levels of total cholesterol, triglycerides, and high-density lipoprotein cholesterol) may 
not adequately provide a complete picture of a disease progression because they are restricted to 
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a known pathophysiologic pathway or reflect only on a specific aspect of the disease process 
[152]. Fortunately, with the emerging of ‘omics’ technology especially metabolomics, an 
unbiased approach to study the breadth of metabolite disturbance following a disease state has 
become possible [39, 40]. The omics approach has allowed scientists to characterize a complex 
myriad of metabolic pathways involving lipids, sugars, organic acids, amino acids and other 
small molecule analytes that are the substrates or byproducts of metabolism, or have been 
ingested [152].  
 However, given the infancy age of the omics approach, there are relatively few literatures 
pertinent to HD patients. Metabolomics has been used to identify potential cardiovascular risk 
biomarkers in several groups [152, 237]. For example, Senn and colleagues studied a large 
cohort of patients undergoing coronary angiography and found that several metabolites such as 
trimethylamine-N-oxide (TMAO), choline and betaine had a dose-dependent relationship with 
regards to the presence of CVD and the severity of atherosclerotic heart diseases [152]. 
Interestingly, in CKD patients not on dialysis, NMR studies of plasma and urine indicates 
accumulation of aliphatic amines including TMAO [238]. In a recent study, Fujiwara and 
colleagues utilized metabolomics for pattern recognition analysis to differentiate plasma 
metabolic profile of pre- versus post- HD treatment. They found that the NMR spectral pattern of 
plasma between pre and post HD treatment was clearly discriminated. Upon identification and 
quantification of the metabolites, they found that significant fluctuations were seen in the levels 
of creatinine, TMAO, glucose, lactate and acetate when comparing pre- and post- HD plasma 
metabolites [239].  
   In Chapter V, we reported that TT administration in the form of TT-rich fraction (TRF) 
in a randomized, double-blinded, placebo-controlled, parallel trial for 16 weeks improved lipid 
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profiles in patients undergoing chronic HD as characterized by lower TAG and higher HDLC in 
the TRF group when compared to the placebo group. This was correlated with higher ApoA1, 
the main protein component of HDLC, while CETP activity, the plasma protein that facilitates 
the transport of cholesterol and TAG between lipoprotein was lower in TRF group. Although 
there were some reduction trends in inflammatory markers and oxidative status parameters, none 
of these achieved statistical  significance. Interestingly, TRF group also had relatively less 
hospitalization days when compared to the placebo groups. We speculate that no significant 
changes were seen in inflammatory markers due to high intra and inter-individual variability of 
these markers due to a dynamic response of the immune system, in-concert with other studies 
[224, 226]. Hence, such study requires a relatively bigger sample size to increase the statistical 
power in order to detect the difference [240]. Therefore, the objective of this specific aim was to 
determine whether the TRF supplementation led to overall changes in patients’ metabolomics 
profile and whether the observed changes in plasma lipids correlate with their metabolomics 
profile. In order to achieve this specific aim, 1H nuclear magnetic spectroscopy (1H NMR) was 
utilized to simultaneously analyze numerous metabolites detectable in patients’ plasma sample, 
to provide an insight in metabolomics shift overtime and their differences between treatment and 
placebo groups. A powerful multivariate data analysis (MVDA) using statistical model such as 
principal component analysis (PCA) and partial least square (PLS) was used to analyze this data 
set.  
Methods 
Subjects and study design 
This experiment is a subset of the previously reported study (Chapter VI and Daud et al 2013 
[208]). The study was approved by the Human Investigation Committees of Wayne State 
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University and Great Lake Dialysis, LLC. Procedures for patient selection and randomization 
were as reported in Chapter VI. Patients were randomly allocated into treatment group (TRF) or 
placebo, and received the respective supplementation for 12 weeks. The study was extended for 
another 4 weeks (for a total of 16 weeks) to confirm some substantial changes observed in week-
12. All of our patients were undergoing dialysis with the same high-flux dialyzer membrane 
(Fresenius Optiflux Dialyzer, Fresenius Medical Care, Waltham, MA, USA). Both groups had a 
comparable dialysis adequacy (Kt/V) (placebo 1.45±0.20; TRF 1.48±0.26, p=0.516) as estimated 
by single-pool model.  
Blood sample collection and preparation for NMR analysis 
Approximately 5mL of fasting (for ~10 hrs) midweek predialysis blood samples were collected 
from existing access sites of each study participant into blood collection tubes containing  
lithium heparin (Becton Dickson, Franklin Lakes, NJ, USA) at baseline and week-12.  Plasma 
was isolated by centrifugation at 2800rpm for 20 minutes at 4oC, divided into aliquots and 
immediately stored at -80oC until further analysis.   
 For NMR analysis, plasma samples were thawed and equilibrated at room temperature. 
Upon thawing, plasma samples were centrifuged at 10,000 rpm for 2 minutes to remove solid 
debris. An aliquot of 400µL of plasma supernatant were transferred into an assembled Amicon 
Ultra 0.5mL 3kDa filter device (Sigma-Aldrich, St. Louis, MO, USA) that had been pre-washed 
three times with deionized water (450µL deionized water, spun for 13,800 rpm for 5 minutes 
each wash). The filter devices containing plasma were centrifuged for 30 minutes, 13,800 rpm at 
room temperature. The ‘filtrates’ were subsequently transferred into new microtubes and were 
diluted with deuterium oxide (D2O) (Cambridge Isotope Inc., Andover, MA, USA) in 1:1 ratio 
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(300µL filtrate + 300µL D2O). NMR cocktail containing 5mmol/L 3-(trimehylsilyl)-1 
propanesulfonic acid (TMS) (Sigma-Aldrich, St Louis, MO, USA) and 10mmol/L Imidazole 
(ACROS Organics, Thermo Fisher Scientific, NJ, USA) was added to the diluted plasma samples 
in 9:1 ratio. The prepared samples were subsequently transferred to 5mm NMR tubes (8 inches 
long) (Sigma-Aldrich, St. Louis, MO, USA). The summary of sample preparation for NMR 
analysis is illustrated in Figure 6-1.  
Proton 1H NMR acquisition 
One dimensional 1H NMR spectra were acquired using a 600MHz Agilent spectrometer, 
performed at a temperature of 27oC. The free induction decays (FIDs) were collected into 32K 
datapoint, for a total of 64 scans, with a spectrum width of 10 ppm, and an acquisition time of 4 
seconds. The water signal was suppressed by a presaturation and set the flip angle to 90o.  
Spectral processing 
FIDs were processed with ACD software version 12.0 (Advance Chemistry Development, Inc., 
Toronto, ON, Canada) by stacking together as a group, followed by Fourier transformation, auto-
phasing and auto-baseline correction. The whole spectra were divided into 1000 equal bins using 
intelligent binning option. The spectra were digitized into a table of common integrals containing 
a non-negative value and exported as a text file for multivariate data analysis. Figure 6-2 
summarized the spectral processing procedure using ACD software.   
Multivariate data analysis 
Multivariate data analysis was performed using SIMCA-P 12.0+ (Umetrics, Umea, Sweden). 
Briefly, the data text file was imported into the software and transposed. Given that, each row 
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represents a case (i.e. a patient) while each column represents a variable (i.e. 1000 binned 
spectra) (Figure 6-3).  Data was statistically analyzed using three types of mathematical 
algorithm, namely 1) principle component analysis (PCA), 2) partial least square (PLS) and 3) 
PLS-discriminant analysis (PLS-DA).  PCA is an unsupervised statistical procedure that is 
designed to display the systematic variation in the data matrix X – this is achieved by showing 
related observations and deviations/similarities in the data set via a score plot and a loading plot. 
PCA is often used for exploratory analysis of the data set. The score plot provides visual 
information regarding the similarities/differences in the data while the corresponding loading 
plot provides information regarding the variables (the part of spectrum) that is responsible for the 
difference/similarities observed in the score plot [151]. PLS and PLS-DA is a supervised method 
of analyses. PLS is basically an extension of PCA in which Y variable(s) is added to connect 
with the information provided by X variables. In addition, PLS-DA identify the model that 
separates the classes of observation based on X variables and hypothetical Y variables.   All x 
variables were Pareto’s scaled before multivariate data analysis.   
Metabolites identification and quantification 
Loading plot of PCA provides a visual indication on the part of the spectra and corresponding 
metabolites that are responsible for the differences in metabolic profile between the two groups. 
These metabolites were identified and quantified using Chenomx NMR 7.1 suite (Edmonton, 
Alberta, Canada). Briefly, FID files were first processed in the Chenomx Processor to adjust for 
pH, assign chemical shift indicator and remove line shape distortion by autophasing, autospline 
baseline correction and reference deconvolution.  The processed spectra were then exported into 
Chenomx Profiler for identification and quantification of the metabolites. There were 313 known 
metabolites in the Chenomx Profiler (using 600Mhz magnet database) that is specific for 
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different magnetic strength and pH ranges. Each metabolite and their corresponding peak 
clusters were matched to the existing database and the area under the peak dictates the 
concentration of that particular metabolites (Figure 6.4). Data on these quantified metabolites 
were exported into SPSS for statistical analysis.  
Statistical analysis 
Apart from multivariate data analyses as explained above, statistical analyses for the identified 
metabolites were carried out using SPSS v.16 (IBM, Chicago, IL, USA). Independence t-test was 
applied to test the difference in the metabolites concentration between TRF and placebo groups. 
P values of <0.05 is regarded as statistically significant. 
Results 
Metabolomics profile at baseline 
PCA was conducted at baseline to investigate whether the metabolomics profiles between TRF 
and placebo groups were different.  The PCA-X score plot at baseline indicates that 
metabolomics profiles between the two groups were not different as evident by the scattered and 
random scores from both groups in the eclipse. There was no particular pattern observed at this 
point (Figure 6-5). 
Metabolomics profile at week-12 
The same analysis (PCA) was performed at week-12 to investigate the difference in 
metabolomics profiles at week-12. PCA-X plot indicates that there was some pattern of scores 
between the two groups; however, no clear separation was observed (Figure 6-6). Further 
analysis using PLS-DA indicates that there was a clear separation between TRF and placebo 
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groups in the PLS-DA score plot by the principal component 1 (Figure 6-7). Hence, this is 
suggesting that TRF supplementation induced specific metabolomics pattern change resulting in 
different profiles.  
Correlation of metabolomics profiles with other parameters 
Two-dimensional PLS plots were also performed to investigate predictive effects of plasma 
metabolome in relation to known biomarkers. Figure 6-9 shows correlation between 
metabolomics profile (x-axis) and inflammatory markers (CRP, IL-6) (y-axis) of the two groups 
at week-12. There was a weak correlation (R2=0.38) between metabolomics profile and 
inflammatory markers. In other words, the PLS regression between the plasma metabolome from 
NMR and plasma inflammatory markers indicate that 38% of the variations in the inflammatory 
markers can be predicted by the treatment conditions (placebo vs TRF).   
 Similarly, the PLS analysis between plasma metabolomics profiles and plasma oxidative 
status (TAP and MDA) revealed a weak correlation (R2=0.26) (Figure 6-10). This may indicate 
that plasma TAP and MDA have less predictive power towards the changes in metabolomics 
profile.  
Meanwhile, plasma HDLC (Figure 6-11) and lipid profiles (TC + TAG + HDLC) 
(Figure 6-12) were also moderately correlated with plasma metabolomics profile (R2=0.49 and 
R2=0.60, respectively) indicating that the observed change in plasma HDLC and lipid profiles 
were reflected in the change in concentration of metabolites present in the plasma. Based on this 
result, 60% of the variations in the lipid profiles can be predicted by the treatment group 
allocation. This is also in concert with the fact that most changes in lipid profile were seen at 
week-12 of the intervention.  
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Metabolites identification and quantification 
PCA loading plot (Figure 6-8) provides a guide on the part of the spectra that is responsible for 
the differences observed between TRF and placebo groups at week-12. By using Chenomx NMR 
Suite software, a total of 33 metabolites were identified and quantified. These metabolites were 
significantly different (p<0.05) or approached significance (0.05<p<0.10). However as the 
metabolites were analyzed from 4 subjects per treatment – the fact that some metabolites were at 
the lower limit of detection in one or two subjects per treatment, invariably skewed group means 
in certain cases. Regardless, some of these metabolites included various compound classes such 
as amino acids (e.g. histidine, methionine), carbohydrates (e.g. galactose, lactose), organic acids 
(e.g. lactate) and phospholipids related compound. Some of the metabolites that have been 
previously shown to be implicated in CKD included 2-Hydroxyglutarate, 3-Hydroxy-3-
methylglutarte, Betaine, Cadaverine, Glycerate, Mandelate, Proline and 2-Hydroxy-3-
methylvalerate as well as  Citrate, N-acetylaspartate, N-acetylcysteine and Ribose. However until 
analyses from more subjects is completed  no definitive statement or conclusion can be made. 
Discussion 
In this experiment, we showed that plasma metabolomic profiles of HD patients between TRF 
and placebo group did not show any different at baseline. After 12 weeks of supplementation, 
initial analysis using unsupervised PCA of the plasma metabolic profiles did not indicate obvious 
treatment related effects, with only some pattern of separation at principle component 1.  
However, by using PLS-DA modeling, TRF group’s plasma metabolomic profile was clearly 
discriminated from the placebo group. The fact that plasma metabolomic profiles were different 
between the two groups after 12 weeks of intervention may indicate 1) real effects of TRF that 
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induced metabolic changes reflected in the plasma metabolic profiles, or 2) potential 
confounders such as medications, dietary intake and life style, that could influence metabolic 
changes. To complicate things, there are also lines of evidence reporting the impact of gut 
bacteria on the metabolome [148].  
 It is unlikely that dietary intake/pattern of a stable chronic dialysis patient had changed 
partly because of diet monotony due to dietary restrictions, which have been consistently 
reported in the literature [32, 241, 242]. However, it is possible that diversity in medication 
profiles of HD patients may contribute to variations in metabolic profiles, resulting in artifact 
and misinterpretation. Given the significant co-morbidity experience by HD patients, many of 
our patients were on a handful of medication such as anti-hypertensive drugs (e.g. atenolol, 
amlodipine, losaratan), blood-thinning medication (e.g. aspirin), diuretics (e.g. furosemide), 
lipid-lowering drug (e.g. statins), and phosphate binders (e.g. calcium acetate). It is almost 
impossible to control on this aspect given the ‘intention to treat’ nature of the clinical study. In 
order to overcome such variations, one may require a relatively larger sample size as compared 
to animal, or cell metabolomics studies [150], but this may not be feasible. Therefore, the 
preferred strategy to overcome this variability is to perform a small-scale untargeted approach as 
outlined by Mamas and colleagues: 
“In metabolomic studies of the general population, the preferred strategy is to perform two 
independent small-scale holistic studies (defined as discovery and validation) where the 
number of samples is typically 10–100s and where many potential confounders (e.g. age, BMI, 
gender) are controlled so that the only ‘random’ variable between classes is the disease or 
drug treatment. These studies define potential biomarkers or disease pathophysiology”  
Mamas et al. (2011) [150]. 
Given limited funding and time constraints, we streamlined this experiment in order to 
evaluate the actual effects of TRF by selected patients with similar medication and demographic 
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profiles. As discussed earlier, we found that the metabolomic profiles of TRF and placebo groups 
were clearly discriminated at week-12 but not at baseline; suggesting TRF induced metabolic 
pattern change. Furthermore, based on two-dimensional PLS analysis, metabolomic profile of the 
patients at week-12 was significantly correlated with lipid profiles in-concert with the changed in 
lipid profile measurements. Interestingly, PLS tests also indicate that plasma metabolomics 
profiles were correlated with serum albumin and inflammatory markers. This is an intriguing 
observation given the fact that we did not see any difference in serum albumin and inflammatory 
markers [208]  which may suggest the need for a bigger sample size due to high variability in 
these traditional biomarkers. However, the correlation between metabolomics profiles and 
inflammatory biomarkers may need to be viewed in relation to anti-inflammatory properties of 
aspirin due to the fact that all subjects in this subset analysis were prescribed aspirin 
(acetylsalicylic acid). Interestingly, removal of aspirin peak clusters (2.32, 7.13, 7.145, 7.35, 
7.37, 7.50, 7.51, 7.52, 7.67, 7.68ppm) in the spectra database from the SIMCA software prior to 
MVDA analysis did show the same pattern of discrimination, suggesting the minimal effects of 
aspirin as anti-inflammatory agent. 
Based on the preliminary metabolites identification data, several metabolites that were 
identified appear to be involved in CKD. Betaine is a metabolite of choline and recent evidences 
indicate that increased levels of choline, betaine and TMAO are associated with increased risk 
for cardiovascular diseases [152, 243].  3-hydroxy-3-methylglutarate (HMG),	  is	  a metabolite that 
accumulates in the urine of patients affected by 3-Hydroxy-3-methylglutaric aciduria. Recent 
evidence indicates that accumulation of HMG in the plasma is associated with lipid and protein 
oxidative damage as well as reduce enzymatic antioxidant defense in rat cerebral cortex [244]. It 
141 
	  
	  
is postulated that the accumulation of HMG in ESRD patients may be due to residual uremia 
because dialysis does not effectively remove uremic toxins.  
Cadaverin and some other polyamines have been reported to increase in the late stage of 
CKD and in HD patients [245]. Accumulation of cadaverin is associated with suppression of 
erythropoiesis [246] leading to hyporensponsive of  anemia treatment by Epogen (human 
erythropoietin produced via recombinant DNA technology), resulting in higher dosage 
requirement [245, 247]. This is exemplify by the fact that patients on peritoneal dialysis 
treatment are generally less anemic than those on HD [248, 249] due to a more efficient middle 
molecules removal [245, 248] and frequent dialysis (four times daily vs three times a week).  It is 
interesting that recent publication indicate that supplementation with vitamin E improved 
Epogen responsiveness in HD patients [250], suggesting a potential target of vitamin E on 
uremic toxins that contribute to erythropoiesis suppression. Cruz et al reported that the use of 
vitamin E coated membranes in 172 maintenance HD patients leads to reduction of Epogen 
dosage and improved hemoglobin levels [251].  
Because kidney plays an important role in the metabolism of protein and amino acids, 
kidney failure results in alteration of plasma amino acids (AA).  It has been found that plasma 
concentration of citrulline, cysteine and taurine are increased in the early stage of CKD [252]. 
On the other hand, most plasma AA in the late stage of CKD and in ESRD undergoing HD 
treatment showe a decreased except for proline, asparagine, citrulline, asymmetric 
dimethylarginine and hydroxykynuerenine that show an increase in their levels [253]. This 
increased is hypothesized to be due to uremic retention and/or systemic over production. It has 
also been reported that the changes in plasma AA are associated with disease severity as 
indicated by the significant correlation in eGFR in a multivariate model [253].    
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Some other metabolites of interest in the initial anlayses  include N-acetylcysteine and N-
acetylaspartate. It is interesting that, levels of N-acetylaspartate and N-acetylaspartylglutamate 
(based on magnetic resonance spectroscopy of the brain) have been found to be reduced in 
dialysis patients, and these are associated with attention deficit, as well as disturbances in 
memory and learning activity [254]. This phenomenon has been postulated to be related to the 
accumulation of neurotoxic metabolites, hormonal disturbance and an imbalance in excitatory 
and inhibitory neurotransmitters following kidney failure [254, 255]. On the other hand, N-
acetylcysteine confers antioxidant effect due to the presence of thiol groups in its molecular 
structure. N-acetylcysteine has been used as adjunct treatment during chemotherapy for the 
cancer treatment [256] and in the management of anemia and oxidative stress in HD patients 
[257]. Thus a complete analysis from the current sample set will yield important and exciting 
clues on the metabolic effects of TRF supplementation  
 Literature pertaining to metabolomics application in HD/ESRD patient is very scarce, 
therefore no direct comparisons are available. Only a few studies have explored the utilization of 
this technology especially for diagnostic purposes. For example, Sato et al [258] explored 
metabolomics analysis of plasma sample of pre- and post- HD treatment, and subsequently 
identified potential novel biomarkers that can be used as alternatives to urea and creatinine to 
determine dialysis dose adequacy. Fujiwara et al [239] utilized metabolomics approach for 
pattern recognition analysis and found that NMR spectra between pre and post HD treatment was 
clearly discriminated due to fluctuation in the levels of creatinine, TMAO, glucose, lactate and 
acetate. Interestingly, both of the studies did not report their patients’ medication profiles.  
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Future directions 
Based on the multivariate data analysis of the plasma metabolomics profile to date, it is now 
understood that supplementation with TRF triggers some metabolic changes which appear to be 
reflected in the plasma metabolites. Preliminary metabolite identification and quantification 
revealed several metabolites that responsible for the differences between TRF and placebo 
groups. These metabolites however need to be firstly confirmed and secondly, validated with 
biochemical assays for confirmation. Upon validating these metabolites, they should be 
compared to known biochemical pathways to examine their relevance in the disease process as 
well as in diagnostic and treatment aspects in relation to TRF supplementation.  
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Table and Figures 
TABLE 6-1. Characteristics of the samples for metabolomic analysis. 
 Placebo 
(n=9) 
TRF 
(n=8) 
P value 
Demographics    
Age (yrs) 54 59 N.S. 
African American (n, %) 9 (100)  8 (100) N.S. 
Gender (males, %) 5 (55.6) 5 (62.5) N.S. 
    
Clinical    
Diabetes Mellitus (n, %) 6 (66.7) 5 (62.5) N.S. 
Time on dialysis (months) 32 35 N.S. 
BMI (kg/m2) 29.3 27.9 N.S. 
Kt/v 1.48 1.45 N.S. 
Statins (n, %) 0 (0) 0 (0) N.S. 
Aspirin (n, %) 9 (100) 8 (100) N.S. 
Anti-hypertensive, one or more type 
(n,%) 9 (100) 8 (100) N.S. 
 
Note: Data are reported as mean for continuous variables and number (percentage) for categorical 
variables. P values are comparison between groups obtained from independent t-test or Pearson χ2 test 
wherever appropriate. 
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FIGURE 6-1. Sample preparation for NMR analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: This figure illustrates steps during sample preparation for NMR analysis: 1) Blood sample were 
collected into lithium heparin tubes, 2) Plasma was obtained by centrifugation, 3) Plasma was transferred 
into a clean micro tube for storage, 4) Sample was stored at -80oC until use, 5) Frozen plasma was thawed 
at room temperature, 6) High molecular weight compound was removed via 3kDa ultracentrifugation 
device, 7) ‘Filtrate’ was used for NMR analysis. During this step, sample was spiked with the internal 
standard (TMS) and pH indicator was added. 8) A total of 600µL sample (diluted 1:1 in deuterium oxide) 
was used for NMR FID acquisition.   
 
 
 
 
- 80oC
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FIGURE 6-2. Illustration for processing of NMR spectra using ACD software v. 12.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  1	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3	  
4	  
All FID files acquired from 600 MhZ 
1H NMR were imported into ACD 
software. The x-axis represents the 
time domain. 
The FID files were Fourier 
transformed followed by auto-phasing 
and auto adjustment for baseline. 
Reference peak (TMS) were also set at 
0 ppm. The x-axis represents chemical 
shift (ppm). 
The spectra were divided into 1000 
equal bins. Each bin represents one 
variable.  
The values from each bin are digitized 
into a non-negative numbers as a table 
of common integrals (TOCI). TOCI is 
then exported to SIMCA P+ software 
as a text file.  
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FIGURE 6-3. Multivariate data analysis processes using SIMCA-P 12.0+ software 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: This figure shows a screen capture of multivariate data analysis (MVDA) processes from SIMCA-
P 12.0+ software (Umetrics, Umea, Sweden). Upon importing table of common integral from ACD 
software, the data was transposed so that each column represents a variable while each row represents an 
observation (subject). The primary ID column (dark yellow) represents the particular subjects while the 
secondary ID dictates their group allocation. The data was further edited by removing corresponding 
variables that did not contain any peak on the spectrum (i.e. <0.5ppm and >8.0ppm), prior to running 
MVDA.   
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FIGURE 6-4. Metabolites identification and quantification using Chenomx software. 
 
 
 
 
 
 
 
 
 
 
 
 
Note: This figure shows one of the processes of metabolites identification and quantification 
using Chenomx NMR Suite 7.7. The processed NMR file (following phasing, baseline correction 
and reference deconvolution) was exported into Chenomx Profiler. Each peak cluster in the 
NMR spectrum was manually matched with the database. In this example, lactate comprised of 
two peak clusters (i.e. at 4.1 and 1.3 ppm). Each peak cluster needs to be matched with the 
pattern of peak cluster in the database. The software will calculate the concentration of the 
particular metabolite based on the matched peak clusters area.  
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FIGURE 6-5. PCA score plot for NMR spectra obtained from plasma samples of HD patients at 
baseline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PCA, principal component analysis; PLA, placebo; TRF, tocotrienol-rich fraction. 
Note: This figure depicts PCA-X score plot indicating metabolomics profile between the two groups at 
baseline. The eclipse represents the 95th percentile of confidence interval, while any score outside of the 
eclipse is consider as an outlier.  One outlier score was excluded from the analysis. Water peaks region 
(4.5 – 5.0 ppm) were removed from the data prior to analysis. The score for TRF and placebo groups were 
scattered indicating that the metabolomics profiles between the two groups were similar.  
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FIGURE 6-6. PCA score plot for NMR spectra obtained from plasma samples of HD patients at 
week-12. 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PCA, principal component analysis; PLA, placebo; TRF, tocotrienol-rich fraction. 
Note: This figure depicts PCA-X score plot indicating metabolomics profile between the two groups at 
week-12. The eclipse represents the 95th percentile of confidence interval, while any score outside of the 
eclipse is considered as an outlier.  One outlier score was excluded from the analysis. Water peaks region 
(4.5 – 5.0 ppm) were removed from the data prior to analysis. The score plot shows there was separation 
trend indicating that metabolomics profiles of the two groups were discriminated.  
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FIGURE 6-7. PLS-DA score plot for NMR spectra obtained from plasma samples of HD 
patients at week-12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PLS-DA, partial least square – discriminant analysis; PLA, placebo; TRF, tocotrienol-rich 
fraction. 
Note: This figure shows PLS-DA score plot depicting metabolomics profile of the two groups at week-12. 
The eclipse represents the 95th percentile of confidence interval, while any score outside of the eclipse is 
considered as an outlier.  One outlier observation was excluded from the analysis. Water peaks region 
(4.5 – 5.0 ppm) were removed from the data prior to analysis. Metabolomics profile of the two groups 
was clearly discriminated as indicated by a clear separation trend. 
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FIGURE 6-8. PCA-X loading plot for NMR spectra obtained from plasma samples of HD 
patients at week-12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PCA, principal component analysis. 
Note: This figure shows the corresponding PCA-X loading plot for Figure 6-6. The loading plot provides 
information regarding the part of the spectrum that was different or common between the two groups. The 
dense, dark area represents common metabolites (part of spectrum) that are shared between the two 
groups while the isolated plots indicate the part of the spectrum that responsible for the difference (yellow 
circles).  
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FIGURE 6-9. PLS score plot for correlation between metabolomics profile and inflammatory 
markers at week-12. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PLS, partial least square; PLA, placebo; TRF, tocotrienol-rich fraction; CRP, C-reactive 
protein; IL-6, interleukin-6. 
Note: This figure shows PLS score plot depicting correlation between metabolomics profile (x-axis) and 
inflammatory markers (CRP, IL-6) (y-axis) of the two groups at week-12. There was a moderate 
correlation (R2=0.38) between metabolomics profile and inflammatory markers. This result indicates that 
there are some metabolites in the plasma sample that are correlated with the inflammatory markers. 
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FIGURE 6-10. PLS score plot for correlation between metabolomics profile and oxidative status 
biomarkers (TAP, MDA) at week-12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PLS, partial least square; PLA, placebo; TRF, tocotrienol-rich fraction; TAP, total 
antioxidant power; MDA, malondialdehyde. 
Note: This figure shows PLS score plot depicting correlation between metabolomics profile (x-axis) and 
total antioxidant capacity (y-axis) of the two groups at week-12. There was a moderate correlation 
(R2=0.26) between metabolomics profile and TAP. This result indicates that there are some metabolites in 
the plasma sample that are correlated with the TAP. 
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FIGURE 6-11. PLS score plot for correlation between metabolomics profile and plasma HDLC 
at week-12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PLS, partial least square; PLA, placebo; TRF, tocotrienol-rich fraction; HDL-C, high-
density lipoprotein cholesterol. 
Note: This figure shows PLS score plot depicting correlation between metabolomics profile (x-axis) and 
total antioxidant capacity (y-axis) of the two groups at week-12. There was a moderate correlation 
(R2=0.49) between metabolomics profile and HDL-C. This result indicates that there are some 
metabolites in the plasma sample that are correlated with the HDL-C.  
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FIGURE 6-12. PLS score plot for correlation between metabolomics profile and plasma lipid 
profiles (TC, TAG, HDLC) at week-12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PLS, partial least square; PLA, placebo; TRF, tocotrienol-rich fraction; TC, total 
cholesterol; TAG, triacylglycerols; HDL-C, high-density lipoprotein cholesterol. 
Note: This figure shows PLS score plot depicting correlation between metabolomics profile (x-axis) and 
plasma lipid profiles (TC, TAG, and HDL-C) (y-axis) of the two groups at week-12. There was a 
moderate correlation (R2=0.60) between metabolomics profile and lipid profiles. This result indicates that 
there are some metabolites in the plasma sample that are correlated with the lipid profiles. 
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FIGURE 6-13. PLS score plot for correlation between metabolomics profile and serum albumin 
at week-12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PLS, partial least square; PLA, placebo; TRF, tocotrienol-rich fraction 
Note: This figure shows PLS score plot depicting correlation between metabolomics profile (x-axis) and 
serum albumin levels (as a marker of nutritional status) (y-axis) of the two groups at week-12. There was 
a moderate correlation (R2=0.65) between metabolomics profile and lipid profiles. This result indicates 
that there are some metabolites in the plasma sample that are correlated with the serum albumin levels. 
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CHAPTER VII 
CONCLUSION AND RECOMMENDATIONS 
Conclusion 
The aim of the first study was to evaluate the effects of omega-3 combined with hydrolyzed 
protein supplementation on the nutritional status, inflammatory markers and lipid profiles in 
chronic HD patients. The study was designed in such way that supplementation intake can be 
directly monitored in real-time in order to maximize the compliance given the fact that our study 
population was mainly comprised of low-income and low-literacy group which often associated 
with poor compliance. We found that omega-3 group had significant improvement in 
LDLC/HDLC ratio while TAG was marginally improved. However, no significant different were 
seen in nutritional and inflammatory parameters between placebo and omega-3 groups after 6-
months of supplementation. While compliance was excellent in patients who attended the 
treatment session, significant numbers of patients missed the treatment due to hospitalization, 
thus also missed their supplementation – this potentially had an impact on the overall study 
results. Results from this study support the hypothesis that the combination of omega-3 and 
protein supplementation improve lipid profiles but fail to show significant effect on 
inflammatory and nutritional indicators.  
 Following a successful ‘directly observed treatment’ approach in omega-3 study, a 
second study was administered using vitamin E tocotrienols (TRF), a nutritional agent that 
exhibit antioxidant, anti-inflammatory with a potential lipid altering effects in the same cohort of 
the patients. Given the significant comorbidities experienced by these patients that resulted in 
significant hospitalization and missed dialysis treatment in the first study, therefore additional 
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steps were taken in order to improve compliance in administering the supplements. Patients were 
provided with capsule organizer for supplement supply during non-dialysis days and compliance 
were monitored via pill counting method and ‘directly observed treatment’. Additional 
monitoring on dietary changes (through 24-hr diet recalls) was also implemented. The results 
showed that TRF supplemented group had significant improvement in lipid profiles as indicated 
by a lower TAG, and higher HDLC at week-12 and week-16 of the study when compared to the 
placebo group. Interestingly, TRF group also exhibit less total hospitalization days as compared 
to the placebo group. However, TRF supplementation did not significantly impact any 
nutritional, inflammatory and oxidative status biomarkers.   
 Following the unexpected outcomes in lipids, we sought to investigate further on several 
key components of lipid metabolism namely, CETP and ApoA1. We found that the change in 
TAG and HDLC seen in TRF group were related to a higher ApoA1 concentration and lower 
CETP activity, indicating a potential increase in HDL particle in TRF group. As a conclusion, 
further study in a larger cohort of patients (multi-center) is needed to confirm this observation. 
Furthermore, an increased in sample size will allow sub-group analyses to elucidate the 
cofounding effect of various medications and underlying diseases in this population.  
 Given the limitation of the traditional biomarkers to provide information on a global 
impact of TRF supplementation, the metabolomics approach was used to elucidate whether the 
TRF supplementation lead to overall changes in patients’ metabolomics profile and whether the 
observed changes in plasma lipids correlates with their metabolomics profile. Based on the 
multivariate data analysis (PCA, PLS-DA), it was shown that metabolomics profiles of TRF 
group were different from placebo group at week-12 of the intervention. Moreover, 
metabolomics profile in both TRF and placebo group was correlated with inflammatory markers 
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and lipid profiles suggesting that some plasma metabolite could predict/ responsible for the 
changes in lipid profiles and inflammatory markers. Preliminary results from metabolites 
identification and quantification revealed that TRF supplementation triggered metabolic changes 
leading to either reduction or increased in several metabolites that have been reported otherwise. 
These include reduction in 2-Hydroxyglutarate, 3-Hydroxy-3-methylglutarte, Betaine, 
Cadaverine, Glycerate, Mandelate, Proline and 2-Hydroxy-3-methylvalerate. On the other hand, 
metabolites that were significantly higher in TRF group include Citrate, N-acetylaspartate, N-
acetylcysteine and Ribose. Further study is needed to validate the respective metabolites that 
contribute to the different metabolomics profile in TRF group with biochemistry test.  
 
Recommendations and future directions 
The first study added to the known knowledge regarding omega-3 fatty acids effects on lipid 
profiles, particularly in reducing TAG. However, additional study in a larger scale is needed to 
confirm omega-3 fatty acids effects on inflammatory markers since literature in this area is still 
ambiguous, partly due to high variability in the inflammatory markers. Such study should also 
include measurement of plasma fatty acids together with dietary records to confirm compliance.  
 The second study has provided exploratory data on the benefit of tocotrienol 
supplementation particularly in improving lipid profiles. However, given the shortcomings of the 
study and the fact that it was conducted in a homogenous population, the impact of TRF in a 
diverse dialysis population is unknown and yet to be recommended. Therefore, the precedent 
study should consider a multi-center approach to confirm the current observation, improve the 
study’s power and enable subgroup analysis (e.g. diabetic vs non-diabetic; statin vs non-statin 
users). Future study should incorporate more robust measurements for lipids and inflammatory 
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parameters (e.g. LCAT, lipoprotein particle size, cytokines and pro-inflammatory eicosanoids) to 
understand the mechanism of action. Moreover, a dose escalation study should also be 
considered to identify optimum dosage and duration to achieve the target lipid and inflammatory 
parameters as well as to recognize adverse effects (if there is any, especially at higher dosage).  
 It would also be of interest to investigate synergistic effects of omega-3 and TT in this 
population. Finally, intervention aimed at improving inflammatory biomarkers would require a 
large study population and extensive funding due to a substantial variability in these biomarkers. 
However, with the use of metabolomics approach, overall understanding of cardiovascular 
disease states beyond traditional biomarkers will facilitate discovery of novel biomarkers and 
metabolic pathways.  
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APPENDIX A:  24-HOUR DIETARY RECALL FORM 
 
 
Time / 
Meals 
 
Food eaten 
 
Quantity /  
portion size / 
amount/  numbers 
Remarks 
(if appropriate – add additional 
information) 
(e.g. how prepared?, brand 
name?, added cream/sugar, where 
eaten?) 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	   	   	  
Date: Name:  
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APPENDIX B: EXAMPLE OF DIETARY ANALYSIS PERFORMED USING 
NUTRITIONIST PRO 
Total Days: 1 Avg. Daily Kcals: 2186.680
Total Foods: 16 Name: 20b
Nutrient Value Unit Goal % Nutrient Value Unit Goal % Nutrient Goal Template
DAILY VALUES/RDI - ADULT
Weight 1914.2 g Phosphorus 1365.460 mg 1000.000 137 %
Kilocalories 2186.7 kcal 2000.0 109 % Iodine 150.000 Analyzed by
Protein 111.4 g 50.0 223 % Magnesium 218.531 mg 400.000 55 % Zul
Carbohydrate 224.9 g 300.0 75 % Zinc 10.774 mg 15.000 72 %
Fat, Total 95.0 g 65.0 146 % Copper 0.847 mg 2.000 42 % Percentage of Kcals
Alcohol 0.0 g Manganese 1.340 mg 2.000 67 % Protein 20.2%
Cholesterol 719.9 mg 300.0 240 % Selenium 139.567 µg 70.000 199 % Carbohydrate 40.9%
Saturated Fat 27.9 g 20.0 140 % Fluoride 265.774 µg Fat, total 0.389
Alcohol 0.0%
Monounsaturated Fat 37.1 g Chromium 0.074 mg 0.120 62 %
Polyunsaturated Fat 21.1 g Molybdenum 185.911 µg 75.000 248 %
MFA 18:1, Oleic 32.4 g Dietary Fiber, Total 12.958 g 25.000 52 % Exchanges
PFA 18:2, Linoleic 14.6 g Soluble Fiber 0.000 g Bread/Starch 6
Fat 6.50
PFA 18:3, Linolenic 1.5 g Insoluble Fiber 0.000 g Fruit 6.50
PFA 20:5, EPA 0.0 g Crude Fiber 4.369 g Meat-High Fat 0.50
PFA 22:6, DHA 0.0 g Sugar, Total 21.292 g Meat-Medium Fat 11.00
Trans Fatty Acid 0.0 g Glucose 4.864 g Other Carbohydrate 0.50
Sodium 4279.4 mg 2400.0 178 % Galactose 0.000 g Vegetable 4.00
Potassium 3377.7 mg 3500.0 97 % Fructose 4.314 g
Vitamin A (RE) 651.8 RE Sucrose 8.605 g
Vitamin A (IU) 3773.9 IU 5000.0 75 % Lactose 0.000 g
Vitamin A (RAE) 505.6 µg Maltose 0.495 g
Beta-Carotene 1680.4 µg Sugar Alcohol
Alpha-Carotene 274.5 µg Other Carbohydrate
Lutein (+ Zeaxanthin) 1943.0 µg Tryptophan 1239.329 mg
Beta-Cryptoxanthin 0.0 µg Threonine 4535.460 mg
Lycopene 1210.0 µg Isoleucine 4730.796 mg
Vitamin C 490.1 mg 60.0 817 % Leucine 8138.050 mg
Calcium 561.7 mg 1000.0 56 % Lysine 8166.761 mg
Iron 14.6 mg 18.0 81 % Methionine 2613.008 mg
Vitamin D (ug) 1.2 µg 10.0 12 % Cystine 1531.321 mg
Vitamin D (IU) 49.6 IU 400.0 12 % Phenylalanine 4439.847 mg
Vitamin E (mg) 6.1 mg 20.0 30 % Tyrosine 3507.970 mg
Vitamin E (IU) 9.1 IU 30.0 30 % Valine 5309.381 mg
Alpha-Tocopherol 1.4 mg Arginine 6189.328 mg
Thiamin 3.9 mg 1.5 263 % Histidine 3439.898 mg
Riboflavin 2.2 mg 1.7 127 % Alanine 5737.192 mg
Niacin 24.5 mg 20.0 122 % Aspartic Acid 9574.290 mg
Pyridoxine (Vitamin B6) 1.7 mg 2.0 86 % Glutamic Acid 16841.620 mg
Folate (Total) 245.2 µg 400.0 61 % Glycine 4990.013 mg
Folate (DFE) 259.9 µg Proline 4971.783 mg
Cobalamin (Vitamin B12) 3.7 µg 6.0 62 % Serine 4830.367 mg
Biotin 24.1 µg 300.0 8 % Moisture 972.189 g
Pantothenic Acid 4.2 mg 10.0 42 % Ash 19.200 g
Vitamin K 27.7 µg 80.0 35 % Caffeine 137.460 mg
Tuesday, October 01, 2013 Page First DataBank Nutritionist Pro™
        Menu Template Nutrient Analysis
 
Note: Example of the output from analysis of energy and nutrients intake from one subject using 
Nutritionist Pro. 
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APPENDIX D: QUANTITATIVE ANALYSIS OF TOCOTRIENOL LEVELS BY 
EXTERNAL LABORATORY 
Introduction 
In this study HPLC was used for separation, determination and quantification of individual 
tocotrienol levels in human plasma after the oral administration of TRF (fasting plasma samples). 
 
Materials and Methods 
Sample Preparation 
Human plasma samples were stored at -80oC until use. For extraction, 150 µL of plasma was 
added to a glass tube with screw cap and kept on ice. To this 2 mL of 1% ascorbic acid in ethanol 
(w/v), 900µL of deionized water, 25 µL of 1% BHT (w/v) in ethanol and 2 mL of hexane were 
added. The tubes were screw capped and contents were mixed by hand inversion followed by 
centrifugation at 1000rpm for 4 min. After the phase separation, supernatant hexane layer was 
taken into a new labeled test tube which consists of lipophilic tocopherols and tocotrienols. The 
extraction was repeated by adding 2 mL of hexane and mixing it by hand inversion followed by 
centrifuigation at 1000 rpm for 4 min. The supernatant hexane layer was added to the previous 
extract and dried under vacuum with centrifugal evaporator. The residue obtained is suspended 
in 200 µL of mobile phase and placed in deactivated glass auto-injector insert for analysis.  
 
Chromatographic conditions 
Analysis of tocotrienols was performed according to the method described below. An aliquot of 
20 µL was injected into HPLC system (Dionex) coupled to Dionex RF 2000 floerescene 
detector. The pump was run at a flow rate of 1.8ml/min and the mobile phase used was 
composed of methanol, isopropanol, NaClO4 (85.10.5). Mobile phase was filtered through 0.2 
µm nylon membrane before use. The total run time was 18 min and chromatographic separation 
was carried out by a phenomenex reversed phase column (5µm, 4.6mm x 250mm). The eluate 
was monitored for peaks by fluorescence detector set at excitation wavelength of 296nm and 
emission wavelength of 330nm. Calibrations were linear for the determination of α-tocopherol 
and γ-tocotrienol. 
 
Standard curve and linearity 
Stock solution of γ-tocotrienol and α-tocopherol (1mM) were prepared in mobile phase. For 
standard curve, γ-tocotrienol was diluted by mobile phase to give concentration of 0.05, 0.1, 
0.25, 0.5, 1 and 2 µM and α-tocopherol was diluted to 0.1, 0.25, 0.5, 1, 2.5 and 5 µM. The 
retention time for γ-tocotrienol and α-tocopherol were found to be 7.1min and 14.2 min (appox.). 
 
 
 
 
 
 
 
 
 
166 
	  
	  
 
Results 
All the standard and test samples were run for analysis and images are shown below. Individual 
tocotrienols were shown in following Table.  
 γ-tocotrienol α-tocotrienol δ-tocotrienol α-tocopherol 
Sample # Peak 
area 
Conc. 
(ng in 
100µL) 
Peak 
area 
Conc. 
(ng in 
100µL) 
Peak 
area 
Conc. 
(ng in 
100µL) 
Peak area Conc. 
(ng in 
100µL) 
Placebo 1 ND ND ND ND ND ND 1921577 157 
Placebo 2 ND ND ND ND ND ND 1576941 103 
Placebo 3 ND ND ND ND ND ND 1172591 100.2 
Placebo 4 ND ND ND ND ND ND 1137831 52.7 
Placebo 5 12114 0.24 ND ND ND ND 635672 209 
TRF1 144047 0.14 ND ND ND ND 1576941 134.6 
TRF2 197457 0.4 ND ND ND ND 3019545 226.5 
TRF3 ND ND ND ND ND ND 2273772 203.9 
TRF4 ND ND ND ND ND ND 3548170 270.9 
TRF5 ND ND ND ND ND ND 3225131 269.2 
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Mortality rate in patients undergoing chronic hemodialysis (HD) in the United States 
remain unacceptably high despite improvement in dialysis technology.  Cardiovascular disease 
(CVD) account for more than 50% of the premature death in this population. Evidences indicate 
that the accelerated CVD are attributed to by malnutrition, inflammation, dyslipidemia and 
oxidative stress. Dietary intervention using nutrients with antioxidant, anti-inflammatory, and 
potential lipid altering properties to correct the aforementioned problems remain inconclusive. 
Furthermore, such nutritional intervention trial is often hampered by poor compliance related to 
medical and socioeconomic barriers.  Therefore, a series of randomized, double-blind, placebo-
controlled, parallel trials were undertaken to document the technical feasibility of ‘directly 
observed treatment’ and the global impact of several nutrients namely omega-3 and vitamin E 
tocotrienols on nutritional and oxidative indicators, inflammatory markers and lipid profiles in a 
cohort of chronic HD patients. 
 The objective of the first study was to evaluate the impact of omega-3 plus liquid protein 
supplement on serum albumin, plasma lipids and other indicator of nutrition and inflammation. 
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markers.  The study recruited 63 subjects and they were randomized into placebo+protein (n=32) 
and omega-3+protein (n=31) groups. The two intervention groups received 30mL of a liquid 
protein plus 2.4g omega-3 or placebo, three times per week after their routine dialysis session for 
6 months. Directly observed nutritional supplement resulted in significant improvement in the 
LDLC/HDLC ratio in the omega-3 group as compared to the placebo group (P=0.043). In the 
omega-3 group, serum albumin was also marginally higher after 6 months as compared to the 
baseline (P=0.07). The observed increase in CRP levels in the placebo group over 6 months was 
not apparent in the omega-3 group, although there was no significant difference between groups. 
NFκB, MIS, nPNA, BMI and hemoglobin were unaffected by the intervention. Therefore, it is 
conclude that ‘directly observed treatment’ with an omega-3 based supplement (as opposed to a 
pure protein supplement) showed beneficial effects on lipid profile, and CRP levels. Further 
studies using a combination of outpatient and inpatient ‘directly observed treatment’ is 
warranted.  
 Given a proven feasibility of directly observed treatment in the first study, we conducted 
a second study using tocotrienol rich fractions (TRF) by incorporating the same design to 
maximize compliance but with additional take home supplements. Vitamin E tocotrienols have 
been reported to confer anti-inflammatory, antioxidant and a potential of lipid altering benefits in 
vitro, in vivo and in some other clinical population. However, the impact of this nutrient in HD 
population is unknown. Subjects were provided daily with capsules containing either vitamin E 
tocotrienol-rich fraction (TRF) (180 mg tocotrienols, 40 mg tocopherols) or placebo (0.48 mg 
tocotrienols, 0.88 mg tocopherols). For the results, TRF supplementation did not impact any 
nutritional, inflammatory, or oxidative status biomarkers over time when compared with the 
baseline within the group (one-way repeated measures analysis of variance) or when compared 
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with the placebo group at a particular time point (independent t-test). However, the TRF 
supplemented group showed improvement in lipid profiles after 12 and 16 weeks of intervention 
when compared with placebo at the respective time points. Normalized plasma triacylglycerols 
(cf baseline) in the TRF group was reduced by 33 mg/dL (P=0.032) and 36 mg/dL (P=0.072) 
after 12 and 16 weeks of intervention but no significant improvement was seen in the placebo 
group. Similarly, normalized plasma high-density lipoprotein cholesterol was higher (P<0,05) in 
the TRF group as compared with placebo at both week 12 and week 16. The changes in the TRF 
group at week 12 and week 16 were associated with higher plasma apolipoprotein A1 
concentration (P<0.02) and lower cholesteryl-ester transfer protein activity (P<0.001).	   As a 
conclusion, TRF supplementation improved lipid profiles in the study of maintenance HD 
patients. A multi-centered trial is warranted to confirm these observations. 
 Finally, following a positive impact of TRF supplementation on lipid profiles, we 
undertook a metabolomics approach to investigate whether the TRF supplementation lead to 
overall changes in patients’ metabolomics profile and whether the observed changes in plasma 
lipids correlates with their metabolomics profile. Based on the principal component analysis 
(PCA), there was a separation pattern between the TRF and placebo groups at week-12. After 
applying partial least square-discriminant analysis (PLS-DA), there was a clear separation 
between the two groups indicating different metabolomics profiles. In addition, metabolomics 
profile in both TRF and placebo group was correlated with inflammatory markers and lipid 
profiles suggesting that some plasma metabolite could predict/ responsible for the changes in 
lipid profiles and inflammatory markers. 
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